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Photodynamic therapy (PDT) is widely used for the treatment of skin cancer. 
Mechanistically, in delta-aminolevulinic acid (ALA)-mediated PDT, the addition of 
ALA to cells bypasses the negative feedback control of heme biosynthesis, leading 
to accumulation of photosensitizing concentrations of protoporphyrin IX (PPIX). 
Subsequent activation of cellular PPIX with an external light source (usually red light, 
550-750 nm) leads to generation of reactive oxygen species (ROS), resulting in cell 
death. The major side effect of ALA-PDT treatment is the pain experienced by 
patients. Management of treatment-related pain still remains a considerable 
challenge in patients. Further optimization of the treatment protocol including light 
source, dose and duration therefore seems crucial to try and address this issue. To 
improve the efficiency of ALA-PDT of skin cells in the present study three 
approaches were used: (i) The conventional light source was changed to UVA (320-
400 nm) that is absorbed more efficiently by PPIX and is 40-fold more potent in 
killing cultured skin cells than red light; (ii) ALA treatment was combined with the 
potent iron chelators, salicylaldehyde isonicotinoyl hydrazone (SIH), pyridoxal 
isonicotinoyl hydrazone (PIH) or desferrioxamine (DFO) to further increase the 
accumulation of PPIX through the depletion of iron available for ferrochelatase-
mediated bioconversion of PPIX to heme; (iii) ALA treatment was combined with 
UVA-activatable caged iron chelators (CICs) that do not chelate iron unless activated 
by UVA. The CICs used were aminocinnamoyl-based SIH derivatives, ‘BY123’ and 
‘BY128’. Upon activation by UVA, these CICs release the active SIH allowing for 
specific localised release of iron chelator in the cells. Spontaneously immortalised 
HaCaT cell line and Met2 cancer line (squamous cell carcinoma) were used as cell 
models. Cells were pre-treated (or not) for 18 h with SIH, PIH or DFO (20-100 µM), 
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then subjected to ALA (0.5 mM) for 2 h and irradiated with low doses of UVA (5-50 
kJ/m2). The quantification of intracellular PPIX was carried out by both HPLC and 
spectrofluorimetry after treatments of cells with ALA alone or combined with 
chelators. Cell death was examined 24 h after UVA exposure of ALA+/-chelators-
treated cells by flow cytometry using Annexin V-propidium iodide dual staining 
assay. Pretreatment of HaCaT cells with ALA caused a substantial increase in the 
intracellular levels of PPIX which in turn sensitized the cells to very low non-cytotoxic 
UVA doses. Pre-treatment with DFO, PIH and SIH followed by ALA treatment further 
enhanced the PPIX level in HaCaT cells and caused an additional level of 
photosensitization to low UVA doses. Among the chelators used, SIH combined with 
ALA provided the most efficient increase in PPIX and cell killing following UVA 
irradiation, even at a lower SIH concentration of 20 µM. Among the CICs used, both 
UVA-activated BY123 and BY128 were as effective as SIH in increasing the level of 
PPIX and cell killing in ALA-treated cells following exposure to low doses of UVA. 
UVA-based ALA-PDT combined with SIH (or its caged-derivatives BY123 and 
BY128) appears therefore to be a promising modality for topical PDT. The high 
lipophilicity of SIH (and its caged-derivatives) which facilitates skin penetration and 
their potent cytotoxicity at low UVA doses should therefore allow the current modality 
for topical PDT to be improved, through a reduction of the time of irradiation and 
therefore the duration of pain experienced during the treatment. The use of SIH-
based CICs will be a safer alternative to topical ALA-PDT than ‘naked’ SIH, as 
application of these pro-chelators will substantially decrease the exposure of the 
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1.1. Human Skin 
Human skin is the largest organ in the body. The skin consists of multilayers of 
ectodermal tissue and also has the role of protecting the underlying muscles, bone 
and internal organs. In an average person, it weighs around six pounds and 
comprises approximately 10% of the total body mass (Williams, 2003). Due to skin 
interactions with the outside environment, it has the very important role of protecting 
the body against pathogens (Proksch et al., 2008) and also excessive water loss 
(Madison, 2003). 
Other important functions of the skin include maintaining the body temperature, 
insulation, synthesis of vitamin D etc. 
Human skin is divided into three distinctive layers: epidermis, dermis, hypodermis 
(subcutaneous adipose layer). 
1.1.1. Epidermis: 
The epidermis starts at the outermost surface of the skin and works inwards. It acts 
as a waterproof base for the skin and consists of stratified squamous epithelia with 
an underlying basal lamina. The main type of cells that exist in the epidermis include 
Markel cells, Langerhans cells, keratinocytes and melanocytes, with keratinocytes 
being the major epidermal cells, making up around 95% of the epidermis (McGrath 
et al, 2004).  
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The thickness of the epidermis varies depending on the area of the body; it ranges 
from the thinnest on the eyelid at around 0.05 mm, to the thickest on the palms and 
soles of around 1.5 mm (Brannon, Heather, 2007). 
The epidermis itself can be further subdivided into four to five distinct layers 
depending on the site of the skin: 
 Cornified layer (stratum corneum). 
  Granular layer (stratum granulosum) - where epidermal nuclei disintegrate. 
 Spinous layer (stratum spinosum) - the bulk of living epidermal keratinocytes. 
 Basal layer (stratum basale) – the only keratinocytes in normal epidermis 
which undergo cell division. 
 Clear/ translucent layer (stratum lucidum) – This layer only exists in palms 
and soles. 
The epidermis is constantly renewed by the cell division which takes place in the 
stratum basale, with cells undergoing several stages of differentiation and moving 
upwards in the layers as they do so, until new keratinocytes are produced. In this 
process these keratinocytes lose their nuclei, dehydrate and flatten out to what 
forms the cornified external layer stratum corneum (SC) (McGrath et al, 2004). 
Keratinocytes in the basal layer divide on average every 4 weeks and the 
daughter cells undergo modifications as they move to up to the skin surface. At 
the most external layer i.e. stratum corneum, dead cells are constantly shed, 
while new cells are being produced at the same level in basal layer. However, in 
the case of hyper-proliferative diseases such as skin cancer or psoriasis as well 
as pathological conditions such as Actinic keratosis (AK), the rate of this division 
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is much higher which indicates a risk factor as there may be some alterations to 
permeability barrier functions (Lippens et al, 2009).  
Other cells of the epidermis mentioned above, also play important roles in 
maintaining the epidermis. 
Langerhans cells are antigen presenting cells which derive from the bone marrow 
and have an important role in the immune surveillance system of the skin (Benjamin 
et al, 2008). 
Melanocytes secrete melanosomes which contain melanin. They form a UV 
absorbing barrier, which in turn reduces the amount of radiation that may penetrate 
the skin (Benjamin et al, 2008). The skin colour is determined by the melanogenesis 
activity of these cells (Biro et al, 2009). 
Markel cells act as mechanoreceptors, responsible for the sensation of touch and 
pressure (Biro et al, 2009). Stratum corneum (SC) is a non-viable epidermal layer 
with a thickness of around 10 µM. Its nucleated keratinocytes form a barrier to the 
transdermal delivery of drugs through the skin. 
Moving downwards through the  layers of epidermis, the stratum granulosum is up to 
3 cell layers thick and contains enzymes that may degrade vital cell organelles i.e. 
nuclei and production of corneocytes (Benjamin et al, 2008).  
Stratum spinosum (otherwise known as spinous layer), is another viable layer 
consisting of 2-6 columnar keratinocyte layers that rearrange themselves into 
polygonal shapes. Desmosomes are produced within this layer from keratins 





The dermis is the middle layer of skin, which acts as a connective tissue matrix 
between the upper epidermis and the subcutaneous layer. The dermis is around 3-5 
mm thick (Barry, 1983) and consists of two layers: the superficial area called the 
papillary region, which is adjacent to the epidermis and a deep thicker layer called 
reticular dermis (James et al, 2005). The upper dermis (papillary region), consists of 
capillaries which nourish the epidermis and the lower thicker layer (reticular layer). 
The major cells in the dermis are fibroblasts which synthesise elastin, and 
components of dermis are elastin fibres providing elasticity, collagen providing 
strength and the extrafibrillar matrix, which is an extracellular gel-like substance 
composed of glycosaminoglycans (GAG). GAG provides viscosity, hydration and 
allows the dermis’s limited movement. There are also mechanoreceptors in the 
dermis that maintain the senses of heat and touch, hair follicles, sweat glands, 
sebaceous glands, lymphatic vessels and blood vessels (James et al, 2005). 
Other cells embedded in the reticular layer are fat cells, mast cells, macrophages, 
dermal dendrocytes and lymphocytes.  
1.1.3. Subcutaneous Layer (Hypodermis): 
This layer is a fibrous fatty layer that spreads all over the body with the exception of 
eyelids and the male genital region (Barry, 1983). This layer is composed of 
adipocytes, fibroblasts and macrophages and is supplied by a network of blood 
vessels and nerve fibres (Biro et al, 2009). 
The hypodermis is known as a site of synthesis of the preadipocytes and adipocytes, 











Figure 1.1: Anatomy of the skin. Reproduced from (training.seer.cancer.gov /melanoma/anatomy).  
 
 
1.2. Skin Cancer 
Skin cancers are classified based on the type of cells they initiate from. There are 
three types of skin cancers:  
1.2.1.  Non Melanoma Skin Cancer: 
Non melanoma skin cancer (NMSC) is a collective term used to describe basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC). 
BCC occurs mostly in white-skinned individuals and it accounts for 80% of NMSC. 
BCCs are slow growing and often appear in local tissues and the chances of 
metastases are very rare (Rajpar et al, 2008). 
The possible signs that should give an indication to non-melanoma skin cancer are 
as follows (Rajpar et al, 2008):   











- Raised, smooth, shiny, and look pearly. 
- Raised, and red or reddish brown. 
- Firm and look like a scar, and may be white, yellow or waxy. 
- Scaly, bleeding or crusty. 
 
 Basal Cell Carcinoma (BCC): This type of cancer is initiated from the lower 
layer of the epidermis. It is the most common and yet least dangerous type of skin 
cancer. BCC is subdivided into three major growth patterns: nodular (nBCC), 
superficial (sBCC) and morphoeiform (or sclerotic; mBCC). Superimposed on any of 
these growth patterns may be ulceration or pigmentation. The likelihood of 
metastasis is extremely small; the related morbidity to BCC is linked to local tissue 
invasion and destruction, which mostly occurs on the head and neck. Most sBCCs 
will progressively enlarge over months to even years and with time, may adopt 
nodular or even sclerotic growth patterns. sBBCs do not penetrate very deeply into 
the skin but are able to grow outward and up to several centimetres in size (Rajpar et 
al, 2008).   
nBCCs lesions that are found on the neck and head of old patients, will progressively 
grow into nodules which may also ulcerate. Central ulcerations in a nodule will 
appear as a raised and rolled edge (Rajpar et al, 2008).  On the other hand, mBCCs 
have a sclerotic growth pattern and present themselves as pale scars that tend to be 
deeply invasive, making surgical and non-surgical treatments less effective (Albert 
and Weinstock, 2003). Their appearance ranges from a translucent to a fleshy colour 
- very small blood vessels are visible on the surface of the lesions which often 
appear as a raised smooth bump, and ulceration may sometimes be seen. 
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The most well-known risk factor causing NMSC is exposure to UV which is directly 
related to sun-exposure habits. Therefore the majority of such lesions are often 
observed on sun-exposed sites in patients. There are some factors making the 
appearance of SCC more probable such as lighter complexion, male gender, 
increasing age, ionizing radiation, immunosuppression, psoralen phototherapy and 
also precancerous skin lesions (Albert and Weinstock, 2003). 
The areas of the body that are most exposed to UV, are the areas that are most 
prone to BCC, i.e. the face. The chances of their metastasis are very low and they 
are usually treatable by surgery or radiotherapy.   
 Actinic Keratosis (AK): is a pre-malignant condition (Prajapati et al, 2008) 
which appears as thick, scaly or crusty patches of skin (Freeberg et al, 2003; 
Quaedvlieg et al, 2006). Its occurrence rate is higher in people with fair skin and also 
those who are frequently exposed to sun, as the incident of AK is often related to 
solar damage. AK lesions are known to be potentially pre-cancerous and if not 
treated there is about 20% chance that they could progress to SCC (Quaedvlieg et 
al, 2006; Weedon, 2010). 
AK sites often range from 2-6 mm in size and may appear in different colours of dark 
to light brown, tan, pink, or a combination of colours, or indeed they may have the 
same pigment as the surrounding skin. AK often appear at areas of the skin that are 
mostly exposed to sun, such as the face, scalp, ears, neck, lips, backs of hands etc. 
AK is subdivided into the following types (Rapini et al, 2007): 
- Hyperkeratotic Actinic Keratosis 
- Pigmented Actinic Keratosis 
- Atrophic Actinic Keratosis 
- Lichenoid Actinic Keratosis 
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The prevalence of AK in Australia is estimated to be approximately 40% (Berlin, 
2010). Sometimes the lesions may increase in thickness and become thick and 
horny and also may cause bleeding. Pathological evidence suggests that AK should 
be regarded as very early SCC (Czarnecki et al, 2002). Since 3-4% of SCCs 
metastasize (Lober and Lober, 2000), it has been recommended that early actions 
should be taken in treating AK in order to avoid malignancy and the need for more 
extensive treatment. 
 Squamous Cell Carcinoma (SCC): This type of cancer arises from the 
middle layer of the skin. It is less common but there are more chances of metastasis. 
If SCC is not treated it may cause death. The tumours are very fast-growing with a 
red, crusted thickened patch on the sun-exposed area. If SCC is not treated it may 
develop further and have more serious consequences. SCC is the second most 
common skin cancer as is quite dangerous but not as much as melanoma. 
Among NMSC conditions, Bowen’s disease (BD) is also a persistent form of intra-
epidermal (in situ) SCC that normally appears as an enlarging, well-demarcated, 
erythematous plaque with an irregular border, a crusted or scaling surface and 
potential for extending along the cutaneous appendages. Nevertheless BD has a 
small potential for invasive malignancy (Morton, 2005). As the incidence of NMSC 
increases, so does the number of modalities used to treat this condition. 
 Melanoma: derives from the pigment producing cells melanocytes. It is less 
common than the other two types of skin cancer, however it is much more 
aggressive and spreads very rapidly, and if untreated it may prove fatal (Kasper et 
al., 2005). The predominant cause of malignant melanomas is UVA radiation via 
indirect DNA damage, which is caused by the production of free radicals and 
reactive oxygen species (ROS) by UVA leading to cell damage. They often irregular 
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in shape with colour variation within the lesion and usually have a diameter greater 
than 6 mm (Kanay and Gerstenblith, 2011). 
Most melanomas are brown to black in colour. There are however some melanomas 
that are red or a fleshy colour. These are the more aggressive lesions. Signs of 
melanoma could be a change in shape, colour, or size of the lesion, itching or pain 
and even evolvement of new moles in adulthood (Rajpar et al, 2008).  
Figure 1.2 illustrates some images of all three types of skin cancer. 
   
Figure 1.2 A: Top: Basal Cell Carcinoma (BCC) (Ref: http://www.skcin.org/Skin-
Cancer/Types/Basal-Cell-Carcinoma-(BCC)). 
 
Figure 1.2 B: Right: Squamous Cell Carcinoma (SCC)(Ref: http://www.skincancer.org/skin-





Non melanoma skin cancer (NMSC) is the most widely occurring cancer in UK with 
official figures reporting around 114000 cases registered in England and Wales 
(Levell et al, 2013).  Since non melanoma skin cancers are relatively easy to treat a 
lot of the referred cases are not reported so the actual number is quite likely to be 
higher (Cancer Research UK). The vast majority of NMSC are BCC which comprise 
75% of all NMSC cases. This makes SCC the second most common type of skin 
cancer in the UK (i.e. 20% of skin cancers). In the USA, one million new cases of 
NMSC are diagnosed each year and of these 80% are BCC and 16% are SCC. The 
overall incidence of SCC is increasing across Europe, the USA and the southern 
hemisphere (see Neville et al, 2007; Schmook and Stockfleth, 2003).  
As mentioned above, the main factor involved in many skin cancers, is sun 
exposure. This could be a long term exposure or short episodes of intense exposure 
and burning (Kanay and Gerstenblith, 2011). 
1.2.2. Diagnosis of Skin Cancer: 
To identify if a lesion is cancerous, a nurse or doctor will discuss the patient’s 
medical history to see if there is a family history of skin cancer. Also the number of 
previous sunburns will be recorded. This will then be followed by a skin examination 
where the suspected lesion will be tested for shape, colour, size and texture. The 
lymph glands will also be examined for signs of swelling, which is a potential sign of 
skin cancer. 
The only way to actually diagnose various types of skin cancer is to take a biopsy of 
the suspected area. A biopsy can reveal very useful information such as the tumour 
depth. Biopsy methods include (http://www.cancerresearchuk.org/skincancer) 
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1. Shave biopsy: This is performed using either a scalpel blade or a curved razor 
blade. If this procedure is performed smoothly, a small fragment of the skin 
should be removed with minimal blemish. This method is ideal for diagnosis of 
BCC and SCC and melanoma in situ.  
2. Punch biopsy: A circular blade is used ranging in size from 1-8 mm. The blade 
is attached to a long handle, and is rotated down through the epidermis and 
dermis, and into subcutaneous tissue, producing a cylindrical core of tissue 
(Zuber, 2002). This is a particularly good biopsy method where a smaller 
punch i.e. 1-1.5 mm is desirable for areas where cosmetic appearance is 
important as minimal bleeding occurs and no stitching is required. The only 
disadvantage of a 1 mm punch is that the tissue obtained is very difficult to 
observe. 
3. Incisional biopsy: A cut is made through the dermis down to the subcutaneous 
tissue. Incisional biopsies can include the whole lesion (excisional), part of a 
lesion, or part of the affected skin and also part of the normal skin (this is to 
show the interface between the normal and abnormal skin). Long and thin 
deep incisional biopsies are excellent on the lower extremities as they allow a 
large amount of tissue to be analysed with minimal tension on the surgical 
wound.  
4. Excisional biopsy: This method is very similar to the incisional biopsy, except 
that the entire lesion or tumour is included. This method is ideal for small 
melanomas, and is often performed with a narrow surgical margin to assure 
the deepest thickness of the melanoma is given before prognosis is decided. 
As many melanomas in situ are quite large, on the face, multiple small punch 
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biopsies are often taken, before committing to a large excision for diagnostic 




1.2.3. Treatment of Small Skin Cancers: 
There are several existing treatments for diagnosis of small skin cancers. The 
treatment options vary depending on the site of cancer, its size and depth, as follows 
(ref: cancerresearchuk.org/skincancer): 
 One of the most common options is operation, which is done under local 
anaesthesia in order to cut the cancer out. 
 Cryosurgery, which is also known as the freezing treatment with liquid 
nitrogen, destroys the cancer cells. This modality is used for low risk tumours 
that are less than 6 mm in diameter. 
 Curettage and cautery- This modality is used for low risk tumours that are less 
than 6 mm in diameter. The tumour or the lesion is scrapped off (curettage). 
This may cause some bleeding to the area which is often stopped by 
application of small electrical burns that are achieved with an electric needle 
(cautery). 
 Chemotherapy creams are another alternative. These creams are applied on 
the area of skin cancer to diminish the cancer cells. Examples of these are 5-
fluorouracil (5-FU) or imiquimod.  
5-Fluorouracil (5-FU) (trademarked as Efudex) is a pyrimidine analogue that 
is widely used in cancer treatment. It belongs to the antimetabolite drug 
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family and works via the irreversible inhibition of thymidylate synthase, 
interrupting this enzyme’s action which leads to blocking of the synthesis of 
the pyrimidine nucleoside thymidine, which is required for DNA replication. 5-
FU is a recommended topical application for AK and some carcinomas. Due 
to some toxicity observed with 5-FU, its precursor 5-Fluoroorotic acid is 
commonly used in laboratories to screen against organisms capable of 
synthesising uracil (Longly et al, 2003). 
Imiquimod (trademark name: Aldara and Zyclara) is known as an immune 
response modifier. This topical cream is used to treat AK and BCC and SCC. 
It is known that imiquimod activates immune cells through the toll-like 
receptor 7 (TLR7), commonly involved in pathogen recognition (Hemmi et al, 
2000). Cells that are activated via TLR-7 secrete cytokines (primarily 
interferon- α (INF-α), interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-
α) (Bilu et al, 2003). It has been shown that upon imiquimod application, 
Langethans cells are activated which in turn activaes the local lymph nodes 
that result in activating the adaptive immune system. Other cells activated 
could be named natural killer cells, macrophages and B-lymphocytes (Miller 
et al, 1999). 
 Moh’s micrographic surgery: This involves cutting the area of cancer, piece by 
piece and looking at each piece under the microscope to confirm the cancer 
cells. It is done bit by bit to assure that healthy tissues are not also cut away. 
This method was first developed in 1938 by the general surgeon named 
Frederic E. Mohs. This therapy is recommended for common types of skin 
cancer. Moh’s surgery is amongst many methods which obtain complete 
margin control during removal of skin cancer using frozen section histology 
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(Minton, 2008).  Treatment modalities already in use are tailored to tumour 
type, location, size and histological pattern. However with the increasing 
incidence of NMSC, there is a requirement for designing new non-invasive 
treatments that target cancer cells more generally throughout all stages of 
tumorogenesis.  
 Photodynamic therapy (PDT) with topical aminolevulinate-based ALA or MAL 
formulations is considered to be one of the most promising treatments for 
NMSC (e.g. Cairnduff et al, 1994; Fink-Punches et al, 1997; Omrod and Jarvis, 
2000; Peng et al, 1997; Lehmann, 2007; Morton et al, 2008; Morton, 2005). It 
is a light-dependent treatment that kills the cancer cells (Rajpar et al, 2008). 
In this project we applied PDT in combination with ALA and a range of iron 
chelators in order to improve the efficiency of PDT for treatment of NMSC. 
 
1.3. Photodynamic Therapy (PDT) 
1.3.1. Definition: 
The combination of photosensitising agents and light in order to treat skin cancers 
has been widely used in the field of dermatology for centuries. This goes back to 
ancient Egypt, Greece and India where psoralen-containing plant extracts were 
applied in combination with a light source to treat psoriasis, and skin cancer (see 
Wilson and Mang, 1995). This concept is known as photo-chemotherapy and 
represents a common basis for various present day treatment procedures such as 
PUVA (i.e. psoralen UVA), and also PDT. 
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PDT depends upon the combination of molecular oxygen (O2), light, and a 
photosensitiser (PS) (see Figure 1.3). 
The first component of PDT is the PS that is a photosensitive molecule that localizes 
to a target cell and/or tissue. This is followed by administration of a light source of a 
specific wavelength that is absorbed by the particular PS applied, thus activating it. 
In the mechanism of PDT, the PS transfers energy from light to molecular oxygen, 
generating reactive singlet oxygen.  These reactions occur in the immediate local of 
the light-absorbing PS, such that the biological responses are induced only in the 
particular areas that have been exposed to light (Wang et al, 2002).  
 
Figure 1.3. Mechanism of action of photodynamic therapy (PDT). PDT requires three elements: 
light, a photosensitiser and molecular oxygen (O2). When the photosensitiser is exposed to specific 
wavelengths of light, it becomes activated from a ground to an excited state. As it returns to the 
ground state, it releases energy, which is transferred to O2 to generate singlet oxygen (
1
O2) which 





1.3.2. Mechanism of Action 
Photodynamic therapy (PDT) is a selective treatment modality that targets the area 
to be treated with high efficiency. This selectivity is based on a difference in the PS 
concentration between normal and targeted tissues and by directing light into the 
target tissue only. One advantage of PDT is that the PS can be administered either 
intravenously or by topical application to the skin. However, depending on the route 
of administration chosen, the bio-distribution of the PS may change over time 
(Dolmans et al, 2003). Managing the timing of light exposure is yet another way to 
control the effects of PDT. Depending on the PS applied, it takes 3-96 hours (h) to 
accumulate in the target tissue. After the accumulation period, light directed to the 
tissue activates the PS and, in the presence of ground-state (triplet) oxygen (3O2), 
ROS are formed. Briefly, following the absorption of light (photons), the PS is 
transformed from its ground state (single state) into a relatively long-lived 
electronically excited state (triplet state) via a short-lived excited singlet state 
(Henderson and Dougherty, 1992). The excited triplet can undergo two kinds of 
reactions (see Figure 1.4).  Radicals are formed by transferring hydrogen atom 
(electron) via reacting either directly with a substrate i.e. cell membrane or a 
molecule i.e. protoporphyrin IX. In type I reactions, these radicals can transfer their 
excessive energy to 3O2 to form singlet oxygen (
1O2) and other oxygenated reactive 
species, whereas in type II reactions, the triplet can transfer its energy directly to 3O2, 
to form 1O2.  
In both types of mechanism, the reactions occur simultaneously and the ratio 
between these processes depends on the type of the PS used, the concentrations of 
biological substrates and O2, as well as the binding activity of the PS for the 
substrate. Due to the high reactivity and the short half-life of ROS, only cells that are 
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located near the area of the ROS production (i.e. areas of PS localisation) are 
directly affected by PDT (Moan and Berg, 1991). Among ROS generated, 1O2 is 
regarded as the main mediator of phototoxicity in PDT as it is a powerful oxidant that 
can react with many kinds of biomolecules. These include unsaturated 
triacylglycerols, cholesterol, phospholipids, amino acids such as tryptophan, histidine 
and methionine, as well as nucleic acid bases such as guanine and guanosine 
(Milgrom and MacRobert, 1998; Stemberg et al, 1998). The generated ROS thus 
damage vital structures and functions of cells, which results in tissue destruction 
(see Bonnet, 1999 and Milgrom and MacRoberts, 1998; Nyman and Hynninen, 
2004). Eventually, the PS is degraded through absorption of light by a process 
known as ‘photo-bleaching’. The photo-bleaching can result from either type I or type 
II reactions. Photosensitized, O2-dependent reactions in biological systems are 




Figure 1.4. Type I and Type II reactions in PDT. There are two types of reactions occurring during PDT. 
Following the absorption of light, the photosensitiser is transformed from its ground state into an excited state. 
The activated photosensitiser can undergo two different types of reactions. It can either react directly with a 
substrate such as the cell membrane or a molecule, transferring a hydrogen atom to form radicals. The radicals 
interact with oxygen to produce oxygenated products (type I reaction). Alternatively the activated photosensitiser 
can transfer its energy directly to oxygen to form 
1
O2 (type II reactions). These species oxidise various substrates 
and damage vital structures and functions in cells.  
The extent of photo-damage and cytotoxicity caused by PDT depends on many 
factors such as the type of PS used, its extracellular and intracellular localisation, the 
administered dose, the total light exposure dose, light fluence rate, oxygen 
availability and the time between the drug administration and the light exposure. All 
these influence the efficiency of PDT independently (Palumbo, 2007; Dolmans et al, 
2003; Nowis et al, 2005).   
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The tumour damage resulting by PDT is caused by three independent processes: 
direct tumour cell killing, damage to the vasculature, and activation of non-specific 
immune responses (Golab et al, 2000; van Duijnhoven et al, 2003; Abels, 2004).  
 
The most important effect caused by photo-activation is direct cell killing (Henderson 
et al, 1985). This killing is the result of the local production of ROS. Cell death in 
PDT may occur by apoptosis or necrosis, depending on the PS, PDT drug-light dose 
and on the cell genotype (Almeida et al, 2004). However the therapeutic responses 
may not be fully achieved due to some factors such as the non-homogenous 
distribution of oxygen within the tumor that would result in non-homogenous 
activation of the PS and also the non- homogenous distribution of the PS within the 
tumor tissue and the surrounding areas (Korbelik et al, 1996). Oxygen shortage can 
arise as a result of the photochemical consumption of oxygen during the 
photodynamic process as well as from the immediate effects of PDT on the tissue 
vasculature. Indeed rapid and substantial reduction in the tissue oxygen tension 
during and after illumination of photosensitised tissue has been reported (Tromberg 
et al, 1990; Pogue et al, 2001). The development of microvascular damage and 
hypoxia after PDT has been shown to contribute to the long-term tumor response, 
but the reduction in oxygen that occurs during PDT can limit the response. There are 
two ways to overcome this problem. One is to lower the light fluence rate to reduce 
oxygen consumption rate, and the other is to fractionate the PDT light delivery to 





1.3.2.1. Reactive Oxygen Species (ROS) 
Oxygen is the most abundant element in the earth’s crust which is required for all 
animals and plants except those that live under anaerobic conditions. Despite its 
important role in energy production, it can also lead to the generation of a variety of 
ROS as part of normal metabolism. 
Oxidative stress occurs when cells are in a situation where the equilibrium between 
pro-oxidant and antioxidant species is broken to favor the pro-oxidant state, due to 
production of ROS.  
Free radicals is a name given to species capable of independent existence which 
contain one or more unpaired electron and are able to react with other molecules to 
lead to potentially damaging effects due to their role in the initiation of free radical 
chain reactions (Riley, 1994; Ryter and Tyrrell, 1998). A biological free radical chain 
reaction can be initiated at the lipid bilayer of the membrane in a process called lipid 
peroxidation. This process will generate in the first instance fatty acid radicals and 
consequently fatty acid peroxyl radicals and aldehydes. The consequence of lipid 
peroxidation is the loss of cellular membrane integrity and necrotic cell death (see 
Girotti et al, 2001; Reelfs et al, 2010). Proteins and carbohydrates may also be 
oxidized by free radicals (see Halliwell and Gutteridge, 1999). 
ROS is a collective term given not only to oxygen-based radicals but also to non-
radical derivatives of oxygen which are able to form radicals. Examples of oxygen-
based radicals include superoxide radical anion (•O2
-), hydroxyl radical (•OH). Non 
radical derivatives of oxygen include 1O2 and H2O2. 
Both exogenous and endogenous factors can generate ROS. Examples of 
endogenous factors include phagocytic oxidative burst, mitochondrial respiration and 
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microsomal and nuclear membrane electron transfer (Danpure and Tyrrell, 1976; 
Tyrrell and Pidoux, 1989). Exogenous factors include ozone, ionizing and UV 
radiations.  
ROS including 1O2 may also be formed as a consequence of photochemical 
reactions between light, O2 and light-reactive PS (Halliwell and Gutterridge, 1990; 
Foote, 1982). These include many natural substances such as porphyrins 
(hematoporphyrin and protoporphyrin IX), chlorophylls (a, b), bilirubin IXa, retinal 
(rhodopsin), quimones and flavins (riboflavin) (see Spikes, 1986).  
Uncontrolled production of ROS is harmful to biomolecules causing cell injury and 
cell death (i.e. apoptosis or necrosis). In addition excessive ROS production has 
been implicated in initiation and progression of a number of pathologic disorders 
notably chronic inflammatory disease and cancer [see Halliwell and Gutteridge, 




1.3.2.1.1.  ROS Production by UVA Radiation 
UVA (320-400 nm) radiation, the  oxidizing component of sunlight produces 1O2 and 
other ROS namely hydroxyl radical (•OH), superoxide anion (•O2
-) and hydrogen 
peroxide (H2O2) through interaction with endogenous photosensitisers such as 
porphyrins in exposed tissues (Tyrrell, 1991; Tyrrell, 1994; Black, 1987; Trenam et 
al, 1992, Yasui et al, 2000).  
Absorption of UVA by biomolecules may have two different outcomes: 
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1. Formation of reactive species in a metastable excited state. 
2. Production of free radicals. 
Both of the above are formed extremely fast, since chemical reactions usually occur 
within microseconds but could last for hours. These fast processes are eventually 
translated into photobiological responses which could occur in seconds but can take 
years to become apparent i.e. cancer. 
Amongst the intracellular ROS that are generated by UVA, 1O2 and H2O2 are thought 
to be the most important species, promoting biological damage in exposed tissues 
via iron-catalysed oxidative reactions (Vile and Tyrrell, 1995). It has been 
demonstrated that physiologically relevant doses of UVA, induce lipid peroxidation in 
membranes of human primary fibroblasts and keratinocytes via pathways involving 
iron and 1O2 (Vile and Tyrrell, 1995; Morlier et al, 1991; Punnonen et al, 1991).  
In relation to UVA, current data suggests that •O2
- is not involved in any of the cellular 
effects mediated by UVA, including lipid peroxidation and protein oxidation (Vile and 
Tyrrell, 1995; Giordani et al, 1997). 
Immediate cellular effects of physiologically relevant doses of UVA include depletion 
of cellular glutathione (GSH) content, membrane lipid peroxidation and alteration in 
nuclear transcription factor activity and gene expression (Tyrrell, 1996; Vile & Tyrrell, 
1995; Djavaheri et al, 1996; Wlaschek et al, 1997; Klotz et al, 1997).The potential 
that UVA has in photokilling by GSH depletion provides further evidence for ROS 
involvement in UVA effects (Tyrrell and Pidoux, 1988). The UVA-induced generation 
of 1O2 has been shown to play an important role in UVA-induced peroxidation of 
membrane lipids of cultured human skin fibroblasts as well as activation of nuclear 
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transcription factors such as nuclear factor kappa-B (NF-kappaB) (Gaboriau et al, 
1995; Reelfs et al, 2004).  
A major consequence of UVA irradiation of human skin cells is the immediate 
release of chelatable ‘labile’ iron (LI) in the cytosol that appears to exacerbate the 
oxidative damage exerted by ROS generated by UVA. The UVA-mediated increase 
in LI in human skin fibroblasts plays a key role in activation of NF-kappa B and UVA-
induced necrotic cell death (Pourzand, 1999; Zhong, 2004; Pourzand and Tyrrell, 
1999; Reelfs et al, 2004; Reelfs et al, 2010). Studies with iron chelators have further 
demonstrated that iron-catalysed ROS are also certainly involved in UVA-induced 
NF-kappaB activation, membrane damage and cell death (Reelfs et al, 2004; Zhong 
et al, 2004; Yiakouvaki et al, 2006; Reelfs et al, 2010).    
 
1.3.3. Cell Death: 
The cells which form a multicellular organism belong to a very highly controlled 
community. This is controlled not only by maintaining the rate of cell division but also 
controlling the rate of cell death. Cell death is a normal part of development which 
continues throughout life and this loss is replaced by cell division. It is now evident 
that cell death may occur via different pathways. Historically three distinct ways of 
cell death have been identified in mammalian cells by morphological criteria. 
1) Apoptosis: Also named type I cell death, is a programmed cell death that often 
occurs in multicellular organisms (Douglas, 2011). The morphological 
changes include chromatin condensation and fragmentation which results in 
an overall shrinkage of cell, blebbing of the plasma membrane and thus 
formation of apoptotic bodies that includes nuclear or cytoplasmic material. 
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Apoptosis is a tightly controlled, energy-consuming process of suicidal cell 
death involving activation of hydrolytic enzymes such as proteases and 
nucleases leading to DNA fragmentation and degradation of intracellular 
structures (see Reed, 2000). 
2) Autophagic Cell death: otherwise known as type II cell death, is described by 
a huge accumulation of double membrane vacuoles otherwise called 
autophagosomes which would in turn fuse with lysosome vacuoles 
(Proskuryakov et al, 2003).  
3)  Necrosis: or type III cell death that leads to the premature cell death in living 
tissues (Proskuryakov et al, 2003). Necrosis is considered as an irreversible cell 
injury and concludes in dense clumping and disruption of genetic material. 
Typical morphological changes include cytoplasmic swelling and vacuolation, 
degradation of plasma membrane, dilation of organelles i.e. mitochondria. Upon 
swelling of cells they burst open and thus elicit a damaging inflammatory 
response (Festjens et al, 2006). Furthermore during necrosis an elevated level of 
intracellular calcium is observed which generally accumulates within the cytosol 
which in turn triggers mitochondrial calcium overload, resulting in inner 
mitochondrial membrane depolarization and prevention of ATP production 
(Orrenius et al, 2003). Increased calcium levels will in turn activate calcium-
dependent proteases, (e.g. calpains), and calcium fluxes, ATP depletion and 
oxidative stress are results of this. These events that occur inside the cell often 
happen under excessive trauma. Necrosis can also be the result of death 
receptor activation or chemotherapy. These were conditions that were originally 




Table 1.1 shows some distinctive features of apoptosis versus necrosis. 
Table 1.1. Morphological, biochemical and physiological features in apototic and necrotic cells 
Apoptosis Necrosis 
Morphological features 
- Membrane blebbing, no loss of integrity 
 
Loss of membrane integrity 
Aggregation of chromatin at the nuclear 
membrane 
No chromatin aggregation 
Begins with shrinking of cytoplasm and nucleus 
condensation 
Cytoplasm and mitochondrial swelling 
Preservation of mitochondria Swelling of organelles 
Formation of apoptotic bodies Total cell lysis 
Biochemical features 
Tight regulation involving mediators and 
enzymes 
 
Loss of ion homeostasis 
Energy (ATP) dependent (active process) No energy required (passive process) 
Non-random inter-nucleosomal DNA 
fragmentation. 
Random digestion of DNA 
 
Release of some mitochondrial proteins i.e. 
cytochrome C 
 
Oxidative stress, calcium overload, ATP 
depletion 
Activation of caspase cascade Activation of calcium depletion proteases 






Removal of damaged, transformed or infected 
cells 
 
Back up mechanism of apoptosis failure 
Initiates via physiological stimuli Induced by severe physical or chemical injuries 
Phagocytosis by adjacent cells or macrophages Phagocytosis by macrophages 
No inflammatory response Extreme inflammatory response 
    Note: Adapted from “Apoptosis, cell toxicity and cell proliferation”, fourth edition, Roche. 
 
 
1.3.4. PDT and Cell Death 
Cell death in PDT may occur by apoptosis or necrosis, depending on the PS, PDT 
drug-light dose and on the cell genotype (Almeida et al, 2004). Necrosis is the 
pathological process, which occurs when cells are exposed to a serious of physical 
or chemical insults whereas apoptosis or programmed cell death is the physiological 
process responsible for the elimination of superfluous, aged or damaged cells.  
Apoptosis was initially determined as the main mode of cell death caused as a result 
of PDT in various experimental settings applying different PS and cell types (Oleinick 
et al, 2002). It was however, the only form of cell death investigated in many of these 
studies. Recent research studies suggest that depending on the PDT conditions, 
cells may also die by necrotic cell death. Indeed increasing amounts of experimental 
data indicate that at optimal PDT conditions such as sufficient PS concentration and 
light exposure, tumour cells die mainly by necrosis (see Nowis et al, 2005). Induction 
of necrosis post-PDT is in fact desirable. This is not only due to the finding that 
tumour cells are resistant to apoptosis (Ahn et al, 2004), but also due to the fact that 
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necrosis also triggers a potent inflammatory response which may result in tumour-
specific immunity (Krishna et al, 2012). Factors influencing necrosis may include 
extra-mitochondrial localization of PS, high dose of PDT, and glucose starvation 
(Almeida et al, 2004; Dellinger, 1996; Kiesslich et al, 2005; Oberdanner et al, 2002; 
Kirveliene et al, 2003; Plaetzer et al, 2002), although the research in this field is still 
ongoing.  
Apoptotic cell death in PDT is mostly observed with PS that accumulate in 
mitochondria (Krieg et al, 2003; Fabris et al, 2001). Increasing the concentration of 
the PS and the light dose usually changes the mode of death from apoptosis to 
necrosis. The latter appears to be related to the availability of intracellular ATP 
following PDT, as the progression of cell death to apoptosis or necrosis is known to 
be dependent on the effect that the damage to the mitochondrial membrane imposes 
on the cellular level of ATP (see Reed et al, 1998). Damage to the mitochondrial 
membrane triggers a series of events that include opening of a high conductance 
permeability transition pore in the inner membrane of the mitochondria and release 
of cytochrome c from these organelles. These events lead to interruption of electron 
chain transport resulting in ROS production, loss of electrochemical gradient across 
the inner membrane leading to ATP depletion followed by necrosis (see Reed, 1999 
and Reed et al, 1998). As the presence of ATP is essential for the activation of 
apoptosis protease activating factor-1 (Apaf-1) and subsequent activation of 
caspases that induce apoptosis (see Pourzand and Tyrrell, 1999 ; Reelfs et al, 
2010), it appears that the high PDT dose insult ( i.e. causing ATP depletion as a 
result of severe damage to the mitochondrial membrane as well as glucose 
starvation (i.e. interrupting the main supply of intracellular ATP) may trigger 
predominantly necrotic cell death in treated cells/tissues. Therefore the extent of 
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photochemical damage to cellular targets involved in energy supply especially 
mitochondria may be the crucial determinant for the mode of cell death.  
For example, in a study by Plaetzer and coworkers (2002) using a human 
epidermoid carcinoma cell line, it has been shown that in cells treated with a 
phthalocyanine-based PS, the intensity of light dose is a major determinant of mode 
of cell death after PDT, depending on the changes occurring in mitochondrial 
function and intracellular ATP. With a moderate dose of light, 50% of cells died by 
either apoptosis or necrosis, but at a higher light dose, cells exclusively died by 
necrosis. The study of mitochondrial function and intracellular level of ATP in the PS-
treated cells revealed that after PDT, necrosis was associated with a rapid decrease 
in mitochondrial activity and intracellular ATP, while with apoptosis, the decline in 
mitochondrial activity was delayed and the ATP level was maintained at near control 
levels.  The results of this study indicate that the magnitude of light dose rather than 
the type of PS plays an important role in the decision of the cell to undergo either 
apoptotic or necrotic cell death after PDT. Hence, apoptosis and necrosis may not 
necessarily be two independent pathways and may even share common events, at 
least in the early phases of the cell death process. This assumption is endorsed by a 
series of studies demonstrating that the magnitude of initial insult of various oxidants 
could be the main determinant of apoptotic and/or necrotic cell death processes (e.g. 
Bonofoco et al, 1995; Hampton et al, 1997).   
Kirveliene and coworkers (2003) demonstrated that in a murine hepatoma cell line, 
the intracellular ATP concentration correlates with the mode of cell death in cells 
treated with PS that localise to mitochondria but not to lysosomes. Photosensitisation 
of cells with TPPS4 (meso-tetra(4-sulfonatophenyl)-porphine) that localises to 
lysosomes caused necrotic cell death and the mode of cell death was independent of 
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the energy metabolism. In contrast, photosensitisation of cells with ALA that localises 
predominantly in mitochondria, under conditions favourable to glycolysis, led to cell 
death by apoptosis, however under conditions unfavourable to glycolysis (ATP 
depletion), caused necrotic cell death. These data suggest that in ALA-mediated 
PDT, intracellular ATP level and caspase activation are the downstream controllers 
of the mode of cell death, directing the photosensitised cells toward either apoptotic 
or necrotic cell death depending on intracellular ATP availability.  
Nevertheless in general in PDT, during the illumination, the photo-bleaching of the 
PS as well as vasculature stasis and tumour oedema can decrease the    
concentration of PS. Under these conditions as well as in deep tumour regions 
(illuminated with suboptimal light from the very beginning of treatment), the 
effectiveness of PDT is compromised and tumour cells will either oppose or repair 
damage induced by the treatment. Upon damage repair, tumour cells will survive the 
treatment and will contribute to tumour relapse (if not damaged by lethal ischemia or 
activation of immune response) (Nowis et al, 2005). In all other cases tumour cells 
will undergo apoptosis or necrosis, depending on the severity of the PDT insult and 
ATP depletion. 
 
1.3.5. Photosensitisers in PDT: 
1.3.5.1 First Generation Photosensitisers 
The use of porphyrin-based photosensitisers, with which many clinical studies have 
been conducted in PDT, was first introduced in 1961 by Lipson and coworkers. 
Through the period of 1961-1983, hematoporphyrin (HP) and its derivatives were the 
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most common photosensitisers used in PDT research (see Bonnett, 1999). 
Therefore these tetrapyrroles comprise the first generation of photosensitisers. 
In 1960, HP was purified and solubilised by Lipson and Baldes by treatment with 5% 
sulphuric acid in acetic acid, then basification and neutralization to pH 7.4 with 
hydrochloric acid. The purified compound was called hematoporphyrin derivative 
(HPD) which had a better affinity for tumour cells than HP, and it could also be 
visualised by fluorescence endoscopy when injected into the tumour (Lipson et al, 
1961). In 1972, Diamond and colleagues suggested that the combination of tumour 
localizing and tumour phototoxic properties of porphyrins might be exploited to 
diminish cancer cells (Diamond et al, 1972). In 1978, a study was carried out by 
Dougherty and co-workers which demonstrated that parenterally administered HPD 
could be activated by light in the red region of the spectrum (630 nm) to cause 
complete eradication of spontaneous or transplanted mammary tumours in mice and 
rats (Dougherty et al, 1978). Meanwhile, Kelly and co-workers found that light 
activation of HPD also eliminated bladder carcinoma in mice (Kelly et al, 1975). 
These studies classified HPD as the benchmark PS for the development of 
forthcoming drugs (see Kalka et al, 2000 and Dolmans et al, 2003). 
HPD is a complex mixture, thus a further chemical purification allows better 
penetration. The purified compound known as Photofrin has shown enhanced 
photosensitising properties (see Liu, 1992; Dougherty, 1987). Photofrin was the first 
approved photosensitising drug for clinical PDT of lung, gastric and cervical cancer 





1.3.5.2 Second Generation Photosensitisers 
The poor selectivity of first generation photosensitisers between tumour and normal 
tissue, and their long clearance time that led to prolonged skin photosensitivity in 
subjects, stimulated the design of improved synthetic photosensitisers for PDT. 
These compounds are referred to as ‘second generation photosensitisers’.    
Second generation photosensitisers have been designed to assure these 
compounds are pure and also able to absorb at higher wavelengths i.e. far red (660-
700 nm) or near infrared (700-850 nm) regions of the spectrum. This also allows 
deeper penetration of activating light (up to 20 mm compared to 5-10 mm in 630 nm) 
into tissues than the first generation photosensitisers. This would thus provide more 
efficient therapeutic effects subject to the presence of a sufficient amount of oxygen 
(Nyman and Hynninen, 2004; Wilson et al, 1984). 
Furthermore, unlike the photosensitisers that absorb in the visible range, the ability 
of second generation photosensitisers absorbing within the near-infrared range 
allows the treatment of highly pigmented tumours such as melanoma metastases. 
Light with a wavelength longer than 850 nm is not typically used however because it 
does not yield enough energy to trigger a photochemical reaction (Calzavara-Pinton 
et al, 2007).  
 
The second generation of photosensitisers comprise families of molecules such as 
modified porphyrins, bacteriochlorins, phthalocyanines, naphthalocyanines, 
pheophorbides and purpurins. These photosensitisers have been used as PDT 
agents in clinical trials to treat various cancers including cutaneous malignancies. 
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A brief description of these photosensitisers is provided below. 
-  Phthalocyanines and naphthalocyanines: This group of photosensitisers contain 
four benzene or naphthalene rings joined to the π-pyrrolic framework of porphyrins, 
with the methine bridge carbons replaced with nitrogens (see Figure 1.5). These 
compounds are known to absorb light at longer wavelengths than simple porphyrins, 
and for this reason may be used in much smaller doses than photofrin (i.e. 4-5 folds 
lower than photofrin). Their absorption at higher wavelengths than 400-600 nm also 
lowers the risk of generalised photosensitivity with sunlight compared to porphyrins 
(Moan and Berg, 1992; Jori, 1992). 
 
Figure 1.5. Chemical structures of phthalocyanines and naphthalocyanines relevant to PDT. (Source: 




There have been some promising effects seen by application of phthalocyanines for 
PDT of cancer. The incorporation of diamagnetic metals such as Zn or Al into the 
phthalocyanine macromolecule increases the half-life of the triplet state and in turn 
increases the yield of 1O2 generation to obtain sufficient photosensitisation and 
resulting phototoxicity in the target tissue (see Jori, 1992). One such derivative is 
AlPcS2 (chloroalmunium sulphonated phthalocyanine).The advantages of these 
compounds may be defined in terms of higher chemical stability, superior direct 
tumour cell phototoxicity, and a strong absorption peak in the red spectrum (650-700 
nm), which assures deeper penetration into the tissue in comparison to porphyrins 
(Spikes, 1986; Oleinick et al, 1993; Rosenthal, 1991). These properties together with 
negligible dark toxicity and excellent photodynamic activity at increased wavelengths 
has resulted in clinical evaluation of AlPcS2 for PDT (Ben-Hur E, 1992; Gerber-
Leszczyszyn et al, 2004). A recent study by Shao and colleagues (2012) has 
focused on developing a new photosensitiser namely “photocyanine” that has 
evolved from meta phthalocyanine that is specifically designed for the treatment of 
cancer and has been tested on hepatocellular carcinoma (HCC) HepG2 cells. The 
chemical structure of photocyanine is shown in Figure 1.6. 
 
Figure 1.6. Chemical structure of Photocyanine. 
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Photocyanine has a high photodynamic activity and low dark toxicity. It is only 
excited at a wavelength of 670 nm, therefore no side effects are produced upon 
exposure to light in the visible range. Once excited, photocyanine has a high 
quantum yield and an appropriate half-time. Furthermore it has a very high selectivity 




- Chlorin and Bacteriochlorin derivatives: 
Chlorins are dihydroporphyrins that are formed by reduction of a peripheral double 
bond in the porphyrin skeleton. This moves the absorption peak to the red (Nyman 
and Hynninen, 2004). Amongst the chlorin derivatives, the meta-tetrahydroxyphenyl 
chlorine (m-THPC) is widely used in the treatment of respiratory, and head and neck 
cancers (see Hopper, 2000 and Figure 1.7). m-THPC (Temoprofin, Foscan®; 
Biolitech Pharma, Edinburgh, Scotland, UK) is a pure compound which is 200-fold 
more effective than Photofrin (see Sharman et al, 1999). It is excited at higher 
wavelengths than Photofrin (650 nm rather than 630nm) and has a higher molar 
absorption coefficient (i.e. 15-fold higher). Also with its higher half-life in the excited 
triplet state and higher hydrophobicity which makes the cellular uptake easier, it has 
shown much improved features for use in dermatological treatments (e.g. Copper et 
al, 2003; Campbell et al, 2004). A water-soluble formulation of m-THPC named 
Fospeg®, shows much reduced dark toxicity in comparison to Foscan® but a similar 
phototoxic efficiency. Both these compounds have been shown to induce apoptosis 
in the epidermoid carcinoma cell line, A431 over a wide range of fluences (Allison et 
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al, 2004; Berlanda et al, 2010). Nevertheless the residual photosensitivity of m-






Figure 1.7. Chemical structure of meta-tetrahydroxyphenyl chlorin (m-THPC). 
 
 
A number of companies have also developed promising bacteriochlorins with 
improved optical properties absorbing light at more than 740 nm that might be 
particularly useful for PDT of pigmented tumours (see Jori, 1992 and Figure 1.8). 
Amongst these compounds, SQN400 (trade name for meta-tetra-hyroxyphenyl 
bacteriochlorin; mTHPBC) has been used in some clinical phase I studies (e.g. van 




Figure 1.8. Completely synthetic chlorin and bacteriochlorin drivatives that have been proposed for PDT. 
(Source; Nyman and Hynninen, 2004). 
 
Figure 1.9. Chemical structure of meta-tetra-hydroxyphenyl bacteriochlorin (mTHPBC). 
- Other porphyrin- and chlorophyll-derived photosensitisers:  
Among synthetic porphyrins, porphines exhibit high photosensitising and anti-mitotic 
potency in tumours (see Kreimeier-Birnbaun, 1989). TPPS4 (tetra-sodium-meso-
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tetraphenylporphine-sulfonate) is a member of this family. Despite its hydrophilic 
nature, it has been investigated for the treatment of skin tumours (Santoro et al, 
1990). TPPS4 is activatable at 630 nm and localizes preferentially in the tumour 
stroma (Kessel et al, 1987). Furthermore in comparison to HPD, it is highly effective 
as a PS (Calzavara-Pinton et al, 2007). The major limitation of TPPS4 is its 
neurotoxicity (Lui and Anderson, 1992). 
 
The benzoporphyrin derivative monoacid ring A (BPD-MA) that is also known as 
verteporphin (Visudyne®, Novartis AG, basel) is a semi-synthetic porphyrin derived 
from protoporphyrin (Henderson and Dougherty, 1992) (see Figure 1.10). Because 
of its poor solubility, this PS has been formulated successfully either in liposomes or 
emulsions (Knobler et al, 1999). BPD-MA has an absorbance peak at 650 nm and is 
used in the treatment of choroidal neovascularisation in age-related macular 
degeneration (AMD). This PS has also been evaluated for PDT of BCC and SCC 
(Kalka et al, 2000). Phase III clinical trials (see Gerber-Leszczyszyn et al, 2004) 
have shown that injectable BPD-MA provides a significant and rapid accumulation in 
the tumour and a low residual skin photosensitivity, and the overall cosmetic effect 
has been found acceptable. 
                                   
Figure 1.10. Chemical structure of benzoporphyrin derivative monoacid ring A (BPD-MA). 
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Porphycenes are structural isomers of porphyrins and texaphyrins are modified 
porphyrins in which a phenyl ring replaces one pyrrole ring. Porphycenes have 
potential to be used as diagnostic tools (Palumbo, 2007) as they possess high 
fluorescence yields and show a 10-fold increase in light absorption at 630 nm when 
compared with HPD (Kreimer-Bimbaum, 1989). The porphycene dye 9-acetoxy-
2,7,12,17-tetrakis-methoxyethyl-porhycene has also been evaluated for potential 
topical PDT of  skin lesions (Karrer et al, 1997) (see Figure 1.11).  
                                      
Figure 1.11. Chemical structure of 9-acetoxy-2,7,12,17-tetrakis-methoxyethyl-porphycene. 
 
Texaphyrins can easily be complexed with large metal cations such as Lu (III) to give 
metal complexes that are photoactive in vivo (Nyman and Hynninen, 2004). The 
Lu(III)-complex of a texaphyrin, also known as Lu-Tex or Lutryn® (Pharmacyclics 
Inc., CA, USA; see Figure 1.12) is a highly fluorescent dye. It absorbs strongly at 
732 nm (Woodburn et al, 1996), and rapidly accumulates in neoplastic tissue 
allowing irradiation within 2-4 h after administration (Kalka et al, 2000). One of the 
main advantages of Lu-Tex is its lack of persistent skin phototoxicity (Sessler and 
Miller, 2000). As a result, Lu-Tex has been evaluated in the therapy of various 
malignancies, such as recurrent breast cancer, invasive SCC, malignant melanoma, 
Kaposi’s sarcoma and BCC. These evaluations have demonstrated the best 
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response rates in breast cancer lesions and partial responses in other treated 
tumours (Renschler et al, 1997; Palumbo, G, 2007). Lu-Tex is known to cause 
severe cutaneous pain during PDT however (Kreimer-Bimbaum, 1989).  
                               
Figure 1.12. Chemical structure of Lu (III) texaphyrin (Lu-Tex). 
 
Pheophorbides are a group of chlorophyll-derived photosensitisers. Within this group 
of photosensitisers, 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) has 
been assessed successfully in Phase II clinical trials (NCT00281736) for the 
treatment of oesophageal cancers with very mild skin photosensitivity declining 
rapidly within days (Bellinier et al, 2005). HPPH-23 is a promising member of this 
group for the management of skin cancer. This PS has been successfully used in 
PDT of SCC in animal studies and has the advantage of being rapidly cleared from 
normal skin (Magne et al, 1997).  
Hypericin (see Figure 1.13) is another PS that is recognised as a potent agent in 
PDT of cancer. It is a naturally occurring substance found in plants (Hypericum 
perforforatum) that possesses strong photosensitising properties, a high yield of 1O2 
and fluorescence emission. These properties of hypericin make it a powerful tool for 
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photodiagnosis of small tumors (e.g. urothelium) (Kubin et al, 2005; Olivo et al, 2003; 
Palumbo, 2007).   
                                               
Figure 1.13. Chemical structure of Hypericin 
 
More current studies have been carried out to try and focus on improving the 
photosensitisers to increase the efficiency of PDT. For example Parihar and 
colleagues (2013) have used a chlorin p6-histamine conjugate (Cp6-his) for improving 
cellular uptake and phototoxicity of Cp6 in an oral cancer cell line. This 
photosensitiser belongs to the chlorin family of photosensitisers and chlorin p6 itself, 
has a very basic tetrapyrrole stucture. In the study mentioned above, it was applied 
intravenously, where the affected tissue was illuminated with red light (660±25 nm, 
100 J/cm2). Its advantages were quick clearance from the body, ~80% 48 h post 
treatment, and also treating bigger tumours (up to 1000 mm in size). It also had a 
very high tumour selectivity.  
1.3.5.3. Topical Photosensitising Mediators: Aminolevulinic Acid and esters: 
An alternative method of photosensitising cells is to stimulate the synthesis of the 
endogenous photosensitiser protoporphyrin IX (PPIX). PPIX is the immediate 
precursor of heme.  Administration of exogenous δ-aminolevulinic acid (ALA) that is 
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an intermediate of the heme biosynthetic pathway can bypass the negative feedback 
control of heme, therefore resulting in intracellular accumulation of photosensitising 
concentrations of PPIX. The photosensitisation obtained by this treatment regimen, 
provided a basis for application of ALA-induced PPIX for PDT of cancer (Malik and 
Lugaci, 1987; Kennedy et al, 1990; Wolf and Kerl, 1991; Peng et al, 1997). 
In ALA-mediated PDT, the porphyrin precursor ALA or its methyl ester derivative, 
(MAL) is administered topically to the skin. ALA can penetrate the skin cells through 
the cell membrane with its chemical composition intact. On the other hand its ester 
derivative MAL once administered goes through a hydrolysis reaction in the 
cytoplasm of tumour cells to release ALA. ALA then goes through a series of 
intermediate reactions which are catalysed by various intracellular enzymes to form 
PPIX. The intracellular accumulation of this PS should then be more concentrated in 
the target tissue (Matei et al, 2013). Supplementation of ALA is followed by 
application of a light source, often red (630-635 nm laser) or blue (380-420 nm) to 
the tumour tissue. In the case of a positive treatment response, the photochemically 
generated ROS formed, will diminish the tumour tissue sparing the surrounding 
normal structures. 
The fluorescence of ALA-induced PPIX can also be used for the purpose of 
diagnostic detection of tumour cells, i.e. in early stages of skin malignancies. This 
procedure, termed photodynamic diagnosis (PDD), allocates the poorly defined 





1.3.5.3.1. Heme Metabolism  
The heme biosynthetic pathway is initiated by the rate-limiting reaction between 
glycine and succinyl-coA to produce ALA by a condensation reaction. This enzymatic 
reaction is catalysed by the enzyme ALA-synthase (Cotter et al, 1992), which is 
regulated via negative feedback mechanism by heme. (See Figure 1.14). 
 
Figure 1.14. Synthesis of delta-aminolevulinic acid (ALA) from glycine and succinyl coA catalysed by   
ALA-synthase. 
Figure 1.15. Illustrates the heme biosynthetic pathway. Following its synthesis, ALA 
exits the mitochondria and enters the cytosol (see Figure 1.15). The next reaction 
takes place by joining of two molecules of ALA to form the monopyrrole 
porphobilinogen (PBG) via another condensation reaction which is catalysed by 
aminolevulinate-dehydratase enzyme (ALAD) (Erskine et al, 1999; Frankenberg et 
al, 1999). A polymer of four molecules of PGB is generated in the cytosol by the 
combined action of the enzymes PBG-deaminase (PBGD) and uroporphyrinogen III 
co-synthase, which is followed by cyclisation of the tetrapyrrole chain to form 
uroporphyrinogen III (Xu et al, 1995). The next product named coproporphyrinogen 
III is formed by removal of four acetic acid carboxyl groups, catalysed by 
uroporphyrinogen decarboxylase (Moore et al, 1987). The subsequent steps in this 




step takes place on the inner surface of the inner mitochondrial membrane where 
iron is brought into PPIX by the enzyme ferrochelatase to produce heme. If an 
excess of PPIX is synthesized, it can diffuse from the mitochondrion into the 
endoplasmic reticulum and also into the plasma membrane, both of which are the 












Figure 1.15. Heme biosynthesis pathway.  
(modified from:https://www.microbewiki.kenyon.edu/index.php/mitochondria) 
 
1.3.6. Topical ALA-PDT 
The most important advantage of application of topical ALA-PDT over the systemic 
HPD/ Photofrin-PDT is the non-existence of the prolonged cutaneous 





reported by patients, whereas this is clearly seen in the systemic HPD/ Photofrin-
PDT up to 4-6 weeks post-treatment. Furthermore, patients treated with systemic 
HPD/ Photofrin-PDT often have to be kept in hospital for a few days unlike the 
patients that have undergone topical ALA-PDT who may be discharged immediately. 
ALA-PDT is relatively inexpensive since the light source used for this treatment may 
be ordinary lamps with the appropriate filters, whereas for HPD/ Photofrin-PDT 
lasers are usually applied as the light source which are much more costly to buy and 
maintain.  
ALA-PDT has been shown to have a very high selectivity for tumour tissues sparing 
the surrounding normal structures, and the porphyrins generated accumulate 
predominantly in the target tissue after administration of exogenous ALA. Also with 
this treatment modality, either a few individual lesions may be targeted and treated at 
the same time or a repeated treatment may be performed on the same lesion. 
The mechanism of ALA penetration through tissues after topical application is not yet 
fully understood, however the fluorescence of ALA-mediated PDT in both normal and 
malignant tissue has shown to increase with time after topical ALA application, 
reaching a plateau within 4-14 h, depending on ALA concentrations used (2-40%) in 
formulations, the amount to be applied (30-50 mg/ cm2), and application time (up to 
24 h) used (Orenstein et al, 1995; Morton et al, 1995; Peng et al, 1997). When ALA 
is topically applied and incubated for up to 4 h the PPIX accumulation will be locally 
at the site of interest. However longer incubation periods with ALA (up to 14 h) or 
when combined with skin penetration enhancers i.e. DMSO, results in a more 
generalised photosensitisation of the skin (Orenstein et al, 1995; Peng et al, 1997).  
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Generally ALA-induced PPIX fluorescence cannot be detected in the skin 24 h after 
completion of topical ALA application.  There is no proof of ALA’s toxicity when 
concentrations < 50% in water/oil emulsion by weight are topically applied for at least 
48 h. Moreover, there is no evidence for toxicity of ALA-mediated PPIX accumulation 
on tissues before light exposure (Peng et al, 1997). Cellular studies have 
demonstrated that ALA can be administered at very high concentrations without 
producing cytotoxic effects in the dark. At concentrations lower than 3 mM, no dark 
cytotoxic effects could be observed (e.g. Pourzand et al, 1999b, Berlanda et al, 2010 
and the present study). The intracellular production of PPIX is almost linear over  
incubation time (up to 30 h), while the accumulated PPIX from the ALA application 
degrades quite rapidly, and therefore decreasing the length of light sensitivity after 
PDT. Another advantage of ALA-induced PPIX is that it is only produced in living 
cells, which is beneficial for treatment of cells without production of ROS in the 
surrounding extracellular matrix (Berlanda et al, 2010).    
While topical ALA-PDT has been shown to have a good cosmetic outcome, it is more 
suitable for superficial lesions than nodular tumours in comparison to HPD/Photofrin-
PDT (Peng et al, 1997). The optimal concentration of ALA for topical application and 
also the incubation period with ALA depends on the characteristic of the targeted 
cells. For example, abnormal keratin shows increased permeability to ALA, which is 
partly responsible for the tumour selectivity. Ironically, this phenomenon contributes 
to a major limitation of ALA-PDT; the poor ALA penetration through intact keratinised 
surface layers of nodular tumours may be responsible for the therapeutic refractivity 




ALA’s hydrophilic nature limits its penetration into tissues. In mammalian cells ALA is 
taken up by cells via active transport mechanisms, i.e. Na+/Cl--dependent beta-
amino acid, including glycine and gamma-aminobutyric acid (GABA) transporters 
(Rud et al, 2000). These systems of uptake seem to be more activated in tumour 
cells; nevertheless they are saturable and slow processes that need energy in order 
to function, as well as depending on pH and temperature (Kloek and van 
Henegouven, 1996; Gaullier et al, 1997; Uehlinger et al, 2000).  
To overcome this problem, the use of ALA-esters i.e. methyl aminolevulinate (MAL) 
which are lipophilic has improved the penetration of the drug through the skin and 
moreover known to selectively accumulate in neoplastic tissues similar to that of 
ALA. 
The methyl ester of ALA, MAL, must be hydrolysed at some stage to release the 
ALA to be absorbed by the targeted tissues, but it is not known at which step this 
mechanism of hydrolysis takes place (Ericson et al, 2008). 
An example in WiDr adenocarcinoma cells shows that MAL gets to the targeted 
tissue via active mechanisms particularly through transporters of non-polar amino 
acids such as L-alanine, L-methionine, L-tryptophan and glycine (Gederaas et al, 
2001). An alternative route of MAL uptake by the cells is by passive trans-membrane 
diffusion which does not require any energy, and is also very efficient in normal cells 
and even to more extent in neoplastic cells. The plurality and efficiency of these 
diverse mechanisms determine the enhanced penetration characteristics of MAL in 
comparison to ALA which could even be seen more significantly in malignant cells 
(Peng et al, 1997). The process of de-esterification of MAL to ALA occurs quickly 
after absorption of the drug by cells, and from then on the metabolic steps remain 
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the same as for ALA (Gaullier et al, 1997). In addition ALA-ester derivatives achieve 
maximum intracellular PPIX concentrations with shorter incubation times of around 3 
h compared to ALA (i.e. 4-6 h) (Juzeniene et al, 2002).  
The stratum corneum (SC), the outer skin layer, seems to be a major factor in 
selectivity of uptake since it has an important impact on the penetration of ALA and 
its methyl esters through the skin (Moan et al, 2001). BCC and SCC cause 
abnormalities to the keratin layer and as a result lead to faster penetration of ALA 
through the SC. However the adjacent normal SC which is intact seems to allow 
slower uptake. This has been confirmed in vivo (Wennberg et al, 2000). There is 
evidence suggesting that MAL is more selective towards neoplastic tissues than ALA 
(Angell- Petersen et al, 2006), however there are not enough comparative studies to 
back this up. 
There are two examples of studies evaluating the efficiency of MAL-PDT in treating 
difficult lesions. Horn and colleagues (2003) evaluated 123 recurrent BCCs, in a mid-
face location or on severely sun-damaged skin. The response to MAL-PDT was 
excellent, with a 3-month CR (clearance rate) in sBCCs of 85% (40/47), nBCCs of 
75% (38/51). A follow up response to the treatment was carried out at 24 months, 
which showed a CR of 78% for sBCCs (28/36) and 86% for nBCCs (24/28). The only 
factor affecting the excellent response was the diameter of the lesions. At 24 months 
follow up, the lesions larger than 30 mm obtained a 66% CR regardless of the site of 
occurrence. Also Vinciullo and colleagues (2005) carried out the treatment of 33 
patients with BCCs. At 24 month follow up they had obtained 86% CR in all patients 
with a lower response for the lesions located on the face/ scalp (54%), but a higher 
response to the ones on the trunk/ neck (88%). They also found the direct 
relationship between the increase of diameter and decrease of response to the 
65 
 
therapy with 84% of lesions at 3-10 mm, 80% at 11-20 mm and 70% clearance at 
20-62 mm.  
Because of the significant results obtained from preclinical and clinical studies (e.g. 
Hongeharu et al, 2000), in 2003, ALA-PDT has also been approved for moderate 
inflammatory acne vulgaris in USA.  
The efficiency of ALA/MAL-PDT for the treatment of superficial BCC, nBCC, AK and 
BD has been repeatedly demonstrated in a large number of preclinical and clinical 
studies that have been carried out in the past 15 years. With the exception of 
surgery, MAL-PDT has the best outcome for the long term cure of NMSC (Stebbins 
et al, 2011).  
A number of other non-malignant conditions such as psoriasis, viral warts and hair 
removal have also been under clinical investigations worldwide for more than a 
decade (e.g. Robinson et al, 1999; Stender et al, 1999; Stender et al, 2000; 
Hongeharu et al, 2000; Robinson et al, 1999; Huang, 2005). In addition to preventing 
the development of scars and the dys-pigmentation that occurs with surgery, ALA-
PDT has the added benefit of photo-rejuvenation and has been used as a treatment 
to soften the appearance of acne scars as well as fine lines and wrinkles of photo-
damaged skin (e.g. Alster et al, 2005; Dover et al, 2005).   
 
1.3.6.1. Various Light Sources Used for Topical ALA/MAL-PDT: 
The first ever light sources applied in PDT were  non-coherent light sources. Ever 
since, various different studies have been focussed on the effectiveness of long-
pulsed dye lasers. Not only do they require much shorter exposure times, but the 
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laser sources also give the user the option of choosing the optimal wavelength for 
their purpose. Flash-lamps are also commonly used in PDT of AK, photo-
rejuvenation and acne vulgaris (Alexiades-Armenakas, 2006). Table 1.3 provides an 
overview of light sources used in PDT. 
 
Table 1.3: Common light sources for PDT  
Non-coherent lamps Laser Other 
- Xenon lamps  
  (400-1200nm) 
- Halogen lamps  
(560-800nm) 
- Pulsed dye laser 
(PDL)     
  (585nm) 
- Long-pulsed dye laser  
  (595nm) 
- Argon dye laser (ADL)  
(450-530nm) 
- Diode laser  
(800-1000nm) 
- Intense pulsed light (IPL)   
   (500-1200nm) 
- Light emitting diode (LED)  
   (631 ± 2nm) 
-Fluorescence diagnosis 
systems 
Note: Modified from Klein et al, 2008 
 
Photodynamic management of dermatologic conditions is simplified by the 
accessibility of the skin to light application and offers the option to use any light 
device with the appropriate spectrum corresponding to the maximum absorption of 
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the PS. Non-coherent sources of light are taking over from the popular filtered slide 
projectors especially for their use in PDT. The PDT 1200 lamp (Waldmann) is a 
metal halogen lamp which emits 600-800 nm radiation at light power density of 200 
mW/cm2; keeping light exposure times within practical limits (see Stables, 1995). An 
alternative source of light for use in PDT is the short-arc xenon lamp with a band 
width of 400-1200 nm which is tunable (Whitehurst et al, 1993). 
Non-coherent light sources are safer, easy to use, and less expensive. They can 
produce spectra of wavelengths to be absorbed by different photosensitisers. The 
broad light beam produced by non-coherent lamps is useful for the treatment of large 
lesions using ALA-PDT. However the lower radiation power at the periphery of the 
treated lesion as opposed to the centre of the irradiation area may result in 
insufficient treatment of the tumour borders (Karrer et al, 1995). In the case of 
multiple lesions e.g. multiple AK on the scalp, it is important to deliver light from 
different directions to ensure the illumination of all the lesions. 
Non-coherent light sources can be used in conjunction with optical filters to output 
selective wavelengths. The disadvantages of conventional lamps include significant 
thermal effects, low light intensity and difficulty in controlling the light dose. However, 
nowadays, most of these drawbacks can be overcome by careful engineering 
design. For example it is known that non-laser light sources emit significant fluences 
of infrared radiation together with light useful for PDT (Stringer et al, 1995). Filtering 
out the infrared radiations would help in avoiding hyperthermia; however there is 
evidence that mild hyperthermia (40-42oC) brings an additional effect or works 
synergistically with PDT (Waldow and Dougherty, 1984; Kimel et al, 1992). The 
recommended fluence rate in order to avoid hyperthermia has been determined to 
be lower than 150 mW/cm2 (Peng et al, 1997). 
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As shown in Figure 1.16, PPIX’s biggest peak falls in to the blue region of 405-410 
nm (soret band), with smaller absorption peaks at 505, 540, 580 and 630 nm. Most 
light sources for ALA/MAL-PDT aim to utilise the 630 nm in the red region to improve 
the tissue penetration. However a blue fluorescent lamp called the BLU-Light 
illuminator (DUSA Pharmaceuticals, Inc), (peak emission 417 nm) is now routinely 
used in Levulan ALA-PDT of AK in USA. There are now several reports that blue, 
green and red light can each be effective in topical PDT of AK, but more deeply 
penetrating red light is superior when treating BD and BCC (Morton et al, 2002). 
 
Figure 1.16. The absortion spectrum of porphyrins (right) as exemplified by protoporphyrin IX (the 
chemical structure; left) (reproduced from Kormeili et al, 2004). 
 
Because of the use of ALA-PDT in the treatment of tumours at the surfaces of 
organs (i.e. the skin, bladder and aero-digestive tract), lamps may be as well suited 
as lasers. Unlike the traditional luminous lamps, lasers provide the exact selection of 
wavelengths to match the absorption of the PS of interest and the precise application 
of light. The tunable argon-dye laser (ADL) is composed of an argon laser that emits 
a blue-green beam in the 450-530 nm range, pumping a dye laser to obtain light in 
the range of the desired wavelength (see Kalka et al, 2000). Emission of light by ADL 
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is on a continuous basis and can be tuned to match the absorption properties of the 
PS of interest within the range of 350-700 nm, making it the most popular light 
device used in PDT (Fisher et al, 1995).  
The few advantages that non-laser light sources possess have made them very 
popular in topical PDT. These include their affordable price, stability, easy 
application, low maintenance and ability to provide wide area illumination fields. 
Retrospective comparison of laser and filtered broadband sources suggests 
equivalent efficacy in topical PDT (Clark et al, 2003). Non-laser light sources have 
also recently been used in ALA-PDT, as opposed to MAL-PDT which typically 
applies light emitting diode (LED) sources. 
In the last few years, LED sources have shown considerable development, with 
improvements in design making these relatively inexpensive sources convenient for 
wide area irradiation and popular for patient use, e.g. the Aktilite 16 and 128 
(Galderma, France) and the Omnilux (Phototherapeutics Ltd, Altincham, UK). These 
LED sources cover the 630/635 nm absorption peak of PPIX while excluding the 
extraneous wavelengths in broadband sources, therefore allowing shorter and 
quicker irradiation times. The light source used in PDT should generally present 
suitable characteristics to show that it does activate the PS of interest i.e. PPIX at 
the maximum absorption wavelength range in order to produce enough ROS to 
obtain a cytotoxic effect (Plaetzer et al, 2008). In photodynamic laser-mediated 
therapy usually longer wavelengths of light range are applied to the target tissues to 
assure increased penetration depth with minimum light scatter and maximum PS 
activation, which would result in tissue destruction and death (Ochsner, 1996). LED 
light sources with peak emission of 631± 2 nm may enhance a deeper PDT action in 
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tissue than a filtered halogen type lamp of 560-740 nm emission, making LEDs a 
more suitable option for treating deeper parts of tumours 
(Juzeniene et al, 2004). LEDs can generate high energy light of the desired 
wavelength and can be assembled in a range of geometries and sizes (Babilas et al, 
2006).  
An in vitro study was performed in cultured human epidermal keratinocytes where 
cells were incubated for 24 h with different concentrations of ALA and then exposed 
to either incoherent or LED light sources. In terms of cytotoxicity, there were no 
significant differences between the two light sources. In a subsequent in vivo 
investigation, patients with at least two AK lesions were exposed to these light 
sources (i.e. half to each light source). There was again no significant difference in 
remission rates, pain or cosmetic results (see Klein et al, 2008). Another study by 
Babilas et al (2007) looked at LED systems and flash lamps (VPL, variable pulsed 
light; Energist Ultra VPLTM, Energist Ltd, Swansea, UK) for the purpose of MAL-PDT 
of AK. Both light sources were similarly effective, however the pain experienced 
during and after the treatment was significantly less using flash lamp illumination 
than the side of lesion that was exposed to LED. A series of studies have suggested 
that pulsed light therapy may be useful for treatment /adjunctive treatment in topical 
PDT of acne vulgaris, AK and photo-rejuvenation (see Morton et al, 2008). Although 
in a recent controlled study done in healthy human skin in vivo post-
microdermabrasion and acetone scrub treatments, it was demonstrated that two 
pulsed light sources (i.e. the PDL and a broadband flash lamp filtered intense pulsed 
light (IPL)), showed minimal activation of PS, with significantly smaller photodynamic 
action than observed with a conventional wave broadband source (Strasswinner and 
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Grande, 2006). Furthermore IPL and PDL sources deliver intense light in periods (i.e. 
20 milliseconds), which might suppress oxygen consumption (Kawauchi et al, 2004). 
Buchczyk et al (2001) also compared the effectiveness of ALA-PDT in human 
cultured skin fibroblasts with three different light sources of (i) red light source (570-
700 nm; PDT1200 illuminator , Waldmann Litchttechnik, Germany) at an intensity of 
50 mW/cm2;  (ii) green light source (545 ± 3 nm; PDT Green Light, Saalmann, 
Herford, Germany) at intensities of 10-20 mW/cm2; (iii) UVA light (320-400nm; 
UVA700 illuminator, Waldmann Lichttechnik, Villingen, Germany) at intensities of 44 
(without ALA) and 10 mW/cm2 (with ALA). The results demonstrated that UVA-ALA-
PDT i.e. blue light is 40-fold more potent in killing cultured human fibroblasts than the 
red light source, and 10-fold more potent in killing in comparison with green light. 
The high level of cytotoxicity of UVA-ALA-PDT can be explained in terms of effective 
formation of 1O2 as was demonstrated with modulators of 
1O2 -half-life. Therefore 
ALA-PDT in the region of UVA (320-400 nm) may be preferable to red or green light 
for the purpose of treatment of readily accessible tissue due to its higher efficiency.  
The two major skin cells epidermal keratinocytes and dermal fibroblasts receive 
different amounts of radiation. The epidermal keratinocytes receive both UVA and 
UVB radiation while the dermal fibroblasts are significantly protected from UV 





Figure 1.17. The depth of penetration of UV and visible wavelengths into the different layers of skin 
(modified from http://www.pgbeautygroomingscience.com/the-sun.html) 
The latter study further justifies the use of blue light for ALA-PDT of superficial skin 
lesions such as AK. Despite the more common use of red light in the region of 630 
nm for ALA-PDT, light in the Soret band (405-410 nm) is actually a good alternative 
as it gives the largest cell inactivation down to about 2 mm from the surface in 
human skin and muscle tissues as well as in superficial BCC. However when treating 
lesions that exceed 2 mm in depth, application of 630-635 nm light source may be a 
better alternative than the blue light (see Szeimies et al, 1995; Peng et al, 1997).   
MAL (Metvix®, Photocure ASA, Oslo Norway and Galderma SA. Paris, France) is 
currently approved for use in Europe with combination with red light for treating AK, 
superficial and nodular BCC and BD. In the United States, a combination of an 
alcohol-containing ALA solution in a special applicator (Levulan Kerastick®, DUSA 
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Pharmaceuticals Inc., USA) with application of blue light (417 nm) has been 
approved for clinical treatment of AK (see Klein et al, 2008).  
 
1.3.6.2. Rate limiting enzymes Influencing the Efficiency of ALA-PDT  
The mechanism(s) of ALA-based PDT has been long investigated to evaluate its 
relative effectiveness in managing and controlling tumour growth in vivo. Hua and 
colleagues (1995) have actually shown that PPIX is the predominant porphyrin 
species which is formed in tumours after exogenous administration of ALA. This 
shows the great dependence of ALA-PDT on the rate of PPIX synthesis. However 
the significant variability in PPIX biosynthesis results in limitations in this therapy. 
The different response rates obtained by ALA-PDT are hugely dependent on sub-
optimal production and accumulation of PPIX, which in turn limit the overall 
anticancer photochemical reactions responsible for different clinical responses 
(Gerritsen et al, 2009; Ickowicz et al, 2004). It seems from the literature that different 
expression levels of the rate-limiting enzymes involved in the heme biosynthesis 
pathway between healthy and malignant cells could play a role in accumulation of 
PPIX in those cells (Greenbaum et al, 2002). These key enzymes include ALAS, 
ALAD, PBGD, and ferrochelatase. Administration of exogenous ALA circumvents the 
first enzyme ALAS, therefore the rate of synthesis is hugely dependent upon the 
other three enzymes notably ALAD, PBD and ferrochelatase, as has been shown in 
several studies (e.g. Grinblat et al, 2006; Ickowicz et al, 2004; Miyake et al, 2009; 
Feuerestein et al, 2009). It is important to understand that the rate of PPIX 
accumulation within the cells in not only influenced by the ratio of ALA conversion to 
PPIX but also related to the ferrochelatase-mediated insertion of ferrous iron into the 
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porphyrin macrocycle in order to produce the heme molecule. It has been 
demonstrated that the different patterns of PPIX accumulation in vivo may be 
dependent on the differences in available iron in cells (Licznerski et al, 1993). It has 
been demonstrated that there is some selectivity in the accumulation of PPIX in 
malignant cells and in some studies this has been linked to their low ferrochelatase 
activity (Schoenfeld et al, 1988; El-Sharabasy et al, 1992). A correlation between cell 
proliferation rates and PPIX synthesis has also been suggested (Rebeiz et al, 1992; 
Malik et al, 1989), but these studies lack an explicitly stated proliferation rate. It is 
difficult to come up with a clear model from all these different studies, as the results 
which have been obtained came from tumours with different origins and thus the rate 
of PPIX accumulating in each would be varied according to specific cellular and 
tissue characteristics. Clinicians could certainly benefit from a standardised PDT 
protocol; however such protocols must be finely tuned to specific lesions depending 
on PPIX synthesis capacity in order to improve the clinical outcome. As a result of 
these findings, there is a need to establish the type of cell and tissue markers that 
will recognise the tumours that are suitable for ALA-PDT, since the effectiveness of 
ALA in inducing PPIX within the cells is cell, tissue and organ specific (Kennedy et 
al, 1990; Feuerstein et al, 2009). Oseroff and coworkers (Rittenhouse-Diakun et al, 
1995) used the transferrin receptors (TfRs, also designated CD71) of the cells as a 
marker for the intracellular level of iron in ALA/PDT. Their findings showed that the 
expression of CD71 was increased in some activated normal and malignant 
lymphocytes that demonstrated the high susceptibility of these cells to ALA-PDT and 
thus could serve as targets for PDT. However there are limitations to this approach 
such as the fact that in some malignant cell lines, the elevated level of TfR 
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expression is not directly related to internal iron stores (Neckers, 1991; Reelfs et al, 
2010).  
It is quite difficult to measure the intracellular level of LI in tumour cells. Pourzand 
and co-workers (1999b) have shown that the sensitive measurement of intracellular 
levels of LI as monitored by the level of cytosolic IRP-1 activation could have a great 
potential as a sensitive marker for developing ALA-PDT protocols as it recognises 
cells and tissue with the tendency to accumulate PPIX and thus is likely to predict 
the effectiveness of such therapies. 
Taketani and colleagues (2011) have carried out a study where they have looked at 
treating the malignant cells (i.e. Hella cells) with quinolone compounds i.e. enoxacin, 
norfloxacin etc. in order to enhance the ALA-induced accumulation of PPIX, and 
therefore provide greater sensitivity of tumour cells to PDT. The use of quinolone 
compounds as synthetic anti-bacterial agents in treating the respiratory tract infection 
is well known. The concentrations of these compounds in cells should be within the 
right range as concentrations above 200 µM proves to be toxic and caused a 
decrease in accumulation of PPIX in cells (Ohgari et al, 2011).  
In a study by Tyrrell et al (2010) the relationship between the PPIX photo-bleaching 
during MAL-PDT and resulting clinical outcome has been investigated. Fluorescence 
imaging was applied to monitor the fluorescent properties of PPIX in order to follow 
its accumulation and distribution during PDT (Allison et al, 2008). They demonstrated 
that there was an improvement in the outcome of therapy by working out the 
percentage change in fluorescent during the light irradiation. These observations 




1.3.6.3. Improving the Uptake of ALA and MAL for Efficient PDT Response   
From various studies carried out on ALA/MAL-PDT, it could be concluded that 
optimisation of topical formulations for both ALA and MAL should certainly lead to 
improvement in efficiency using these techniques. For instance, a study in 2007 by 
Christiansen and co-workers, examined the fluorescence pattern of 20% ALA in a 
cream vehicle when compared to 0.5% and 1% ALA in a liposomal vehicle using ten 
young subjects with healthy skin. The results demonstrated that the maximum 
fluorescence with the liposomal formulation was already achieved after 2 h, but using 
a cream-based ALA the maximum effect was only obtained after 8 h.  
Another advantage in the application of liposomal formulations aside from superior 
penetration, is that the concentrations may be significantly reduced and yet still give 
optimal results for PDT.  
Nanotechnology has recently been explored as a novel approach in order to improve 
cancer treatments by designing so called nano-carriers for drugs, i.e. ALA. The aim 
is to enhance and improve the efficiency of the drug, since the nano-carriers can be 
engineered in such a way as to modulate drug release, helping improve drug 
stability, and lengthening the circulation period. These nanoscale carriers can also 
be tailored to accumulate only in targeted tissues (Cormode et al, 2009; Chatterjee 
et al, 2008). So far several types of nanoparticles have been specifically designed for 
PDT applications. These range from liposomes, oil-based dispersions, polymeric 
particles and hydrophilic polymer-photosensitiser conjugates (de Leeuw et al, 2009; 
Konan et al, 2002; Gomes et al, 2007; Jang et al, 2005). More recently, silica-based 
nanoparticles have been developed for efficient drug delivery, based on their small 
pore size, large surface area and pore volume, as well as their lack of toxicity and 
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biocompatiblity (Brevet et al, 2009; Roy et al, 2003). Particularly with attention to 
ALA penetration, their porous structure makes them ideal carriers for hydrophobic 
photosensitisers, and allows oxygen permeability which plays a very important role in 
PDT (Roy et al, 2003; Bechet et al, 2008). 
A study was carried out by Yang and colleagues (2010) to investigate the effect of 
temperature on the uptake of ALA and therefore improve the efficiency of PDT. 
Their conclusions led to the assumption that temperature may have an effect on the 
outcomes of the in vitro anti-tumour PDT effect. A direct relationship was seen 
between increasing in temperature and an increase in ALA uptake and PPIX 
accumulation. The rate of ALA uptake was however shown to increase more than 
PPIX accumulation suggesting that the effect of increased temperature is more 
significant for ALA than PPIX. 
Hyperkeratosis is often the reason for a poor response to topical ALA/MAL-PDT of 
skin lesions, notably AK and BCC. Limited uptake of topically applied ALA/MAL and 
suboptimal production of PPIX may account for these differences. A time-consuming 
aspect of ALA-PDT of skin lesions is the removal of crusts with a curette (keratolysis) 
to improve penetration and decrease the incubation time of ALA or MAL (e.g. 
Thissen et al, 2000; Morton, 2003; Moore and Allan, 2003). Overnight incubation 
with an ointment for easy mechanical removal might also be beneficial. Other 
modalities include the use of keratolytics, tape stripping, microdermabrasion or laser 
ablation. Penetration enhancers may also be beneficial as they may alter the 
composition or organisation of the intracellular lipids of the SC.  
A recent study carried out by Togsverd-Bo et al (2012) used Ablative Fractional 
Laser Resurfacing (AFXL) to create vertical channels in order to facilitate MAL 
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uptake that would in turn improve PDT efficacy. This was the first study done to 
evaluate the efficiency and safety of AFXL-assisted PDT (AFXL-PDT) compared to 
conventional PDT in treating AK. The light source used was red LED light (630 nm). 
The results indicated that AFXL-PDT particularly increased the efficiency of AK 
treatment as opposed to conventional PDT using LED light sources. This 
improvement was mostly observed on thicker AK lesions (88% vs. 59%) as opposed 
to thinner AK lesions (100% vs. 80%), suggesting that AFXL-PDT may be more 
beneficial in the treatment of thick AK lesions. 
 
Several Phase III clinical studies have been performed for the use of liposomal or 
non-colloidal ALA preparations in the treatment of AK, one of which is the study 
carried out by Foguet and colleagues (2012) looking at PDT therapy with BF-200 
ALA for treatment of AK compared to MAL. BF-200 ALA (Biofrontera Bioscience 
GmbH, Leverkusen, Germany) is a gel formulation of ALA with a nano-emulsion 
containing 7.8% ALA (10% ALA hydrochloride) while the registered dug Levulan® 
(Dusa Pharmaceuticals, Wilmington, MA, U.S.A) (Dusa Pharmaceuticals, 2009) uses 
20% ALA hydrochloride, and Metvix® 16% MAL (corresponding to 21% MAL 
Hydrochloride) (Galderma, 2008). BF-200 ALA has been used for treatment of AK 
and has proved more successful than ALA alone as it has better solubility and 
therefore a better skin penetration. Based on these advantages, lower final 
concentrations of ALA could be applied with a satisfactory outcome. In a recent 
study, the efficiency and safety of BF-200 ALA was compared with 16% MAL for 
PDT of AK when both narrow and broad spectrum light sources were applied 
(Szeimies et al, 2010). The results highlighted the higher efficiency of BF-200 ALA 
than MAL when both light sources were applied. However, better results were 
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obtained by using the narrow-spectrum light source with BF-200 ALA giving a CR of 
84.8% whereas treatment with MAL led to a CR of 67.5%. These figures were 
somewhat decreased when a broad spectrum light source was applied with BF-200 
ALA, but were still superior to MAL with 71.5% and 61.3% CR, respectively. In 
conclusion the use of BF-200 ALA in PDT of AK has proven to be very effective. The 
fact that the effect observed with BF-200 ALA is much superior to that obtained with 
MAL is particularly striking (Dirschka et al, 2012). 
Several studies have been performed on the use of DMSO, ozone, glycolic acid, 
oleic acid to increase the penetration of ALA (e.g. Ziolkowski et al, 2004; Orenstein 
et al, 1996; Ibboston et al, 2006; Lopez et al, 2003). One possibility is to administer 
ALA via a topically applied patch. A marketing authorisation has recently been given 
to Alacare® (Medac, Hamburg, Germany), which is a 4 cm2 plaster which contains 8 
mg solid ALA hydrochloride which would be in direct contact with the lesions. 
Despite the good outcome with these plasters, their use is restricted to mild AK 
lesions (Hauschild et al, 2009).  
Table 1.4 provides the product name and ingredients of some ALA preparations 









Table 1.4: ALA Preparations  
Product Name Ingredients 
Metvix® 16% aminolevulinic acid methyl ester 
hydrochloride 
Levulan Kerastick® (not approved in 
Europe) 
20% aminolevulinic acid hydrochloride 
Magistral preparation  20% ALA gel/cream/emulsion 
Alacare® 4 cm
2
 plaster containing 8 mg ALA 
hydrochloride 
BF-200 ALA  5-ALA nano-emulsion containing 7.8% 
ALA 
Note: Reproduced from Klein et al, 2008; Foguet et al, 2012. 
 
1.3.6.4. Iron Chelators and Topical ALA-PDT:  
The important role of iron in determining the efficiency of PPIX accumulation in ALA-
MAL PDT has been repeatedly observed in the literature (Curnow et al, 2006; Berg 
et al, 1996; Liu et al, 2004). Because of this, iron chelator treatment in combination 
with ALA-PDT has been proposed in order to improve the efficiency of this therapy. 
Temporary removal of Fe2+ by iron chelation prevents its insertion into PPIX, thus 
preventing formation of heme and therefore helping to accumulate more significant 
levels of PPIX within the targeted cells/ tissues (Curnow et al, 2006). Iron chelators 
are typically small molecule agents that may enter the cell and bind iron (Richardson, 
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2011). In general, the use of selective iron chelators could be a therapeutic good 
strategy in situations wherein a local increase in iron concentration is causing an 
undesired pathology. 
As cancer cells are rapidly dividing, their higher requirement for iron as opposed to 
normal cells is well known, and this makes the use of chelators very attractive for the 
therapy of cancer (Richardson, 2005). Pre-clinical studies have already shown that 
iron chelators such as EDTA, desferrioxamine mesylate (Desferal®, Novartis, Basel, 
Switzerland), 2-allyl-2-isopropylacetamide and 1,10-phenanthroline have potential for 
increasing PPIX accumulation upon administration of ALA (e.g. Licznerski et al, 
1993; Hanania et al, 1992; Iinuma et al, 1994, He et al, 1993; Berg et al, 1996; Liu et 
al, 2004).  
DFO is a hexadentate siderophore which is isolated from Streptomyces pilosus, and 
has been used clinically for the treatment of iron-overload diseases such as β-
thalassemia major. It has been demonstrated that DFO shows anti-proliferative 
activity against many tumour cells (Buss et al, 2003; Kalinowski and Richardson, 
2005; Pahl and Horwitz, 2005; Richardson, 2005). The antiproliferative effect that 
DFO treatment shows towards cells is thought to be due to its ability to inhibit 
ribonucleotide reductase (RR) activity. RR is the rate-limiting enzyme in the 
formation of deoxyribonucleotides which are required for DNA synthesis (Oexle et al, 
1999). 
 This property of iron chelators such as DFO provided a base for their use in iron 
chelation therapy of cancer (ICT). ICT may be more advantageous than 
chemotherapy as the problems of unresponsiveness of cancer cells to 
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chemotherapeutic drugs may be resolved by using this alternative therapy (Whitnall 
et al, 2006). 
However DFO is expensive to produce and its hydrophilic nature makes it un-
suitable for topical application. The calculated n-octanol-water partition coefficient, 
log Pcalc= -0.14 (Ihnat et al, 2000), indicates a very poor plasma membrane 
permeability. Cellular studies indeed indicate that it takes several hours for DFO to 
enter the cell via endocytosis. It is then transported into lysosomal compartments 
where it remains undegraded and decreases the cytosolic labile iron pool (Kurz et al, 
2006; Kurz et al, 2008; Lloyd et al, 1991; Glickstein et al, 2005). It has also been 
shown that prolonged exposure to DFO results in iron starvation in tissue due to 
removal of iron from multiple sites including the healthy tissues which therefore leads 
to cell cycle arrest and cell death (Doulias et al., 2003; Yu et al., 2006). These effects 
also limit the use of DFO for topical ALA-PDT of skin lesions. The chemical structure 









Studies from the MacRobert and Curnow laboratories (2006) have introduced CP94 
(1,2-diethyl-3-hydroxypyridin-4-one hydrochloride) which seems to be a better 
candidate for dermatological ALA-PDT. CP94 is a low molecular weight bidentate 
chelator that has a high specificity for iron (Hider et al, 1994). Unlike DFO and EDTA, 
CP94 is a lipophilic chelator, which makes it suitable for topical application (Smith et 
al, 1997; Liu and Hider, 2002). CP94 has been shown to be orally active and of very 
low toxicity. CP94 has also been studied in humans (Hider et al, 1994; Porter et al, 
1994; Hider et al, 1992). The effectiveness of this chelator in enhancing PPIX levels 
following ALA administration has been shown in in vitro cell culture studies as well as 
in in vivo animal models and skin explants (Bech et al, 1997; Casas et al, 1999; 
Chang et al, 1997; Curnow et al, 1998 and 2006; Pye and Curnow, 2007; Blake and 
Curnow, 2010). The use of lipophilic strong iron chelators such as CP94 in 
combination with ALA/MAL may solve the issues of unresponsiveness of deep 
dermatological lesions in topical ALA-PDT and should therefore improve the 
efficiency of ALA-PDT in skin tumours with low response to ALA-PDT alone. In a 
recent study, Pye et al (2008) and Blake et al (2010) demonstrated the improved 
efficiency of ALA/ MAL-PDT of nodular BCC and SCC when combined with CP94. 
The chemical structure of CP94 is shown in Figure 1.19: 
 
 
Figure 1.19: Chemical structure of CP94. 
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 Blake et al (2011) also proposed Dexrazoxane (ICRF-187) as a potential iron 
chelating agent for ALA/MAL-PDT in SCC. Dexrazoxane is a hexadentate chelator 
that binds iron in a 1:1 ratio. This iron chelator is a clinically approved drug which has 
been successfully used as a cardio-protective agent for the past 20 years (Junjing et 
al, 2010). Blake et al (2010) compared the efficiency of the hexadentate 
Dexrazoxane to the bidentate CP94 which binds iron in a 3:1 ratio. Therefore 
concentrations of the solutions were determined to provide an equal iron binding 
potential, which was at 150 µM for CP94 and 50 µM for Dexrazoxane. They also 
tested equimolar concentrations of both compounds to see if any significant 
differences were observed. CP94 out-performed both concentrations of 50 and 150 
µM of Dexrazoxane, however the clinical use of CP94 still remains experimental and 
is not yet licenced to be used in vivo at the present time. 
A quick analysis as to why CP94 and DFO proved to be more efficient in increasing 
the level of PPIX in tumour cells than EDTA, led to the conclusion that since EDTA is 
a non-specific chelator and it does also chelate other cation metals, this lowers its 
affinity for iron compared to DFO and CP94  (Pye et al, 2007). EDTA is considered 
to be a membrane impermeable chelator, although it was amongst the first chelators 
used in initial ALA-PDT studies. In a study by Berg and colleagues (1996), it was 
demonstrated that EDTA only moderately increased the levels of intracellular PPIX in 
epithelial skin tumours in combination with ALA treatment. There are also two 
studies in which EDTA has been used in ALA-PDT therapy in the form of a cream 
formulation (2%) in combination with ALA and DMSO  (i.e. as penetration enhancer) 
for topical application of tumour and skin overlying the tumour in mice bearing 
subcutaneously transplanted C26 colon carcinoma (Heyerdahl et al, 1993; Orenstein 
et al, 1995).  
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The chemical structure of EDTA is shown in Figure 1.20. 
 
Figure 1.20. Chemical structure of EDTA. 
 
In the present study, the suitability of aroylhydrazone iron chelators pyridoxal 
isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) was 
assessed to improve the efficiency of topical ALA-PDT. These iron chelators have 
presented themselves as effective iron chelators for ICT (Richardson and Ponka, 
1994; Richardson et al, 1995). Both SIH and PIH are tridentate ligands which bind 
iron in a 2:1 ratio through the carboxyl oxygen, imine nitrogen and phenolic oxygen. 
They are able to bind to both ferric and ferrous iron with a stronger affinity for ferric 
iron similar to that of DFO (Richardson, 1995; Vitolo et al, 1988). At physiological pH 
PIH and SIH are mostly in the non-ionised form (80% and 86% for PIH and SIH 
respectively), resulting in efficient permeability of both chelators through cell 
membranes. The lipophilicity of SIH is sufficient to readily cross the cell membrane 
and even transport iron to the extracellular media (Yiakouvaki et al, 2006). The high 
lipophilicity of both these compounds (log P= 0.69 for PIH and 2.07 for SIH) 
(Richardson et al, 1995; Ponka et al, 1979, 1994; Huang and Ponka, 1983; Epsztejn 
et al, 1997) makes them suitable for topical applications in the treatment of iron-
related hyper-proliferative skin disorders, notably skin cancer (see Aroun, 2011, PhD 
thesis, this laboratory). It has been shown that prolonged treatment of cells with 
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these chelators may cause iron starvation which leads to cell death (Gao and 
Richardson, 2001; Buss, Neuzil, et al, 2004). There is also considerable literature 
that shows the great potential of PIH for ICT of mammary tumours and certain 
leukemias in mice (Sah and Peoples, 1954). In a comparative study, Johnson and 
colleagues (1982) showed that SIH had a greater chelating activity in tumours than 
PIH. The antiproliferative activity they show towards cells is related to their ability to 
chelate the iron pool which is required for RR activity in DNA synthesis, thus leading 
to apoptotic cell death (Green et al, 2001; Chaston and Richardson, 2003). 
 
Figures 1.21 and 1.22 show the chemical structures of free SIH and PIH and their 













1.3.6.5. Caged Iron Chelators 
Extensive pre-clinical and clinical studies have demonstrated that prolonged 
systemic application of iron chelators for therapeutic purposes are accompanied by 
severe toxicity (Yu et al, 2006). This is because iron chelators can inhibit the acitivity 
of ribonucleotide reductase, the critical enzyme involved in DNA synthesis (Buss et 
al, 2004; Kalinowski and Richardson, 2005) provoking G1 to S arrest in cell cycle 
that leads to cell death. Unpublished data from this laboratory with both monolayer 
and 3-dimensional organotypic skin cultures have also demonstrated that prolonged 
exposure of healthy skin cells to iron chelators such as DFO and SIH leads to cell 
death due to G1/S arrest in cell cycle (see Aroun, PhD thesis, 2012).  So while the 
potential of iron chelators in improving the efficiency of topical ALA/ MAL PDT has 
been demonstrated, the topical application of strong iron chelators to skin lesions 
may affect the normal tissue surrounding the lesion as a result of severe iron 
starvation. To overcome this problem, there is a clear need to develop smart iron 
chelating agents that could be administered to the skin lesion as a ‘pro-drug’ and 
then activated within the lesion. One way of achieving such in situ activation is by 
applying light-activatable caged iron chelators (CICs) that are ordinarily inactive as 
chelators, but which upon exposure to relevant UVA dose, are converted to free iron 
chelating agents in a highly selective and dose-controlled manner (Yiakouvaki et al, 
2006; Reelfs et al, 2010). The use of UVA-activatable CICs in conjunction with ALA 
may provide a powerful and yet a safer alternative for ALA-PDT of skin lesions than 





In this study, we selected two candidate CICs (i.e. BY123 and BY128) in which a key 
iron binding function of SIH was blocked by a photolabile aminocinnamoyl-based 
caging group. Upon activation by UVA, these CICs are uncaged releasing SIH and 3-
methylquinolin-2-one co-products. Therefore the effect of these chelators in ALA-
treated cells to enhance PPIX production can be triggered on demand allowing 
controlled and dose- and context-dependent effects within the targeted cells.  
The chemical structures of these CICs are shown in Figure 1.24 (for full details see 
Results and Materials and Methods sections).  
 
Figure 1.24. SIH and the caged derivatives, BY123 and BY128. 
 
1.3.6.6. Side Effects of ALA- and MAL-PDT   
Topical ALA- or MAL-based PDT has considerably advanced the management of 
NMSC, providing a treatment option for AK, BCC and BD, with good clinical 
outcomes, low recurrence rates and enhanced cosmetic acceptability. However the 
key disadvantage of the therapy remains the burning or stinging pain that patients 
experience during the course of treatment and sometimes even post-exposure in a 
minority of patients. Pain is restricted to the illuminated area and may reflect nerve 
stimulation and/or tissue damage by ROS, possibly aggravated by hyperthermia 
(Morton et al, 2002). Treatment of psoriasis and viral warts in particular is frequently 
limited by pain (Schleyer et al, 2006). Pain seems to be more intense in larger area 
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lesions, in AK, BD and BCC covering an area of > 130 mm2 being significantly more 
painful to treat (Grapengisser et al, 2002, Sandberg et al, 2006).  
The pain is most significant when patients are being treated with PDT for AK in the 
face and scalp (Grapengiesser et al, 2002; Sandberg et al, 2006). This disadvantage 
often causes patient incompliance or they will refrain from treatment in the future. It 
has been demonstrated that if AK lesions are left untreated, there will be a risk of 
developing SCC in the long run (Anwar et al, 2004; Salsche SJ, 2000). As topical 
ALA/MAL-based PDT has good cure rates in the treatment of extensive AK and 
gives excellent cosmetic results, it is necessary to find new strategies to reduce the 
pain experience to an acceptable level.  
MAL may offer advantages over ALA in terms of its deeper skin penetration (up to 2 
mm in depth) due to potentially enhanced lipophilicity and greater specificity for 
neoplastic cells (Peng et al, 2001). Unlike ALA, the transport pathway of MAL is not 
by GABA receptors; therefore it is thought that MAL may provoke less nerve fibre 
stimulations and subsequent pain than ALA (Rud et al, 2000). These comparative 
studies with topical ALA or MAL are still ongoing. While some studies have 
demonstrated significantly higher amounts of pain in ALA- than MAL-treated sites 
(both during and after PDT) (Morton et al, 2008; Wachowska et al, 2011), there are 
other studies showing that the difference in pain endured in ALA or MAL-PDT is not 
significantly different from one another (Haedersdal et al, 2008).  
A recent study carried out by Ibbotson and colleagues (2012) has weighed up in 
particular the pain issue of PDT in ALA-treated versus MAL-treated patients using 
red light (632 nm) with BD and sBCC. Interestingly, there was a slight but not 
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significant increase in pain scores when patients were treated with ALA as opposed 
to MAL with very similar clearance rates on a one year follow up. 
Literature shows that there is around 20% patient incompliance due to what is 
described as ‘unbearable pain’ due to application of ALA/MAL using red light for 
illumination (Wiegell et al, 2003, 2006 and 2008; Kasche et al, 2006; Kujjpers et al, 
2006; Moloney et al, 2007). More comparative studies are necessary to elucidate the 
pain associated with either compound, as the high inter-subject variability within 
small subject group studies potentially obscures any significant relationship.  
The degree of pain experienced with ALA/MAL has been linked to age (patients 
older than 70 experience more pain), lesion size and redness, and Fitzpatrick skin 
type I or II (Steinbauer et al, 2009; Aritz et al, 2010; Sandberg et al, 2006). The level 
of pain has also been linked to the intensity of light delivery; fractionated light doses 
increase tolerance of the procedure and may at the same time increase cure rates 
(Ericson et al, 2004; Babilas et al, 2007). Some efforts have been made in the 
direction of trying to reduce the topical ALA/MAL-PDT related pain and discomfort. 
These include: local anaesthesia, and cooling the skin with fans or sprayed water. 
Cold-water spray is used routinely as a pain relief but is not sufficient when larger 
areas like the scalp or forehead are involved. 
The difficulty in finding a pain-relieving strategy has been shown in earlier studies, 
e.g. three studies have shown the inefficacy of topical anaesthesia such as 
tetracaine gel, a mixture of lignocaine 2.5% and prilocaine 2.5%, or morphine gel 
0.3% (Holmes et al, 2004; Langan et al, 2006; Skiveren et al, 2006). Blowing cold air 
(-35oC) on the treatment area during PDT also seems to fail to reduce the pain 
significantly (Pagliaro et al, 2004). There is proof from two independent recent 
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studies that the use of natural daylight instead of red light in ALA-PDT of patients 
with multiple AK lesions has helped to keep the pain to a lower level (Wiegell et al, 
2008, 2011). There is more recent evidence of the pain in a few studies in the 
literature. Drischka and colleages (2012) looked at ALA/MAL PDT with regards to AK 
and there was a report of local adverse reactions at the application site and 
discomfort during and after the treatment. 
Transcutaneous electrical nerve stimulation has been tried as a pain reducing 
method but had limited effect. Subcutaneous infiltration anaesthesia has been used 
during PDT of extensive AK of the cheek. The pain decreased but this type of 
anaesthesia is not possible to use on the forehead and scalp. Applying local 
anaesthesia to such areas is also inappropriate due to the large number of painful 
injections needed. Nerve blocks have also been used to provide effective pain relief 
during PDT for extensive AK in the face (Paoli et al, 2008).  
Two studies also combined the benefits of supraorbital and supraocular nerve blocks 
of the latter study with nerve blocks of the greater and lesser occipital nerves to 
anesthetize both the forehead and scalp in order to alleviate pain during PDT in 
these areas (Paoli et al, 2008; Halldin et al, 2009). However in both studies 
intervariability was observed between the patients, emphasizing the need for 
individual considerations to find the most adequate pain-relieving method for each 
patient.    
1.3.6.7. Pre-Clinical and Clinical Studies with ALA- and MAL-PDT  
 Photodynamic therapy with topical ALA/MAL formulations represents one of the 
most promising treatments for NMSC, AK and BD. Table 1.5 summarises the 
outcome of some of the clinical studies that have been carried out during the last 
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decade with ALA/MAL-PDT using various light sources for the treatment of BCC, 
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Because of the significant results obtained from preclinical and clinical studies (e.g. 
Hongeharu et al, 2000), in 2003, ALA-PDT was also approved for moderate 
inflammatory acne vulgaris in USA.  
Preclinical and clinical studies have also demonstrated the great potential of 
ALA/MAL-PDT for treatment of Mycosis fungoides (e.g. Stables et al, 1997), human 
papilloma virus-associated cutaneous pathologies, lymphocytoma cutis, 
leishmaniasis, alopecia areata, erythroplasia of Queyret and benign familial 
pemphigusand hidradentis suppurativa (see Tierney et al, 2009; Kalka et al, 2000; 
Huang, 2005). Other non-malignant conditions such as psoriasis, viral warts and hair 
removal are still under clinical investigation worldwide (e.g. Robinson et al, 1999; 
Stender et al, 1999; Stender et al, 2000; Hongeharu et al, 2000; Robinson et al, 
1999; Stender et al, 2000; Huang, 2005). Clinical investigations of ALA-PDT have 
also extended to basaloid follicular hamartomas, cutaneous T-cell lymphoma and 
sebaceous gland hyperplasia in recent years (e.g. Leman et al, 2002; Hayami et al, 









1.4. Aims and objectives 
While much effort has been invested in the development of protocols to improve the 
effectiveness and cosmetic outcome of topical ALA-based PDT of skin lesions, 
notably multiple actinic keratoses (AK), few studies report approaches to reduce the 
pain associated with the therapy. Most of the time a complete response to ALA-PDT 
is achieved only following treatment with either high irradiation doses or long 
irradiation times with high intensity visible light. However, these conditions cause 
discomfort (stinging and burning pain) and severe complications in 20% of patients 
treated, despite the number of modalities in use for pain relief. As a consequence, 
the patient may choose to interrupt the treatment, with the risk that the untreated AK 
lesions may develop into squamous cell carcinoma (SCC). Therefore, an 
improvement of the current ALA-PDT protocol, aiming at a reduction of the pain 
incurred will be clearly beneficial to the patient.  
UVA (320-400 nm) is absorbed more efficiently by PPIX and is also 40-fold more 
potent in killing cultured skin cells than conventional red light (550-750 nm) 
(Buckczyck et al, 2001). In the present project, we hypothesized that the use of UVA 
as the light source may provide a rapid means to improve the effectiveness of ALA-
PDT of skin lesions while reducing considerably the therapy time and the 
discomfort/pain associated with conventional topical ALA-PDT. Two keratinocyte-
based cancer cell models, HaCaT (spontaneously immortalised keratinocyte cell 
line) and Met 2 (keratinocyte cell line originating from the skin of a patient suffering 
from SCC) were chosen for the study.  The extent of cell damage and cell death in 
ALA-treated cells was evaluated following UVA irradiation with three independent 
assays of MTT, Annexin V/propidium iodide and, colony forming.  
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To further improve the efficiency of ALA-PDT of cells with UVA, ALA treatment was 
also combined with potent iron chelators salicylaldehyde isonicotinoyl hydrazone  
(SIH), pyridoxal isonicotinoyl hydrazone (PIH) or desferrioxamine (DFO) to further 
increase the accumulation of PPIX through the depletion of iron necessary for 
ferrochelatase-mediated bioconversion of PPIX to heme.  
As topical application of ‘naked’ iron chelators to skin lesions may cause toxicity to 
the surrounding normal tissue due to iron starvation, we also evaluated the potential 
of UVA-activatable caged- iron chelators (CICs) as a safer alternative to improve the 
efficiency of topical ALA-PDT of skin lesions. CICs do not chelate iron unless 
activated by relevant doses of UVA, allowing for specific localised release within the 
targeted tissue and therefore substantially decreasing the risk of toxicity to the 
surrounding normal tissue. The caged chelators used in this study were 
aminocinnamoyl-caged SIH derivatives BY123 and BY128.  
The ultimate goal of this project was to demonstrate that UVA irradiation in 
combination with iron chelators and ALA may be an effective intervention strategy to 
decrease the time of radiation treatment and therefore reduce the pain associated 
with prolonged conventional topical ALA-PDT of skin lesions such as AK. The use of 
caged-chelators may also provide a safer and more targeted strategy for topical 








MATERIALS AND METHODS 
 
2.1. Chemicals 
All the reagents were from Sigma-Aldrich Chemical Co. (Poole, UK) unless 
otherwise specified. All the cell culture materials were obtained from Life Sciences 
Technologies (Paisley, UK), except the foetal calf serum (FCS), which was obtained 
from PAA (Austria). Dulbeco’s Minimum Essential Medium (DMEM) was supplied by 
Gibco BRL Invitrogen Corporation (Life Technologies, UK).  
MilliQ water used to prepare phosphate buffered saline (PBS) and other stock 
solutions were issued from a Millipore purification system (MilliQ cartridge: Millipore, 
Bedford, MA) in order to minimize the presence of trace elements such as transition 
metals.  
 Annexin V was from Roche (UK), and dimethyl sulphoxide (DMSO) and 
desferrioxamine mesylate Ph. Eur. (Desferal, DFO) were purchased from Sigma. 
5-Aminolevulinic acid hydrochloride (ALA) was supplied from Sigma- Aldrich. 
 
 
2.2. Cell Culture 
All the cell models used in this study were cultured routinely and incubated in a 5% 
CO2 cell culture incubator set at 37ºC. 
 
2.2.1. Cell models 
HaCaT: Is a spontaneously immortalized human skin keratinocyte cell line that was 
originally derived from an adult back in Boukamp’s laboratory. This cell line 
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maintains full epidermal differentiation capacity, but remains non-tumorigenic. 
(Boukamp et al, 1988). The medium was 10% FCS DMEM (high glucose Dulbecco’s 
modified Eagles medium) with 0.25% sodium bicarbonate, 2 mM L-glutamine, and 
50 IU/ml of each of penicillin / streptomycin (P/S). The FCS stock was heat-
inactivated at 56oC for 45 min before use.  
Cells were passaged once or twice a week and seeded for experiments as follows: 
For MTT, flow cytometry, PPIX measurement and ROS measurement 8x104 cells 
were seeded per 3 cm plate in 2 ml of media. 
For colony forming ability assay, 700 or 1000 cells per condition were seeded in 6 
well plates in 2.5 ml of media. 
 
 
Swiss 3T3: The Swiss 3T3 are spontaneously immortalized mouse embryonic 
fibroblasts (a kind gift from Prof I. Leigh, Dundee).These cells are used as a feeder 
layer for the cultivation of keratinocytes (see Proby et al, 2000). The 3T3 cells 
secrete extracellular matrix proteins that help the attachment of keratinocytes and 
also growth factors that enhance the proliferation rate of the seeded keratinocytes.  
3T3 cells were grown in culture in 15% FCS EMEM (Earl’s modified minimum 
essential medium) supplemented with 15 % FCS, 0.25% sodium bicarbonate, 2 mM 
L-glutamine and 50 IU/ml of each of P/S.  
For feeder layer preparation, cells were first grown in flasks till they reached 80% 
confluency. The cells were then treated with mitomycin C at a final concentration of 4 
µg/mL and incubated for 2 h at 37ºC. Mitomycin C is a DNA cross linker that inhibits 
DNA replication in 3T3 cells in order to stop further growth and any possible 
interference with keratinocyte growth in culture. After the incubation period, the 
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medium containing mitomycin C was aspirated and the cells were rinsed with PBS to 
ensure no mitomycin C remained to inhibit keratinocyte growth. The mitomycin C-
treated 3T3 cells were trypsinised and resuspended in RM+ media (see below). The 
cell suspension was then used as the feeder layer for the matrix-dependent culture 
of Met2 keratinocyte cell line. 
 
 
Met2: Met2 is a squamous cell carcinoma (SCC) keratinocyte cell line, clonally 
derived from a local recurrence of invasive SCC (a kind gift from Prof Irene Leigh, 
Univ. Dundee, see Proby et al, 2000 and Popp et al, 2000). 
 Met 2 cell lines were cultured routinely in flasks in the presence of the feeder layer 
and RM+ medium. The rich medium (RM+) was prepared by mixing DMEM and 
Ham’s F12 media at a ratio of 3:1 and supplemented with hydrocortisone  (0.4 
g/ml), cholera toxin (10-10 M), epidermal growth factor (10 ng/ml), insulin (5 g/ml), 
transferrin (5 g/ml), liothyronine (2x 10-11 M), 0.25% sodium bicarbonate, 2 mM L-
glutamine and 50 IU/ml of P/S. 
For the experiments performed with these cells, 5x104 cells were seeded per 3 cm 
dish containing 2-3 ml of RM+ media. 
 
 
2.2.2. Trypsinisation  
Stock cells were passaged by trypsinisation once or twice a week. As a general rule, 
stock cell flasks were maintained in culture until they reached a confluency of 80%, 
after which they were trypsinised as detailed below: 
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The medium was removed from the flask and retained in a separate tube. Cells were 
then washed with PBS and treated with 2ml of 0.25% trypsin. Trypsin is a protease 
which detaches cells from the surface of the flask. Cells were incubated at 37oC until 
detached. Retained media was added back to the flask in order to inactivate the 
trypsin. The cells were then centrifuged for 5 min at 1200 rpm (Jouan B3.11 
centrifuge). The supernatant was then removed and the cell pellet was resuspended 
in fresh media. A small aliquot of the cell suspension was mixed with trypan blue dye 
and then counted under a microscope using a Neubauer-improved haemocytometer 
purchased from Marienfeld (Germany). Cell were then diluted with fresh medium at 





2.3.1. Chemical Treatments 
 
2.3.1.1. Stock Solutions  
SIH (RMM of 241): The SIH powder was synthesized in Dr Eggleston’s laboratory 
(B.Young, PhD thesis, University of Bath, 2013). The stock solution was prepared at 
a concentration of 100 mM in DMSO and aliquoted and stored at -20°C. 
 
 PIH (RMM of 286): The PIH powder was synthesized in Dr Eggleston’s laboratory 
B.Young, PhD thesis, University of Bath, 2013). PIH powder was first dissolved in 
1M HCl at a final concentration of 250 mM and then further diluted in PBS to reach a 
106 
 
final concentration of 25 mM. Since PIH had a tendency to precipitate over time, this 
stock solution was usually prepared freshly just before adding to the cells.  
 
 DFO (RMM of 657): The DFO powder was purchased from Sigma (Cat. No. 
D9533). The stock solution was prepared at a concentration of 100 mM in H2O and 
aliquoted and stored at -20°C. 
 
 BY123 (RMM of 460.48): BY123 powder was synthesized in Dr Eggleston’s 
laboratory (B.Young, PhD thesis, University of Bath, 2013). The powder was 
weighed and accordingly dissolved in DMSO at a final concentration of 100 mM. It 
was then aliquoted in dark eppendorf tubes to be protected from light and stored at -
20ºC.  
 
 BY128 (RMM of 444.44): BY128 powder was synthesized in Dr Eggleston’s 
laboratory (B.Young, PhD thesis, University of Bath, 2013). The powder was 
weighed and dissolved accordingly in DMSO at the final concentration of 100 mM. It 
was then aliquoted in dark eppendorf tubes to be protected from light and stored at -
20°C. 
 
ALA (RMM of 167.59): ALA powder was purchased from Sigma (Cat. No. A3785). 
The powder was weighed and dissolved in PBS at the final concentration of 100 mM. 
Solutions of ALA in PBS buffered at physiological pH were found to be unstable over 





2.3.1.2. ALA and Iron Chelator Treatments 
For iron chelator/CICs treatments that were performed for 18h, cells were seeded at 
the required density and grown for 48 h prior to addition of compounds.  
For ALA treatment and iron-chelator treatments that were carried out on the day of 
UVA irradiation, cells were seeded at the required density for 72 h prior to addition of 
compounds and UVA irradiation.  
 
 
2.3.1.3. Iron Chelator Treatment 
Iron chelators/CICs treatments were carried in conditioned medium (CM, i.e. the 
medium in which cells were grown for 48-72 h) for 2 or 18 h at 37ºC in the dark. For 
HaCaT cells the chelators’ concentrations were at a range of 20 -100 M. For Met2 
cells, iron chelators were used at a concentration of 50 µM for SIH and 200 µM for 
DFO and PIH.  
 
2.3.1.4. ALA Treatment 
ALA treatment was carried out in 1% FCS DMEM. Cells were incubated with ALA or 
not at a final concentration of 0.5 mM in 1% FCS DMEM media and incubated for 2 h 
at 37oC in the dark prior to irradiation.   
 
 2.3.2. UVA irradiation 
2.3.2.1.1. UVA Lamp  
The broad spectrum 4kW lamp (Sellas, Germany) emits primarily UVA irradiation 
(significant emission in the range of 350-400 nm) and some near visible radiation 
longer than 400nm. Figure 2.1 illustrates the spectrum of the lamp. This lamp is 
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suitable for ALA-PDT studies, as the absorption spectrum of PPIX is known to have 
a maximum at 405nm. Excitation at this wavelength produces an intense red 
emission with its maximum at 635nm (Ericson et al, 2004).  
Furthermore blue light has been shown to be more potent than red light at activating 
PPIX (Peng et al, 1997).  
 
 
 Figure 2.1: The spectrum of the Sellas 4kW UVA lamp as measured in Prof. Rex Tyrrell’s laboratory by     
spectroradiometer (Ref: Radka, T, MPhil thesis, University of Bath, 2010).  
 
 
2.3.2.2. UVA Doses  
The UVA dosimeter was from International Light Technologies Inc.  
(Peabody, MA, USA) calibrated against spectroradiometric measurements of the 
source made by a DM150 double monochromator Bentham spectroradiometer 
(Bentham Instruments, Ltd., Reading, UK) calibrated against national UK standards. 
The UVA doses were 5, 10, 20 and 50 kJ/m2. Typically with a fluence rate of 150 
W/cm2, and the distance of 30 cm, the irradiation time was between 15 sec to 2.5 
min for all the doses used. At natural sunlight exposure level, these doses will 
correspond to radiation times of between 2 to 20 min at sea level (see Pourzand et 
109 
 
al, 1999). The higher doses of 20 and 50 kJ/m2 will be more relevant for skin 
therapeutic purposes. This is because of the attenuation of the applied UVA dose by 
passage through the outer skin layers. The UVA doses were measured using an 
IL1700 radiometer (International light, Newbury, MA).  
 
2.3.2.3 Irradiation Procedure 
Irradiation was carried out in an air conditioned room at 18ºC in order to maintain the 
temperature of the cells to approximately 25ºC throughout the radiation procedure. 
Prior to irradiation, cells were washed with PBS, and covered with PBS containing 5 
ppm Ca2+ and Mg2+. Cells were then irradiated with UVA doses of 5, 10, 20 or 50 
kJ/m2. After irradiation, cells were incubated in conditioned medium (the retained 
medium in which the cells had been grown). The control samples were treated in the 
same manner except that they were not irradiated (i.e. kept in dark). 
 
 
2.3.2.4. Chemical and Cell Culture-based Uncaging of BY123 and BY128 by 
UVA Irradiation 
The BY123 and BY128 were uncaged by UVA either in a simple chemical system  or 
in a cell culture system. 
For simple chemical uncaging, BY123 and BY128 stock solutions were prepared in 
DMSO at a final concentration of 100 mM and then UVA irradiated in quartz 
cuvettes.  
For experiments involving the addition of uncaged CIC as a control, the compounds 
were usually uncaged with a UVA dose of 250 kJ/m2 and then added to the cells at a 
final concentration of 20 M in CM.  
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For experiments involving the determination of the uncaging profile of CICs by 
reverse HPLC, BY 123 and BY128 stock solutions were prepared in DMSO at a final 
concentration of 1 mg/ml and then irradiated in quartz cuvettes with increasing UVA 
doses of 10-500 kJ/m2.   
Uncaging process in a cell culture system was based on the addition of CICs (i.e. 
BY123 or BY128) to the growth medium of cells over 18 h at 37 ˚C followed by 
irradiation with UVA doses of 20 or 50 kJ/m2 which uncaged the compounds inside 
the cells. 
 
2.4. MTT Assay 
2.4.1. Principle of the Assay 
Cellular and mitochondrial dehydrogenase enzymes converts MTT [3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] that is a yellow water soluble 
substrate into a dark blue formazan product that is insoluble in water. The amount of 
formazan produced is directly proportional to the number of viable cells. So the MTT 
colorimetric assay may be used as a cell viability assay (Mosmann, 1983; Doyle and 
Griffiths, 1998).  
2.4.2. MTT Stock Solution: The MTT stock solution was prepared at a final 
concentration of 5 mg/ml in PBS. The solution was then filtered through a 0.22 m 
filter for sterilization and stored in small aliquots at -20ºC.  
2.4.3. Procedure 
On the day of the experiment, MTT stock solution was diluted in Serum Free DMEM 
Medium (SFM) to a final concentration of 0.5 mg/ml (i.e. MTT/SFM solution). From 
this solution, 0.5 ml was added into each 3 cm plate. The cells were then incubated 
for 3 h at 37ºC.  The MTT/ SFM solution was then aspirated and 0.5 ml of DMSO 
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was added to each well. The plates were then swirled for 3 min on a 3D rocking 
platform (Stuart Scientific, UK). A small aliquot (i.e. usually 100 l) was transferred 
from each plate to a 96 well plate in triplicate for each condition and the optical 
density was measured by Dynatech plate reader MR-5000 (Dynatech, Guernsey 
Channel Islands) at 570 nm using DMSO as a blank control.  
The mean values calculated from the raw data (optical density) for each condition 
was then expressed as the percentage enzymatic activity (i.e. dehydrogenases) of 
the untreated control that was set as 100.  




Figure 2.2: Summary of the treatments carried out in cells prior to MTT analysis.   
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2.5. Colonogenic Assay (Colony Forming Assay) 
 
2.5.1. Principle of the Assay 
This assay is considered to be the most reliable technique  in cell culture synthesis 
to assess viable cell numbers. It is based on the ability of a single cell to form a 
colony and to undergo unlimited division. A colony is considered to consist of at least 
50 cells or more (Doyle and Griffiths, 1998). 
2.5.2. Methodology 
After treatments, cells were trypsinised and seeded back in 6 well plates in triplicate 
at a density of 700 or 1000 cells/ well for HaCaT cells and 800 cells/ well for Met2 
cells in their respective fresh media (i.e. 10% FCS-DMEM for HaCaT and 10% FCS-
RM+ for Met2 cells). Cells were then left to divide for 12 days. 
On the day 12, media was removed and cells were fixed and stained with 0.2% w/v 
crystal violet solution (in 20% v/v methanol, 2% w/v paraformaldehyde) for 15 min. 
After the 15 min period, the crystal violet was removed and cells were rinsed with 
water or PBS and left to dry before colonies were counted by hand after the initial 
confirmation of colony forming was established by microscope. The data were 








2.6. Annexin V/Propidium Iodide Dual Staining Assay by Flow 
Cytometry 
 
2.6.1. Principle of the Assay 
Quantification of apoptotic and necrotic cells was scored by flow cytometry after dual 
staining of cells with Annexin V-Fluoroscein isothiocynate (FITC) and propidium 
iodide (PI). In the early stages of apoptosis phosphatidylserine (PS) translocates 
from the inner part of plasma membrane to the outer layer. Annexin-V is a 
phospholipid-binding protein with a high affinity for PS. Identification of cell surface 
PS with Annexin-V-FITC serves as a marker for apoptotic cells. On the other hand, 
necrotic cells that lose cell membrane integrity are stained with both PI and Annexin-
V. Thus, Annexin-V-FITC and PI double staining can differentiate between necrotic 
and apoptotic cells (see Zhong et al, 2004). 
 
2.6.2. Procedure: Following various treatments, cells were incubated with incubation 
buffer (10mM Hepes/NaOH, pH 7.4, 5M NaCl, 100 mM CaCl2) containing Annexin-V-
FITC (20 µl/ml) and PI (20 µg/ml) for 15-20 min. Double stained cells were counted 
as necrotic, whereas Annexin-V-FITC positive, PI negative cells were scored as 
apoptotic. A minimum of 10000 cells were analysed per sample on a BD FACS 
Canto™ flow cytometer (Becton Dickinson, Erembodegem, Belgium). These 
experiments always include a positive control (i.e. ALA-10 kJ/m2) and a negative 
control (Control-no UVA). A coefficient variation of 20% was obtained for the positive 
control. 
The following settings were used for the analyzed cell line (HaCaT): FL1 (530+/- 
15nm) in log data collection and FL3 in log data collection. 
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Two dimensional dot plots were used to analyse the data of FL3 versus FL1 
fluorescent profiles. Cell Quest software (Becton-Dickinson, Eremdodegem, 
Belgium) was used to analyse the data with a dual parameter of FL1 (Annexin-V-
FITC) and FL3 (PI). 
 
 
2.7. Measurement of Protoporphyrin IX by Spectrofluorimetry 
 
2.7.1. Preparation of Standard Curve 
A standard curve for PPIX was obtained by preparing standard solutions containing  
increasing concentrations of commercial PPIX dissolved in 1.5 M HCl and by 
measuring the fluorescence with a Perkin-Elmer LS5 luminescence spectrometer 
(excitation: 404 nm, emission: 604 nm)(see Figure 2.3). 
 
 
Final Conc(uM) Mean PpIX Fluorescence (n=5) SD 
0 0.17 0.05 
0.01 11.05 2.34 
0.02 19.57 2.24 
0.05 46.67 2.47 





Figure 2.3. Standard curve of PPIX obtained by spectrofluorimetry of a series of PPIX standard solutions.  
 
2.7.2. Procedure 
After various treatments, cells were trypsinised with 0.25% trypsin and spun down at 
1000 rpm (120 x g) for 10 min in a Falcon 6/300 MSE centrifuge. Cells were then 
resuspended in PBS and counted for normalisation. Cells were this time re-
suspended in acetic acid (750 µl) and kept on ice while sonicated (Branson B-12 
sonicater, Branson Sonic Power, Danbury, CT) at 13000 rpm for 7 sec twice with 10 
sec interval, before addition of 2.25 ml of ethyl acetate to each sample. The samples 
were then vortexed and centrifuged at 2500 rpm (120 x g) for 5 min in a Falcon 
6/300 MSE centrifuge. The supernatant (organic phase) was collected from each 
sample and transferred to a new falcon tube and 1 ml of 1.5 M HCl was added to 
each sample. The samples were vortexed and centrifuged at 2500 rpm (120 x g) for 
4 min in a Falcon 6/300 MSE centrifuge.  
The porphyrins were isolated in the acetic acid phase and quantified using a Perkin- 
Elmer LS5 luminescence spectrometer (404 nm excitation and 604 nm emission). 
y = 890.71x + 1.4296 




















PpIX Concentration (µM) 
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Results were calculated by normalising with cell number (1x106 cells/ condition) and 
were then expressed as fold difference compared to the untreated control (i.e. 1). 
A stock sample of PPIX was prepared and aliquoted, where every time before 
measuring the samples, a sample of PPIX was defrosted from the batch and 
measured. The coefficient variation was shown to be around 5%. 
 
 
2.8. Reactive Oxygen Species (ROS) Measurement 
2.8.1. Principle of the Assay 
In this project, a general ROS detector dye named CM-H2DCFDA was used. This 
dye is a chloro-methyl derivative of H2DCFDA (2', 7’-dichlorodihydrofluorescein 
diacetate). CM-H2DCFDA exhibits an improved retention in live cells compared to 
H2DCFDA. Upon addition of the compound, CM-H2DCFDA is diffused into cells, 
where its acetate groups are cleaved by intracellular esterases and its thiol reactive 
chloro-methyl group reacts with intracellular glutathione and other thiols. Subsequent 
oxidation gives a fluorescent adduct that is trapped inside the cells. The excitation 
wavelength for this dye is 492-495 nm and the emission wavelength is 517-527 nm. 
This dye will be oxidized by air therefore it should be stored under argon or nitrogen. 
 
2.8.2. Procedure 
Cells were irradiated with UVA doses of 5 and 10 kJ/m2 and then were incubated 
with CM-H2DCFDA at a final concentration of 5 µM in PBS for 30 min at 37ºC. The 
dye was then rinsed off the cells with PBS. This was followed by trypsinisation and 
re-suspension of cells for each condition in 0.1% BSA-PBS and PI (2 µM) before 
being measured by flow cytometry (Ex 492-495, Em 517-527). 
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2.9 Reverse Phase HPLC Analysis 
 
2.9.1. Reverse Phase HPLC Analysis for PPIX Detection  
To detect and evaluate the level of PPIX in various samples, i.e. ALA or 
chelator+ALA, porphyrins extracted from each sample were subjected to HPLC 
analysis.  
HPLC was performed on a Dionex Ultimate 3000 system (Sunnyvale, California, 
USA), equipped with a Phenomenex Gemini, 5 µm C-18 (150x4.6 mm) column, with 
a flow rate of 1 ml/min, and detection at 404 nm. Mobile phase A was 0.1% TFA in 
water, and mobile phase B was 0.1% TFA in acetonitrile. Gradient was T = 0 min, B= 
20%, T= 3 min, B= 20%, T= 13 min, B= 100%, T= 17 min, B= 100%. The retension 
time was 11.8-11.9 min for all samples. The detection and quantification limits (LOD 
and LOQ) were calculated as described by ICH guidelines (ICH-Q2(R1) 2005@ 
http://www.ich.org/), using equation LOD=3.3xσ and LOQ=10xσ, where σ is the 
standard deviation of the blank noise. Solutions of PPIX were prepared at the LOD 
and LOQ, corresponding to 0.01 and 0.1 µM, respectively. 
 
2.9.2. Reverse Phase  HPLC Analysis of Uncaged CICs 
HPLC chromatograms of BY123 and BY128 along with SIH were obtained after the 
uncaging of these CICs  with a UVA dose of  250 kJ/m2 in a simple chemical system 
. 
HPLC was performed on the Dionex system as above with detection at 214 nm. 
Mobile phase A was 0.1% TFA or HCOOH in water, mobile phase B was 0.1% TFA 
or HCOOH in acetonitrile.  Gradient was T = 0 min, B = 5%; T = 10 min, B = 95%; T 
= 15 min, B = 95%; T = 15.1 min, B = 5%; T = 18.1 min, B = 5%.   
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2.10. Statistical Analysis 
Results were expressed as mean +/- standard deviation (SD). Data were analysed 
using paired and unpaired t-tests (Excell 2010). The p value of < 0.05 was 
considered as a significant difference between groups of data. The ranges given to 
the number of experiments for each graph presented in the result’s section (i.e.n=3-
8), indicates the number of independent experiments carried out with different 
compounds/treatments (e.g. 3) while including the overall number of independent 



















The use of UVA radiation for selective ALA-PDT of superficial skin lesions such as 
AK may be advantageous as UVA is potentially more damaging than visible light. 
Indeed UVA radiation is a strong oxidizing agent that generates ROS in exposed 
cells. The present study, first investigated the suitability of UVA radiation as a light 
source to improve the efficiency of cell killing following ALA administration using two 
different skin cancer cell models of HaCaT and Met 2. As iron chelation has been 
shown to boost the level of accumulation of PPIX in ALA-treated cells (Curnow et al, 
2007), three iron chelators SIH, PIH and DFO were tested to assess the potential to 
further improve the efficiency of ALA-PDT of cultured skin cells using UVA radiation 
as the light source. Finally since prolonged exposure of skin cells to ‘naked’ iron 
chelators may result in toxicity as a result of iron starvation, the potential of UVA-
activatable caged-iron chelators (CICs) BY123 and BY128, derived from parental 
chelator SIH, was investigated as a safer intervention strategy to improve the 
efficiency of ALA-PDT in skin cells using UVA radiation.  
The proof of concept studies were first performed with the spontaneously 
immortalised keratinocyte HaCaT cell line that is hyper-proliferative and has 
significantly higher proliferation rate than normal human skin keratinocytes and 
fibroblasts (A. Aroun, PhD thesis, 2011; this laboratory). In numerous ALA-PDT 
studies, this cell line has been used as a reliable in vitro model for human skin cell 
carcinoma. In this project, the key data obtained with HaCaT cells was then further 
confirmed in a skin cancer keratinocyte cell line (i.e. Met 2) clonally derived from a 
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local recurrence of invasive SCC (originally isolated from the back of the hand of the 
same patient (see Proby et al, 2000 and Popp et al, 2000). Unlike HaCaT cells, the 
growth of Met2 cells’s growth is dependent upon a feeder layer composed of 
mitogen-inactivated 3T3 fibroblasts that complicates its long-term maintenance in 
culture. As a result, the experiments with Met2 cell line were only carried out to 
confirm some of the key data obtained with HaCaT cell line.  
To evaluate the extent of ALA-induced cell damage and death upon UVA radiation of 
HaCaT cells, the level of cell damage was first monitored by MTT assay 4 and 24 h 
following UVA irradiation. The level of cell death was then also scored by flow 
cytometric Annexin V/PI dual staining 4 and 24 h after UVA radiation. The long-term 
effect of ALA+/-chelator treatments were also monitored with colony forming assay 
10-14 days following UVA irradiation of the cells. The level of cell damage and cell 
death following various treatments involving ALA + UVA treatment alone or 
combined with chelator pre-treatment was also correlated with the level of PPIX 
accumulation obtained with the same treatments. The level of PPIX accumulation in 
cells treated with chelator +/- ALA-treated cells was also corroborated with the extent 
of ROS generation under the same conditions following UVA radiation. These 


















Scheme 3.1. The effect of chelator and ALA treatment on PPIX and ROS production. HaCaT 
cells were first treated with iron chelators (20-100 µM) and incubated for 2 or 18 h, before treating the 
cells with 0.5 mM ALA or not and incubated for 2 h in the dark. This increased the PPIX levels 
significantly. Upon UVA exposure (5-50 kJ/m
2
), significant amount of ROS was produced which in 
effect caused toxicity and cell death. 
3.2. The Effect of ALA on HaCaT Cell Survival Following Irradiation 
with Low Doses of UVA 
 Data from this laboratory have previously indicated that a 2 h treatment with 0.5 mM 
ALA could significantly sensitise HaCaT keratinocytes to the damaging effects of 
UVA (T. Radka, MPhil thesis, 2010). To confirm these data and to establish a range 
of doses of UVA that may be suitable for the present project, the HaCaT cells were 
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Iron Chelator treatment (20-100 uM) 















treated with 0.5 mM ALA for 2 h and then exposed to an increasing doses of UVA 
(i.e. 10, 20 and 50 kJ/m2). MTT analysis was performed 4 and 24 h after irradiation. 
The MTT assay evaluates to what extent cellular dehydrogenases convert the yellow 
soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) into an 
insoluble purple formazan product. The level of formazan production is directly 
proportional to the level of cellular dehydrogenases activity and is therefore used as 
a measure of cell viability. Therefore MTT is often used as a rapid and sensitive first 
line of evaluation for screening of novel compounds in cytotoxicity studies. The data 
obtained with MTT analysis in the present study was expressed as a percentage of 
the enzymatic (i.e. dehydrogenase) activity of the untreated control cells (set as 
100%).   
The results (Figures 3.1 A- B) revealed that in the absence of ALA, low doses of 
UVA (i.e. 10 kJ/m2) had no significant effect on the enzymatic activity of cells when 
compared to the corresponding untreated control cells either 4 or 24 h after 
irradiation. However 0.5 mM ALA treatment substantially increased the susceptibility 
of HaCaT cells to UVA-induced damage in a dose-dependent manner 4 h following 
UVA exposure, as reflected by a significant and dose-dependent decrease in the 
percentage enzymatic activity of ALA-treated cells, following UVA irradiation. The 
decrease in the percentage enzymatic activity in ALA-treated cells was even more 
pronounced 24 h following UVA radiation of cells, especially with UVA doses of 10 
and 20 kJ/m2.     
 
 






Figures 3.1 A-B: The effect of ALA on cell viability 4 h (A) and 24 h (B) after irradiation of cells with low 
doses of UVA by MTT assay. 
HaCaT cells were treated with 0.5 mM ALA for 2 h at 37ºC in the dark prior to irradiation with UVA doses of 10, 
20 or 50 kJ/m
2
. Control cells were treated identically except that they were either not irradiated (i.e. 0) and (or) 
not treated with ALA (i.e. dark grey columns). MTT analysis was performed 4 h (A) and 24 h (B) after irradiation. 
The results were expressed as mean ± standard deviation (n=3-4). 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
†: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 10 kJ/m
2
. 
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To confirm the results obtained with the MTT assay, the level of apoptotic and 
necrotic cell death was scored by flow cytometry using the dual Annexin V/PI 
staining method. For this purpose, the ALA-treated cells were exposed to UVA doses 
of 5-50 kJ/m2 and then incubated for either 4 or 24 h at 37oC prior to flow cytometry 
analysis. The results (Figures 3.2 D-G) revealed that while UVA irradiation per se 
had no significant effect on cell death in HaCaT cells, in ALA-treated cells, UVA 
triggered a significant and dose-dependent increase in the percentage of cell death, 
4 and 24 h following radiation treatment. Furthermore, with higher UVA doses of 10 
and 20 kJ/m2, the level of necrotic cell death was much higher than apoptotic cell 
death in ALA treated cells at both 4 and 24 h time points. Since necrotic cell death is 
known to occur following severe physical or chemical insult in cells, it appears that 
ALA treatment substantially sensitises the cells to higher doses of UVA, resulting in 
necrotic cell death. The observed dose-dependent increase in the percentage of cell 
death in ALA+UVA-treated cells in flow cytometry analysis (Figures 3.2 D-G) 
correlated well with a reciprocal decrease in the percentage of cell viability of the 
same conditions observed in MTT analysis (Figures 3.1 A-D).  
Taken together, the flow cytometry analysis was in agreement with the MTT 
analyses, as both assays confirmed that ALA-treatment strongly sensitises the 
HaCaT cells to UVA-induced cell damage and death. Furthermore it was apparent 
that necrosis was the primary mode of cell death induced by higher UVA doses of 20 
and 50 kJ/m2 in ALA-treated cells.  
Figure 3.2 (A-C) shows some examples of the raw data obtained by the flow 










Figure 3.2 (A-C): A representative example of flow cytometry analysis of HaCaT cells with ALA treatment 
alone or in combination with chelators (e.g. PIH) 24 h following UVA irradiation.HaCaT cells treated with 
UVA dose of 10 kJ/m
2
 alone (A) or treated with 0.5 mM ALA for 2 h at 37ºC in dark followed by UVA irradiation 
with a dose of 10 kJ/m
2





) treatments. Flow cytometry analysis was performed 24 h after UVA irradiation following Annexin 
V-PI dual staining. The diagrams on the left (P1) represent the gated cell population (i.e. excluding cell debris), 
while the middle and the right diagram represent the quadrants (Qs) and therespective percentages of live (Q3), 









Figures 3.2 D-E: The effect of ALA treatment on the percentage of necrosis and apoptosis in HaCaT cells 
4 h following varying UVA doses. 
HaCaT cells were treated with 0.5 mM ALA for 2 h at 37ºC in the dark prior to irradiation with UVA doses of 0, 10, 
20 or 50 kJ/m
2
. Control cells were treated identically except that they were either not irradiated and (or) not 
treated with ALA. Flow cytometry analysis was performed 4 h after UVA irradiation following Annexin V-PI dual 
staining (n=7-12). Figure 3.2 A represents the percentage of live, apoptotic and necrotic cells 4 h following UVA 
irradiation of ALA-treated or untreated cells at varying UVA doses; e.g. “U5-4h”. Figure 3.2 B compares the 
percentage of “Live” cell population in ALA-treated and untreated cells 4 h following UVA irradiation. ”U” in the 
graph refers to the UVA dose applied. 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
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Figures 3.2 F-G: The effect of ALA treatment on the percentage of necrosis and apoptosis in HaCaT cells 
24 h following UVA irradiation. 
HaCaT cells were treated with 0.5 mM ALA for 2 h at 37ºC in the dark prior to irradiation UVA doses of 5, 10, 20 
or 50 kJ/m
2 
(i.e. Conditions ALA_U5_24 h, ALA_U10_24 h, ALA_U20_24 h, and ALA_U50_24 h, respectively)
 
. 
Control cells were treated identically except that they were either not irradiated (i.e. C_24 h and ALA_U0_24 h), 
and (or) not treated with ALA (i.e. U5_24 h, U10_24 h, U20_24 h and U50_24 h respectively).  
Flow cytometry analysis was performed 24 h after UVA irradiation following Annexin V-PI staining (n=7-12). 
Figure 3.2 C represents the percentage of “Live”, “Apoptotic” and “Necrotic” cells as scored by flow cytometry, 24 
h following UVA irradiation of ALA-treated or untreated cells. Figure 3.2 D compares the percentage of “Live” cell 
population in ALA-treated and untreated cells 24 h following UVA irradiation. ”U” in the graph refers to the UVA 
dose applied. 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
¥: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 5 kJ/m
2
. 
§: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 10 kJ/m
2
. 



















































3.3. The Cytotoxic Effect of Iron Chelators on HaCaT Cells 
3.3.1. Comparison of the Cytotoxic Effect of Equimolar Concentrations of DFO, 
PIH and SIH in HaCaT Cells 
Prolonged exposure of cells to strong iron chelators has been linked to severe 
toxicity and cell death due to iron starvation (Richardson et al, 2007). Previous 
studies from this laboratory have shown that short exposure (i.e. 4-18 h) of cultured 
human skin cell lines FEK4 and HaCaT to iron chelators DFO, PIH and SIH up to a 
final concentration of 100 µM deplete the basal and UVA-induced levels of labile iron 
in cells without causing significant toxicity (Yiakouvaki et al, 2006; Pourzand et al, 
1999; Zhong et al, 2004; Reelfs et al, 2004; Aroun, 2012). 
In the present project we re-evaluated the potential toxicity of the above chelators in 
HaCaT cells under the growing conditions set in Materials and Methods. HaCaT 
cells were exposed to DFO, PIH and SIH at final concentrations of 20, 50 and 100 
µM for 24 and 72 h at 37oC, the level of cytotoxicity of the compounds was then 
evaluated with the MTT assay. 
 The results (Figure 3.3) showed that at 72 h, there was a significant reduction in 
enzymatic activity in cells treated with DFO and SIH at a final concentration of 100 
µM. For example, the comparison of the values obtained from MTT assay in cells 
treated with 100 M DFO for 24 or 72 h revealed a significant drop in percentage 
enzymatic activity from 93.1% at 24 h to 18.5% at 72 h. Similarly in cells treated with 
100 M SIH, the percentage enzymatic value dropped from 60.2% at 24 h to 22.9% 
at 72 h. However when HaCaT cells were treated with 20 M SIH, there was no 
toxicity observed up to 72 h. On the other hand PIH treatment appeared to have no 
significant toxicity to cells at all concentrations used, either at 24 h or 72 h. 
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In the light of these data in the present study, the incubation periods with the iron 
chelators were set up to a maximum of 18 h to avoid toxicity via iron depletion. In 
terms of concentration, DFO and PIH were used at a final concentration of 100 M, 
as these chelators did not exhibit any toxicity when incubated with cells for 24 h. SIH 
however was used at a lower concentration of 20 M, as the higher concentrations 
50 and 100 M were toxic to the cells even when incubated for 24 h.  
The calcein fluorescence assay was used to confirm that these concentrations of 
chelators were effective in depleting the intracellular labile iron after a period of 18 h 
incubation with cells (data not shown).    
 
Figure 3.3: Evaluation of the toxicity of DFO, PIH and SIH on HaCaT cells by MTT assay. 
HaCaT cells were treated with DFO, SIH and PIH at final concentrations of 20 µM, 50 µM  and 100 µM. MTT 
analysis was performed 24 h and 72 h following addition of the compounds (n=3-4). 
*: p<0.05, significantly different from cells treated with the corresponding compound at a final concentration of 20 
µM at 24 h time point. 
¥: p<0.05, significantly different from cells treated with the corresponding compound at final concentration of 20 
µM at 72 h time point.  
§: p<0.05, significantly different from the untreated cells at 24 h time point. 


































3.3.2. The Effect of ALA and Chelator Treatment on the Percentage of 
Apoptosis and Necrosis in HaCaT Cells 4 and 24 h Following UVA Irradiation 
To evaluate the effect of iron chelation in further improving the efficiency of ALA-PDT 
with UVA, the percentage of cell death was quantified using the sensitive flow 
cytometry-based Annexin V/ PI dual staining assay. For this purpose the 
exponentially growing HaCaT cells were treated with DFO (100 M), PIH (100 M) 
and SIH (20 M) for 18 h at 37ºC prior to ALA administration (0.5 mM, 2 h). Cells 
were then irradiated with UVA doses of 10, 20 or 50 kJ/m2 and analysed with flow 
cytometry 4 or 24 h following irradiation. Figures 3.4, 3.5 and 3.6 show the flow 
cytometry analysis of HaCaT cells that were treated with DFO (100 µM), PIH (100 
µM) and SIH (20 µM) prior to ALA and UVA treatments. In general the treatment of 
cells with all iron chelators alone, UVA alone or iron chelators + UVA combinations 
did not show any significant toxicity to the cells when compared to the corresponding 
untreated controls. However ALA-treatment of cells that were pre-treated with iron 
chelators, substantially sensitised the cells to UVA irradiation as monitored 4 or 24 h 
following radiation by flow cytometry. In terms of mode of cell death, the chelator + 
ALA-treated cells died predominantly by necrotic cell death at 24 h time points after 
UVA irradiation with both UVA doses of 10 and 20 kJ/m2.  
The comparison of the percentage of cell death between UVA-irradiated cells treated 
with ALA alone or combined with iron chelator pre-treatment clearly showed the 
higher efficiency of the chelator + ALA treatments in inducing cell death following 
UVA radiation. While this effect was observed both at 4 and 24 h time points with all 
UVA doses used, the higher efficiency of the chelators + ALA combination 
treatments was evident from the higher cell killing observed at the lowest UVA dose 
of 10 kJ/m2 when compared to the corresponding ALA-treated cells alone. Indeed 
131 
 
while the percentage of cell death in ALA-treated cells was 50.7% and 56.8% 
respectively, 4 and 24 h after UVA dose of 10 kJ/m2, in chelator + ALA-treated cells, 
the percentage of cell killing increased up to 86.6% and 90.4% respectively, 4 and 
24 h after the same UVA dose.  
Among the chelators used, SIH (20 M) appeared to be the most potent chelator 
when combined with ALA providing a substantial increase in the percentage of cell 
death following UVA irradiation. For example at 4 h time point with UVA dose of 10 
kJ/m2, the comparison of the percentage of cell death in chelator + ALA-treated cells 
revealed 71.1% cell death in DFO + ALA-treated cells, 68.1% cell death in PIH+ 
ALA-treated cells and 86.6% cell death in SIH+ALA-treated cells, when compared to 
untreated control cells. At 24 h with a UVA dose of 10 kJ/m2, the percentage of cell 
death increased up to 87.8% in cells treated with 20 µM SIH and ALA and up to 
90.4% and 82.5% in cells treated with 100 µM DFO and ALA and 100 µM PIH and 























 Figures 3.4 A-B: The effect of ALA and DFO (100 µM) on the percentage of necrosis and apoptosis in 
HaCaT cells 4 h following UVA irradiation. 
In DFO + ALA condition,  HaCaT cells were first treated with 100 µM DFO for 18 h and then with ALA 0.5 mM for 
2 h at 37 
o
C in the dark followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2
.( i.e. DFO+ ALA_U10_4h 
and DFO+ ALA_U20_4h). In ALA condition, cells  were treated with 0.5 mM ALA  alone (ALA) for 2 h at 37ºC 
under dark condition, followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2
 (i.e. ALA_U10_4h and  
ALA_U20_4h). Control cells were treated identically except that they were either not irradiated (i.e. C_4h, 
ALA_U0_4h, DFO100_U0_4h and DFO100+ALA_U0_4h) and (or) not treated with DFO or ALA (i.e. U10_4h and 
U20_4h). Flow cytometry analysis was performed 4 h after the UVA irradiation following Annexin V-PI staining 
(n=3-11). Figure 3.4 A  represents the percentage of “Live”, “Apoptotic” and “Necrotic” cells as scored by flow 
cytometry, 4 h following UVA irradiation of ALA-treated only or ALA treated in combination with DFO (100 µM). 
Figure 3.4B compares the percentage of “Live” cell population in ALA-treated, chelator+ALA treated and 
untreated cells 4 h following UVA irradiation. ”U” in the graph refers to the UVA dose implied. 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
¥: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 10 kJ/m
2
. 




















































Figures 3.4 C-D: The effect of ALA and DFO (100 µM) on the percentage of necrosis and apoptosis in HaCaT cells 24 h 
following UVA irradiation. 
In DFO + ALA condition, HaCaT cells were first treated with 100 µM DFO for 18 h and then with ALA 0.5 mM for 2 h at 37 
o
C in 
the dark followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2 
( i.e. DFO+ ALA_U10_24h and DFO+ ALA_U20_24h). In 
ALA condition, cells were treated with 0.5 mM ALA alone for 2 h at 37ºC in the dark, followed or not by UVA irradiation with 
UVA doses of 10 or 20 kJ/m
2 
(i.e.ALA_U10_24h and ALA_U20_24h). Control cells were treated identically except that they 
were either not irradiated (i.e. C_24h, ALA_U0, DFO100_U0_24h and DFO100+ALA_U0_24h) and (or) not treated with DFO or 
ALA (i.e. U10_4h and U20_4h). Flow cytometry analysis was performed 24 h after the UVA irradiation following Annexin V-PI 
dual staining (n=3-11). Figure 3.4 C (top) represents the percentage of “Live”, “Apoptotic” and “Necrotic” cells as scored by flow 
cytometry, 24 h following UVA irradiation of ALA-treated only or ALA treated in combination with DFO (100 µM). Figure 3.4 D 
(bottom) compares the percentage of “Live” cell population in ALA-treated, ALA+chelator treated and untreated cells 24 h 
following UVA irradiation. ”U” in the graph refers to the UVA dose implied. 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
¥: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 10 kJ/m
2
. 


















































Figures 3.5 A-B: The effect of ALA and PIH (100 µM) on the percentage of necrosis and apoptosis in 
HaCaT cells 4 h following UVA irradiation. 
In PIH + ALA condition,  HaCaT cells were first  treated with 100  µM PIH for 18 h and then with ALA 0.5 mM for 
2 h at 37 
o
C in the dark followed  by UVA irradiation with UVA doses of 10 or 20 kJ/m
2
( i.e. PIH+ ALA_U10_4h 
and PIH+ ALA_U20_4h)
 
. In ALA condition, cells were treated with 0.5 mM ALA alone for 2 h at 37ºC in the dark, 
followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2
 (i.e. ALA_U10_4h and ALA_U20_4h). Control cells 
were treated the same except that they were either not irradiated (i.e. C_4h, ALA_U0_4h, PIH100_U0_4h and 
PIH100+ALA_U0_4h) and (or) not treated with PIH or ALA (i.e. U10_4h and U20_4h). Flow cytometry analysis 
was performed 4 h after the UVA irradiation following Annexin V-PI dual staining (n=3-12). Figure 3.5 A (top) 
represents the percentage of “Live”, “Apoptotic” and “Necrotic” cells as scored by flow cytometry, 4 h following 
UVA irradiation of ALA-treated only or ALA treated in combination with PIH (100 µM). Figure 3.5 B (bottom 
graph) compares the percentage of “Live” cell population in ALA-treated, ALA+chelator treated and untreated 
cells 4 h following UVA irradiation. ”U” in the graph refers to the UVA dose implied. 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
¥: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 10 kJ/m
2
. 
































































Figures 3.5 C-D: The effect of ALA and PIH (100 µM) on the percentage of necrosis and apoptosis in 
HaCaT cells 24 h following UVA irradiation. 
In PIH + ALA conditions,  HaCaT cells were first treated with 100  µM PIH for 18 h and then with ALA 0.5 mM for 
2 h at 37 
o
C in the dark followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2
 (i.e. PIH+ALA_U10_24h 
and PIH+ALA_U20_24h) In ALA condition, cells  were treated with 0.5 mM ALA alone for 2 h at 37ºC in the dark, 
followed or not by UVA irradiation with UVA doses of 10 or 20 kJ/m
2 
(i.e. ALA_U10_24h and ALA_U20_24h) . 
Control cells were treated identically except that they were either not irradiated (i.e. C_24h, ALA_U0_24h, 
PIH100_U0_24h and PIH100+ALA_U0_24h) and (or) not treated with PIH or ALA (i.e. U10_24h and U20_24h). 
Flow cytometry analysis was performed 24 h after the UVA irradiation following Annexin V-PI dual staining (n=3-
12). Figure 3.5 C (top) represents the percentage of “Live”, “Apoptotic” and “Necrotic” cells as scored by flow 
cytometry, 24 h following UVA irradiation of ALA-treated only or ALA treated in combination with PIH (100 µM). 
Figure 3.5 D (bottom) compares the percentage of “Live” cell population in ALA-treated, chelator+ALA treated 
and untreated cells 24 h following UVA irradiation. ”U” in the graph refers to the UVA dose implied. 
 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
¥: p<0.05, significantly different from the ALA -treated cells irradiated with UVA dose of 10 kJ/m
2
. 







































UVA Dose (kJ/m2) 
Control (no compound)
ALA (0.5 mM,2h)
PIH (100 uM, 18h)
PIH+ALA
* 








Figure 3.6 A-B: The effect of ALA and SIH (20 µM) on the percentage of necrosis and apoptosis in HaCaT 
cells 4 h following UVA irradiation. 
In SIH + ALA conditions,  HaCaT cells were first treated with 20 µM SIH for 18 h and then with ALA 0.5 mM for 2 
h at 37 
o
C in the dark followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2
 (i.e. SIH+ALA_U10_4h and 
SIH+ALA_U20_4h). In ALA condition, cells were treated with 0.5 mM ALA alone for 2 h at 37ºC in the dark, 
followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2 
(i.e. ALA_U10_4h and ALA_U20_4h). Control cells 
were treated identically except that they were either not irradiated (i.e. C_4h, ALA_U0_4h, SIH20_U0_4h and 
SIH+ALA_U0_4h) and (or) not treated with SIH or ALA (i.e. U10_4h and U20_4h). Flow cytometry analysis was 
performed 4h after the UVA irradiation following Annexin V-PI dual staining (n=3-12). Figure3. 6 A (top) 
represents the percentage of “Live”, “Apoptotic” and “Necrotic” cells as scored by flow cytometry, 4 h following 
UVA irradiation of ALA-treated only or ALA treated in combination with SIH (20 µM). Figure 3.6 B (bottom) 
compares the percentage of “Live” cell population in ALA-treated, chelator + ALA treated and untreated cells 4 h 
following UVA irradiation. “U” in the graph refers to the UVA dose implied. 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
¥: p<0.05, significantly different from the ALA treated cells irradiated with UVA dose of 10 kJ/m
2
. 



























































Figures 3.6 C-D: The effect of ALA and SIH (20 µM) on the percentage of necrosis and apoptosis in HaCaT 
cells 24 h following UVA irradiation. 
In SIH + ALA conditions,  HaCaT cells were first treated with 20 µM SIH for 18 h and then with ALA 0.5 mM for 2 
h at 37 
o
C in the dark followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2
 (i.e. SIH+ALA_U10_24h and 
SIH+ALA_U20_24h). In ALA condition, cells were treated with 0.5 mM ALA alone for 2 h at 37ºC in the dark, 
followed by UVA irradiation with UVA doses of 10 or 20 kJ/m
2 
(i.e. ALA_U10_24h and ALA_U20_24h). Control 
cells were treated identically except that they were either not irradiated (i.e. C_24h, ALA_U0_24h, 
SIH20_U0_24h and SIH+ALA_U0_24h) and (or) not treated with SIH or ALA (i.e. U10_24h and U20_24h). Flow 
cytometry analysis was performed 24 h after the UVA irradiation following Annexin V-PI dual staining (n=3-11). 
Figure 3.6 C (top) represents the percentage of “Live”, “Apoptotic” and “Necrotic” cells as scored by flow 
cytometry, 24 h following UVA irradiation of ALA-treated only or ALA treated in combination with SIH (20 µM). 
Figure 3.6 D (bottom) compares the percentage of “Live” cell population in ALA-treated, chelator + ALA treated 
and untreated cells 24 h following UVA irradiation. “U” in the graph refers to the UVA dose implied. 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 
¥: p<0.05, significantly different from the ALA -treated cells irradiated with UVA dose of 10 kJ/m
2
. 




























































3.4. Protoporphyrin IX (PPIX) Measurement in HaCaT Cells 
3.4.1. PPIX Detection by HPLC in Chelator +/- ALA-treated HaCaT Cells  
To evaluate the level of PPIX produced in ALA-treated HaCaT cells pretreated or not 
with 20 M SIH, porphyrins were first extracted from cells as outlined in the 
Materials and Methods (section 2.7.2) section and then subjected to HPLC 
analysis. To identify the PPIX peak in the HPLC analysis, a pure PPIX standard was 
obtained from Frontier Scientific (Logan, UT, USA), and injected as a 1 µM solution 
in 0.1% TFA/ acetonitrile. As depicted in Figure 3.7A, this standard provided a peak 
at a retention time of 11.88 min. This was followed by injecting a similar standard 
PPIX sample prepared at final concentration of 0.1 µM in DMSO from PPIX powder 
purchased from Sigma (Cat No: P8293-1G). As depicted in Figure 3.7B, this sample 
although less pure than previous standard sample, also showed a major peak at the 
same retention time. Figure 3.7C shows the HPLC profile of the porphyrins 
extracted from untreated control HaCaT cells. As can be seen, the HPLC profile 
shows a single peak for PPIX at the expected retention time. Figures 3.7D, E and F 
illustrate the HPLC profiles obtained for porphyrins (material) extracted from HaCaT 
cells treated with 0.5 mM ALA alone, SIH+ALA and SIH+ALA, spiked with authentic 
pure PPIX from the Frontier Scientific kit, respectively. Overlapping these profiles 
(Figure 3.7G) confirms that upon ALA or SIH+ALA treatment of HaCaT cells, PPIX is 
the predominant porphyrin formed. The only difference is the amount of PPIX formed 
which as expected increased between ALA treated samples versus untreated 
controls and SIH+ALA treated samples versus samples treated with ALA alone. 
The treated samples were run by HPLC which was carried out by Dr R.Dondi from 
































































A. 1 µM PPIX (standard kit) 
B. 0.1 µM PPIX  




































































Figures 3.7 A-G: HPLC analysis of porphyrin extracts from HaCaT cells treated with ALA or 
SIH+ALA. HPLC was performed on a Dionex Ultimate 3000 (Sunnyvale, California, USA), equipped 
with a Phenomenex Gemini, 5 µm C-18 (150 x 4.6 mm) column, with a flow rate of 1 ml/min, and  
detecting at 404 nm. Mobile phase A was 0.1% TFA in water, and mobile phase B was 0.1% TFA in 
acetonitrile. Gradient was T = 0 min, B= 20%, T= 3 min, B= 20%, T= 13 min, B= 100%, T= 17 min, B= 
100%. A and B show the elution profiles obtained for PPIX standards from respectively Frontier 
Scientific (1 M in 0.1% TFA in acetonitrile), and Sigma (0.1 M in DMSO). Porphyrins were also 
extracted from HaCaT cells treated with 0.5 mM ALA alone or with 20M SIH+ALA as described in 
section 2.9.1. An equivalent amount of porphyrin extracts from the untreated control- (i.e. C), ALA- 
(i.e. D) and SIH+ALA- (i.e. E) were injected and the PPIX peak was observed at 11.88 min. F shows 
the HPLC profile of the SIH+ALA sample spiked with pure PPIX standard as in A. G shows an overlay 
of the profiles from D-F. Methodology described in section  2.9.1. The LOD value was calculated to be 


















































3.4.2. PPIX Measurement in HaCaT Cells Treated with ALA Alone 
As HPLC analysis confirmed that, PPIX was the predominant porphyrin formed in the 
cells after ALA or SIH+ALA treatments, the quantification of the PPIX induced 
following various treatments was now performed. This was carried out by fluorometer 
using the Sigma PPIX as the standard as detailed in Materials and Method 
section. 
. Figure 3.8A shows that ALA treatment significantly increases the intracellular level 













Figure 3.8 A: The effect of ALA treatment on the accumulation of intracellular protoporphyrin IX (PPIX) in 
HaCaT cells. 
HaCaT cells were treated with 0.5 mM ALA and incubated for 2 h at 37ºC in the dark. PPIX was extracted with 
1.5 M HCl. The increase in fluorescence was measured 4 h following ALA treatment by spectrofluorometer 
(excitation 404 nm, emission 604 nm). Data was expressed as mean ± SD (n= 5-13) and plotted as fold increase 
in PPIX levels when compared to untreated control set as 1. 












































3.4.3. PPIX Measurement in Chelator + ALA-treated HaCaT Cells 
 
The PPIX accumulation in HaCaT cells was also measured in cells that were treated 
with DFO, PIH and SIH at final concentrations of 20 and 100 M prior to ALA 
administration (0.5 mM, 2h). As can be seen in Figures 3.8B-D, the chelator 
treatment per se did not significantly increase the PPIX level in cells when compared 
to the corresponding untreated controls. However when the chelator treatment was 
followed by ALA administration, the PPIX levels in cells substantially increased when 
compared to cells treated with ALA alone. While PPIX accumulation in PIH + ALA- 
and DFO + ALA-treated cells was higher in cells treated with chelator concentrations 
of 100 µM than 20 µM, in ALA+SIH-treated cells both concentrations of 20 and 100 
µM yielded the same increase in PPIX level. In terms of fold-difference in PPIX level, 
the comparison between ALA-treated and chelator + ALA- treated cells revealed that 
20 µM SIH + ALA- and 100 µM DFO + ALA-treated cells accumulated 2.4- and 2.3- 
fold higher levels of PPIX than ALA-treated cells alone (Figures 3.8D and 3.8B, 
respectively). On the other hand, PIH+ALA-treated cells accumulated 1.5-fold higher 




3.8 B: The effect of ALA treatment alone and/or combined with DFO on the accumulation of intracellular 
protoporphyrin IX (PPIX) in HaCaT cells. 
HaCaT cells were treated with DFO at final concentration of 20 or 100 µM for 18 h at 37ºC. Cells were then 
treated with 0.5 mM ALA and incubated for 2 h at 37ºC in the dark. PPIX was extracted with 1.5 M HCl. The 
increase in fluorescence was measured 4 h following ALA treatment by spectrofluorometer (excitation 404 nm, 
emission 604 nm). Data was expressed as mean ± SD (n= 5-13) and plotted as fold increase in PPIX levels when 
compared to untreated control set as 1. 
*: p< 0.05, significant difference between ALA(0.5 mM)+DFO(100 µM) and ALA(0.5 mM). 






























Figure 3.8 C: The effect of ALA treatment alone and/or combined with PIH on the accumulation of 
intracellular protoporphyrin IX (PPIX) in HaCaT cells. 
HaCaT cells were treated with PIH at final concentration of 20 or 100 µM for 18 h at 37ºC. Cells were then 
treated with 0.5 mM ALA and incubated for 2 h at 37ºC in the dark. PPIX was extracted with 1.5 M HCl. The 
increase in fluorescence was measured 4 h following ALA treatment by spectrofluorometer (excitation 404 nm, 
emission 604 nm). Data was expressed as mean ± SD (n=5-13) and plotted as fold increase in PPIX levels when 
compared to untreated control set as 1. 
*: p< 0.05, significant difference between ALA (0.5 mM)+PIH(100 µM) and ALA(0.5 mM). 







































Figure 3.8 D: The effect of ALA treatment alone and/or combined with SIH on the accumulation of 
intracellular protoporphyrin IX (PPIX) in HaCaT cells. 
HaCaT cells were treated with SIH at final concentration of 20 or 100 µM for 18 h at 37ºC. Cells were then 
treated with 0.5 mM ALA and incubated for 2 h at 37ºC in the dark. PPIX was extracted with 1.5 M HCl. The 
increase in fluorescence was measured 4 h following ALA treatment by spectrofluorometer (excitation 404 nm, 
emission 604 nm). Data was expressed as mean ± SD (n=5-13) and plotted as fold increase in PPIX levels when 
compared to untreated control (i.e. 1). 
*: p< 0.05, significant difference between ALA(0.5 mM)+SIH(20 µM) and ALA(0.5 mM). 







































3.5. Reactive Oxygen Species (ROS) Measurement in HaCaT Cells 
3.5.1. ROS Measurement in HaCaT cells Treated with ALA Alone 
To evaluate the level of ROS generation by UVA in ALA-treated HaCaT cells, cells 
were first treated with ALA (0.5 mM) for 2 h and then exposed to UVA doses of 5 and 
10 kJ/m2. Next, cells were loaded with the dye indicator H2DCF-DA for 30 min and 
then the level of fluorescence generated by oxidised H2DCF-DA was measured by 
flow cytometry.  
 In this study we omitted the higher UVA doses of 20 and 50 kJ/m2, as these doses 
were highly damaging to ALA-treated cells and therefore it was anticipated that 
under these conditions, the dye would leak from the cells and as a result the 
accuracy of the measurement will be compromised. Furthermore the H2DCF-DA 
loading was done after UVA irradiation, as the dye is known to be oxidised by UVA 
radiation (unpublished data, this laboratory).   
Figure 3.9 illustrates a representative analysis of the ROS assay by flow cytometry. 
The displayed samples are the control (no compound) (3.9A), ALA (0.5 mM) (3.9B) 
and ALA+SIH (20µM) (3.9C) treated cells irradiated with a UVA dose of 5 kJ/m2 to 










Figure 3.9A-C: Representative example of ROS measurement in ALA/ALA+chelator ± UVA treated HaCaT 
cells (include the graphs with the shift) 
The scatter graphs are obtained from the FACS Canto machine and samples were analysed by flow cytometry. 
The first graphs on the left represent the gated cell population to be analysed. The graphs in the middle represent 
the shift to the right depending on extent of damage which expresses the increase level of cell death. The amount 









Figure 3.9 D: Measurement of intracellular reactive oxygen species (ROS) in ALA ± UVA treated HaCaT 
cells  
HaCaT cells were first treated with 0.5 mM ALA for 2 h at 37ºC in the dark and then irradiated with UVA doses of 
5 and 10 kJ/m
2
. Control cells were either not treated with ALA and /or not irradiated. 
Cells were then incubated with the fluorophore compound H
2
DCF-DA (5 µM final concentration) for 30 min in 
dark conditions at 37ºC. 
Cells were then rinsed and re-suspended in 0.1% BSA-PBS prior to analysis by flow cytometry.  
Data was expressed as mean ± SD (n=7) and plotted as fold increase in ROS when compared to untreated 
control (i.e. 1). 








































3.5.2. ROS Measurement in HaCaT Cells Treated with Chelators +/- ALA 
The level of ROS production was also evaluated in UVA-irradiated HaCaTcells that 
were treated with iron chelators DFO (100 M), PIH (100 M) and SIH (20 M) prior 
to ALA administration. The results (Figures 3.9 E-G) revealed that there was no 
significant ROS production in cells either irradiated with UVA doses of 5 or 10 kJ/m2 
alone or pre-treated with iron chelators and then irradiated with UVA doses of 5 or 10 
kJ/m2. However irradiation of cells treated with chelators + ALA with UVA dose of 5 
kJ/m2 caused a substantial increase in the production of ROS, although the level 
was comparable to that observed under identical conditions without chelator. Given 
the higher accumulation of PPIX observed in chelator + ALA-treated cells when 
compared to ALA-treated cells alone (see Figures 3.7A-D), the latter result 
suggested that the dye might have leaked out of the cells due to the higher extent of 
UVA-mediated damage in UVA-irradiated chelator + ALA-treated cells. This 
assumption was further strengthened by the observation that at a higher UVA dose 
of 10 kJ/m2, the level of ROS recorded by flow cytometry in chelators + ALA-treated 
cells was even lower than that measured with chelators + ALA-treated cells 
irradiated with the lower UVA dose of 5 kJ/m2.  
These results clearly showed the limitation of the H2DCF-DA assay in our study, and 
suggested that although the ROS production in UVA-irradiated chelator + ALA-
treated cells must have been higher than the corresponding UVA-irradiated ALA-
treated cells alone, the leakage of the dye from damaged cells had compromised the 





















































































Figure 3.9 E-G: Measurement of intracellular reactive oxygen species (ROS) in ALA- and/ or chelator treated HaCaT 
cells following UVA irradiation 
HaCaT cells were first treated with DFO (E) PIH (F) and SIH (G) at final concentrations of 20 or 100 µM for 18 h followed by 
treatment with 0.5 mM ALA for 2 h at 37ºC in the dark. Cells were then irradiated with UVA doses of 5 or 10 kJ/m2. Control cells 
were either not treated with ALA or chelators or not irradiated with UVA. 
Cells were then incubated with the fluorophore compound H2DCF-DA (5 µM final concentration) for 30 min in dark conditions at 
37ºC. 
The ROS measurement was performed by flow cytometry after UVA irradiation. 
Data was expressed as mean ± SD (n=7) and plotted as fold increase when compared to un-treated control (i.e. 1). 
*: p< 0.05, significant difference between ALA-treated and the corresponding UVA treated cells alone. 
¥: p<0.05, significant difference between ALA-+chelator-treated and the corresponding UVA treated cells alone. 














































3.6. Effect of Chelators +/- ALA Treatments on HaCaT Cell Survival Using 
Colony Forming Ability Assay 
Colony forming assay (CFA) examines the ability of a single cell to adhere, divide 
and form colonies 12-14 days following a given treatment. Hence this method shows 
the long-term effect of a particular treatment in terms of ‘true’ cell death as reflected 
by the inability of a cell to divide and form a colony. CFA has been found to be a 
valuable method for evaluating the effectiveness of iron chelators in improving the 
efficiency of ALA-PDT in treatment of various cancer i.e. skin cancer (Aroun, 2011, 
PhD thesis).  
In the present study, CFA was used to complement the data obtained by MTT and 
Annexin/PI flow cytometry assays that had only provided cytotoxicity information in 
chelator +/- ALA-treated cells up to 24 h after UVA irradiation (i.e. short-term effect).    
For the CFA assays, the exponentially growing HaCaT cells were first treated (or 
not) with SIH (20 µM), DFO (100 µM) and PIH (100 µM) for 18 h at 37ºC and then 
incubated (or not) with 0.5 mM ALA for 2 h at 37ºC in dark conditions. Cells were 
then irradiated with UVA doses of 5, 10 or 20 kJ/m2, and detached by trypsinization 
and seeded at a density of 1000 cells per plate. Cells were then left to grow and form 
colonies for 12-14 days at 37oC. After this period, cells were fixed and stained with 
crystal violet solution. The colonies were then counted and the values were 
expressed as a percentage of colony forming ability of the untreated control. The 
results (Figs 3.10 A-C) demonstrated that treatment of cells with ALA alone had no 
effect on cell survival. However UVA irradiation of ALA-treated cells caused a dose-
dependent decrease in percentage colony formation when compared to the 
untreated control cells. The UVA dose of 5 kJ/m2 already caused a 50% decrease in 
percentage colony formation of ALA-treated cells when compared to untreated 
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control cells. At a higher UVA dose of 20 kJ/m2, few colonies were observed in 
ALA+UVA-treated cells.  
The pre-treatment with chelators caused a substantial decrease in the percentage 
colony formation of ALA-treated cells with all UVA doses used. Fig. 3.10A shows the 
CFA data obtained with HaCaT cells treated with SIH alone, SIH + ALA followed or 
not by UVA irradiation. As can be seen, SIH treatment of cells per se at a final 
concentration of 20 M had no significant effect on percentage colony formation of 
unirradiated or UVA-irradiated cells when compared to untreated (and unirradiated) 
control cells. Similarly in unirradiated but SIH+ALA-treated cells, there was no 
significant decrease in the percentage colony formation when compared to untreated 
(and unirradiated) control cells. However in UVA-irradiated SIH + ALA-treated cells 
there was a significant decrease in the percentage colony formation when compared 
to untreated control cells. The comparison of CFA data between UVA-irradiated ALA 
-treated cells and UVA-irradiated SIH + ALA-treated cells further illustrated that SIH 
treatment prior to ALA-treatment of cells had caused a substantial decrease in the 
percentage colony formation with all UVA doses used. At UVA doses of 10 and 20 
kJ/m2 almost no colony was observed in SIH + ALA-treated plates, in agreement with 
the notion that increasing the PPIX levels by chelator pre-treatment significantly 
improves the percentage cell killing of ALA-treated cells following exposure to low 
doses of UVA.  
Figs 3.10B and 3.10C illustrate the CFA data obtained with cells treated with PIH +/- 
ALA +/- UVA- and DFO +/- ALA +/- UVA, respectively. As can be seen, in contrast to 
cells treated with SIH alone at a final concentration of 20 M, PIH and DFO 
treatments of HaCaT cells alone at final concentration of 100 M caused a significant 
decrease in percentage colony formation when compared to untreated control cells. 
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These results indicated that overnight treatment of cells with PIH and DFO at a final 
concentration of 100 M causes toxicity to cells presumably as a result of severe iron 
starvation. These results that are in contrast with data obtained with MTT and 
Annexin V/PI assays (i.e. Figs 3.3 and 3.4) and suggest that the CFA approach may  
provide information about the long-term effect of the chelator treatments which 
should be a crucial checkpoint for evaluating the cytotoxicity of the chelator 
treatments. Nevertheless with both PIH and DFO, the CFA data showed that PIH + 
ALA- and DFO+ALA-treated cells were more efficient in cell killing by UVA than ALA 
+UVA-treated cells alone, as illustrated with substantial decrease in the percentage 
colony formation of PIH/DFO + ALA + UVA-treated cells when compared to the 
corresponding ALA + UVA-treated cells alone.  
Overall these data illustrate that a combination of 20 M SIH with 0.5 mM ALA and 
UVA radiation is the most effective approach studied for improving the efficiency of 
the ALA-PDT approach in cultured HaCaT cells. At 20 µM, SIH exhibits no 
cytotoxicity per se by CFA method, but causes a substantial decrease in cell survival 
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Figure 3.10 A-C: The evaluation of the effect of SIH, DFO and PIH on HaCaT cells treated or not with ALA 
and/or UVA radiation with colony forming ability assay. 
Cells were first treated with A: SIH (20 µM), B: PIH (100 µM) and C: DFO (100 M) for 18 h at 37ºC and then 
treated or not with 0.5 mM ALA for 2 h at 37ºC in the dark. Cells were then irradiated (or not) with UVA doses of 
5, 10 and 20 kJ/m
2
. After treatments, cells were trypsinised and seeded at cell densities of 700 or 1000 cells/plate 
and allowed to grow for 12-14 days at 37
o
C. After this period cells were stained with crystal violet dye. The 
colonies were then counted and expressed as mean percentage colony formation of the untreated control (i.e. set 
as 100%) ± SD (n=4-7).  
*: p< 0.05, significant difference between ALA-treated and the corresponding UVA-treated cells alone. 
§: p<0.05, significant difference between ALA-treated at UVA dose of 5 kJ/m
2




¥: p<0.05, significant difference between SIH+ALA-treated and ALA treatment alone in cells irradiated with the 
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3.7. A Pilot Study with Met2 SCC Cell Line 
3.7.1. The Evaluation of the Cytotoxicity of Chelators SIH, PIH and DFO in Met2 
cell line by MTT Assay 
Based on the proof of concept data obtained with the HaCaT cell line, a small pilot 
study was carried out with a genuine skin cancer cell line (i.e. Met2). Met 2 cell line 
was derived from the skin of a patient suffering from SCC. Previous data from this 
laboratory using the calcein-based fluorescent assay had revealed that compared to 
HaCaT cells, Met2 cells have a 2-fold higher basal level concentration of labile iron 
and require higher concentrations of iron chelator treatment than HaCaT cells for 
complete labile iron depletion (A. Aroun, 2011, PhD thesis). As a result, in the 
present study it was speculated that Met2 cells may also require higher 
concentrations of iron chelator, than HaCaT cells to produce the same damaging 
effect following ALA and UVA treatments.  
For the pilot study, a dose-response study was performed by MTT assay where the 
Met2 cells were treated with increasing concentrations of the iron chelators DFO, 
PIH and SIH for 24 or 72 h. The rationale behind this study was to choose the 
maximum non-toxic concentration of each chelator at 24 h. Based on the IC50 
values obtained by A. Aroun (PhD thesis, 2011, this laboratory) for these chelators at 
72 h, i.e. 200 M PIH, 50 M SIH and 10 M DFO, the dose-response 
concentrations for the pilot study in Met 2 cells were chosen as follows: DFO 10-200 
M, SIH 10-200M and PIH 50-200 M. From the MTT data (Figure 3.11), the 
maximum non- toxic concentrations of chelators at 24 h were 50 M for SIH, 200 M 
for PIH and 100 M for DFO. These concentrations were chosen for the 18 h 





Figure 3.11. The Evaluation of the cytotoxicity of DFO, PIH and SIH in Met2 cells by MTT assay. 
Met2 cells were treated with SIH (20, 50, 100 and 200 µM) represented as “S” in the graph, DFO (10, 20, 50 and 
100 µM) represented as “D” in the graph and and PIH (50, 100 and 200 µM) represented as “P” in the graph. 
MTT analysis was performed 24 and 72 h following addition of compounds  
(n=3-4). 
 











































3.7.2. The Evaluation of the Level of Cell Damage in Chelator + ALA-treated 
Met2 Cells following UVA Irradiation with MTT Assay 
After the optimum concentration of chelators were determined, Met2 cells were 
treated with chelators for 18 h at 37oC prior to ALA administration (0.5 mM, 2 h) and 
then irradiated with UVA doses of 5, 10 and 20 kJ/m2.  MTT assay was performed 24 
h after UVA irradiation. Control cells were treated identically except that they were 
either not treated with chelators and (or) ALA, or not irradiated. The results (Fig 3.12 
A-C) showed a dose-dependent increase in cell damage in ALA + UVA-treated cells 
when compared to untreated, or unirradiated but ALA-treated cells. However 
compared to HaCaT cells, ALA-treated Met2 cells appeared to be more resistant to 
the UVA doses used. The chelator treatment of Met 2 cells prior to ALA 
administration did substantially sensitise the Met2 cells to UVA-induced cell damage, 
however the latter data was similar to that obtained with HaCaT cells. For example 
DFO+ALA treated Met2 cells irradiated with a UVA dose 10 kJ/m2 exhibited an 
enzymatic activity of 1.9±0.5% when compared to UVA-irradiated Met 2 cells treated 
with ALA alone ( i.e. 59.4±14.5%). In PIH + ALA- and SIH +ALA-treated Met 2 cells 
irradiated with a UVA dose of 10 kJ/m2, the percentage enzymatic activity also 
decreased to 2.2±1.1% and 1.9±0.7% respectively, when compared to untreated 
control cells (set at 100%).These results illustrated that chelator treatment prior to 
ALA-administration abolished the observed resistance of ALA-treated Met2 cells to 
UVA radiation.  The latter result demonstrated the effectiveness of the chelator 
treatment in improving the efficiency ALA-PDT with UVA in a genuine skin cancer 
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3.12 A-C: The effect of ALA and chelators on cell viability 24 h after irradiation of cells with low doses of 
UVA by MTT assay. 
Met2 cells were first treated with A: 50 µM SIH, B: 100 µM DFO and C: 200 µM PIH for 18 h at 37ºC. Cells were 
then treated with 0.5 mM ALA alone, for 2 h at 37ºC in the dark, prior to irradiation with UVA doses of  5, 10 or 20 
kJ/m. Control cells were treated identically except that they were either not irradiated and (or) not treated with 
chelator or ALA. MTT analysis was performed 24 h after irradiation. The results were expressed as mean ± SD 
(n=3-12). 
*: p<0.05, significantly different from the untreated control cells at corresponding UVA doses. 
§: p<0.05, significantly different from the ALA-treated cells. 
¥: p<0.05, significantly different from the ALA-treated cells irradiated with corresponding UVA doses. 
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3.7.3. The Evaluation of the Level of Cell Survival with CFA in Chelator + ALA-
treated Met2 Cells following UVA Irradiation 
To study the long-term effect of chelators with or without ALA- and (or) UVA 
treatments, exponentially growing Met2 cells were first treated with 50 µM SIH, 100 
µM DFO or 200 µM PIH for 18 h at 37ºC. This was followed by treatment of cells with 
0.5 mM ALA for 2 h at 37ºC in dark condition. Cells were then irradiated with at UVA 
doses of 5, 10 or 20 kJ/m2, after which they were detached by trypsinisation, and 
seeded at a cell density of 400 cells per dish and left to grow and form colonies for 8-
10 days at 37oC. After this period, cells were stained with crystal violet dye and the 
colonies were counted and the values expressed as percentage of colony forming 
ability of the untreated control. The results (Figs 3.13 A-C) demonstrated that in 
Met2 cells, ALA treatment had substantially decreased the cell survival of UVA-
irradiated cells, even with a low dose of 5 kJ/m2. Indeed, the results revealed that the 
low dose of 5 kJ/m2 already decreased the percentage colony forming of ALA-
treated Met2 cells to 13±7% of the untreated control. At a higher UVA dose of 10 
kJ/m2, the percentage colony forming of the ALA-treated cells was further decreased 
to 5.5±2% of the untreated control. At the highest UVA dose of 20 kJ/m2, no colony 
was observed in the ALA-treated plates. These data indicated that while the study of 
the short-term effect by MTT assay suggested that ALA-treated Met2 cells are more 
resistant to UVA than HaCaT cells, in the long-term, ALA-treated Met2 cells appear 
to be as sensitive as ALA-treated HaCaT cells to UVA-induced cell killing. The effect 
of chelator and ALA treatment on Met 2 cells was more drastic than that observed 
with HaCaT cells, as no colony was observed in chelator + ALA-treated cells with all 
UVA doses used. Taken together these data suggest that both in HaCaT and Met2 
cells, the chelator combination with ALA improves the efficiency of cell killing 
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following UVA irradiation when compared to ALA-treated cells alone. Furthermore 
the CFA data demonstrate that unlike HaCaT cells, in Met2 cells, the chelator 
treatment per se does not appear to be toxic to the cells, as the percentage colony 
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Figure 3.13 A-C: The evaluation of the Met 2 cell survival treated with SIH, DFO and PIH and (or) ALA and 
(or) UVA radiation with colony forming ability assay. 
Cells were first treated with A: SIH (50 µM), B: DFO (100 µM) and C: PIH (200 µM) for 18 h at 37ºC and then 
treated or not with 0.5 mM ALA for 2 h at 37ºC in the dark. The cells were then irradiated (or not) with UVA doses 
of 5, 10 and 20 kJ/m
2
. After treatments, cells were trypsinised and seeded at 400-800 cells density and allowed 
to grow for 8-10 days. 
After this period cells were stained with crystal violet dye. The colonies were then counted and expressed as 
mean percentage colony formation of the untreated control (set as 100%) ± SD (n=3-9). 
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3.8. Photo-Damaging Effects of Caged Iron Chelators:   
 
Out of all the chelators used in this project, SIH proved to be the optimum chelator 
for ALA-PDT with UVA despite the much lower concentration used. The lipophilic 
nature of SIH also makes it suitable for topical ALA-PDT of some skin conditions e.g. 
SCC. However prolonged topical application with such a chelator will have its own 
disadvantages as it could cause toxicity due iron starvation affecting the normal 
tissue surrounding the skin lesion. To overcome this problem, in collaboration with 
the group of Dr I. M. Eggleston (Pharmacy & Pharmacology department, Bath), we 
have designed a series of novel caged iron chelators (CICs) for topical application 
that only become activated upon exposure to UVA light. The caging groups render 
these compounds temporarily inactive as chelating agents, so ‘CICs’ do not chelate 
iron unless activated by external light sources (e.g.UVA), allowing for specific 
localised release within the targeted tissue (i.e. skin lesion) and therefore 
substantially decreasing the exposure of the surrounding normal skin tissue to strong 
iron chelators and their toxic side effects (Yiakouvaki et al, 2006). In practice these 
compounds could be applied topically to the affected area prior to ALA administration 
and selectively activated within the targeted area with low doses of UVA, sparing the 
normal tissue surrounding the skin lesion. 
In this study we selected two candidate CICs (i.e. BY123 and BY128) in which a key 
iron binding function of SIH is blocked by a photolabile aminocinnamoyl-based 
caging group. Upon activation by UVA, these CICs are uncaged releasing SIH and 3-
methyl-quinolin-2-one co-product. Therefore the photodamaging effect of these 
chelators in ALA-treated cells can be triggered on demand allowing controlled and 
dose- and context-dependent effect within the targeted cells. 
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Chemical structures of these chelators along with their photo-products are shown in 
schemes 3.2 (A) and (B) respectively. 
 
 
Scheme 3.2 (A): The figure on the left is the chemical structure of SIH (naked chelators, R=H). The  




Scheme 3.2 (B): 3-methylquinolin-2-ones, derived from BY123 (I) and BY128 (II).  
 
 
3.8.1. Chemical Analysis of BY123 and BY128 
For the purpose of this thesis, it was necessary to generate data to compare the 
effect of uncaged CICs generated in a simple chemical system (i.e. when SIH 
released by UVA) with that of parental chelator SIH in inducing damage in ALA-
treated cells following UVA radiation.  
BY123 and BY128 have been synthesised in the laboratory of Dr Eggleston 
(B.L.Young, PhD thesis, University of Bath, 2013), and was fully characterised by 1H 
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and 13C NMR and mass spectrometry. Purity was assessed to be > 95% by 
analytical HPLC. 
The uncaging of BY123 and BY128 with UVA has been studied in detail in the 
Eggleston laboratory. For BY123, exposure to a UVA dose of 250 kJ/m2 leads to 
clean and efficient uncaging. 
Fig 3.13A shows the HPLC chromatogram of the caged BY123, which upon UVA 
irradiation is transformed to two photoproducts namely SIH and the corresponding 3-
methyl-quinolin-2-one shown in Figure 3.13 B(i). A magnified profile as shown in Fig 
3.13 B(ii) confirms the formation of two products. 
 
Figure 3.13 A-B (i-ii): HPLC was performed on a Dionex Ultimate 3000 system (Sunnyvale, California, USA), 
equipped with a Phenomenex Gemini 5 µm C-18 (150 x 4.6 mm) column, with a flow rate of 1 ml/min, and detecting at 214 nm. 
Mobile phase A was 0.1% HCOOH in water, mobile phase B was 0.1% HCOOH in acetonitrile.  Gradient was T = 0 min, B = 5%; 
T = 10 min, B = 95%; T = 15 min, B = 95%; T = 15.1 min, B = 5%; T = 18.1 min, B = 5%. Chromatograms are of 4,5-
dimethoxyaminocinnamoyl-SIH derivative BY123, showing the intact CIC (A) and the UVA (250 kJ/m
2
)-irradiated compound (B 
(i)), which is magnified in B (ii) for ease of visibility with retention times of 7.708 min (A) and 6.517 and 6.625 (Bi) min. 
Taken from Benjamin. L. Young, PhD thesis, University of Bath, 2013 (with permission). 
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For BY128, HPLC also confirms that exposure to a UVA dose of 250 kJ/m2 leads  
to efficient uncaging. Unlike its corresponding 4,5-dimethoxy analogue (i.e. BY123),  
the uncaging of the methylenedioxy compound BY128 also generated a small amount  
of an unidentified photoproduct   in addition to SIH and the quinolin-2-one (Fig 3.14 B(i)).  
Once again the uncaging profile of BY128 also demonstrated that the retention times  
for the two photoproducts, namely SIH and the corresponding 3-methyl-quinolin-2-one  
were very similar as shown in Figs 3.14 B(i) and B(ii). 
 
 
Figure 3.14 A-B(i-ii): HPLC was performed on a Dionex Ultimate 3000 system (Sunnyvale, California, USA), 
equipped with a Phenomenex Gemini 5 µm C-18 (150 x 4.6 mm) column, with a flow rate of 1 ml/min, and 
detecting at 214 nm. Mobile phase A was 0.1% HCOOH in water, mobile phase B was 0.1% HCOOH in 
acetonitrile.  Gradient was T = 0 min, B = 5%; T = 10 min, B = 95%; T = 15 min, B = 95%; T = 15.1 min, B = 5%; 
T = 18.1 min, B = 5%. Chromatograms are of 4,5-methylenedioxyaminocinnamoyl-SIH derivative BY128, 
showing the intact CIC (A) and the UVA (250 kJ/m
2
)-irradiated compound (B (i)), which is magnified in B (ii) for 
ease of visibility. Retention times were 8.217 min (A) and 6.6 and 6.775 min in B(i). 
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Recent unpublished studies from the laboratories of Pourzand and Eggleston have 
revealed that aminocinnamoyl-based CICs can be effectively uncaged in a simple 
chemical systemwith a range of UVA doses between 50-500 kJ/m2 (see Figure 
3.15). This is illustrated for BY123 in Figure 3.15. HPLC analysis of uncaging with a 
range of UVA doses shows that parted uncaging of BY123 may be achieved at as 
low as 5 kJ/m2. However the lowest UVA dose that showed an effective uncaging 
effect was 20 kJ/m2 which yielded 76.9% of the uncaged compound. Any UVA doses 




Figure 3.15. The quantification of BY123 uncaging by UVA using HPLC. BY123 was irradiated in a quartz 
cuvette at exponential UVA doses of 5, 10, 20, 50, 100, 250 and 500 kJ/m
2
. The HPLC analysis was performed 
immediately after UVA irradiation. HPLC was performed on a Dionex Ultimate 3000 system (Sunnyvale, 
California, USA), equipped with a Phenomenex Gemini 5 µm C-18 (150 x 4.6 mm) column, with a flow rate of 1 
ml/min, and detecting at 214 nm. Mobile phase A was 0.1% HCOOH in water, mobile phase B was 0.1% HCOOH 
in acetonitrile.  Gradient was T = 0 min, B = 5%; T = 10 min, B = 95%; T = 15 min, B = 95%; T = 15.1 min, B = 
5%; T = 18.1 min, B = 5%. 



























3.8.2. Biological Evaluation of BY123 and BY128  
3.8.2.1. The Evaluation of the Cytotoxicity Effect of Uncaged CICs prior to 
application to cells in ALA-treated HaCaT Cells following UVA Irradiation  
The biological evaluations with CICs were first performed with uncaging of BY123 
and BY128 ina simple chemical system. The purpose of these experiments was to 
ensure that in ALA + UVA-treated cells, pre-treatment with uncaged CICs would 
provide the same superior photodamagaing activity that was observed with the 
parental chelator SIH when compared to the ALA + UVA-treated cells alone. For this 
purpose, the compounds were irradiated in quartz cuvettes with a UVA dose of 250 
kJ/m2 and their uncaging profiles were checked by HPLC (see Figures 3.13 and 
3.14) . HaCaT cells were treated with uncaged CICs (20 M) or parental iron 
chelator SIH (20 M) for 18 h prior to ALA treatment (i.e. 0.5 mM for 2h). Cells were 
then irradiated with a UVA dose of 10 kJ/m2. MTT analysis was then performed 24 h 
following UVA irradiation. The results (Figs 3.16 A-B) demonstrated that uncaged 
CICs per se did not cause any damage to the cells. However in CICs + ALA-treated 
cells, there was a substantial decrease in percentage enzymatic activity following 
UVA irradiation when compared to ALA + UVA-treated cells. The results also 
demonstrated that the extent of photodamage in CICs + ALA-treated cells following 
UVA irradiation is comparable to the effect observed in cells treated with SIH + ALA 
and UVA-irradiated. The latter data suggested that uncaging the CICs in a cell 
culture system, exhibits similar iron chelation properties to their parental iron chelator 
counterpart SIH. In other words the active SIH released by efficient uncaging of CICs 
by UVA appears to chelate intracellular labile iron to a comparable extent to that of 








Figure 3.16 A-B: The effect of uncaged BY123 (20 µM) (A) and BY128 (20 µM) (B) on HaCaT cell viability 24 
h after UVA irradiation: 
HaCaT cells were treated either with SIH (20 M) or CICs BY123 (20 µM) (A) and BY128 (20 µM) (B) that were 
uncaged in a simple chemical system with a UVA dose of 250 kJ/m
2
 for 18 h at 37ºC.
 
Cells were then treated/not 
with 0.5 mM ALA for 2 h at 37ºC in the dark prior to irradiation with a UVA dose of 10 kJ/m
2
. Control cells were 
treated identically except that they were either not irradiated and (or) not treated with ALA or chelator. 
MTT analysis was performed 24 h after irradiation. The results were expressed as mean ± SD (n=6-12) and 
plotted as percentage enzymatic activity of the untreated control. 
*: p<0.05, significantly different from the UVA irradiated cells alone. 
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3.8.2.2. The Evaluation of the Cytotoxicity Effect of the CICs Uncaged in ALA-
treated HaCaT Cells following UVA Irradiation  
It was also important to evaluate the photo-damaging effect of BY123 and BY128 un-
caged in a cell culture system . For this purpose, exponentially growing HaCaT cells 
were initially treated with BY123 or BY128 for 18 h at a final concentration of 20 µM, 
followed by irradiation with UVA doses of 20 or 50 kJ/m2 in order to uncage these 
CICs inside the cells. This was then followed by treatment of cells with ALA 0.5 mM 
for 2 h in dark conditions at 37 ºC and UVA irradiation with a dose of 10 kJ/m2.  
In these experiments, it was anticipated that in CIC-treated plates, UVA irradiation 
will uncage the compounds, releasing the active SIH inside the cells which then 
during the 2 h incubation following addition of ALA, will boost the level of PPIX 
accumulation to a higher extent than ALA-treated cells alone. To mimic the uncaging 
of CICs in cells by UVA and to ascertain the efficient release of SIH in irradiated 
cells, SIH was used as a control in some tissue culture plates where treatment was 
carried out for 2 h in conjunction with ALA treatment. It was anticipated that the 
response of cells to UVA would be similar in cells pre-treated either with CICs and 
ALA or  SIH and ALA , pending the efficient uncaging of the compounds in cells. 
Furthermore, to ascertain that the pre-irradiation of cells with UVA doses of 20 or 50 
kJ/m2 does not affect the result obtained, all plates destined to be treated with SIH 
(20 M) or ALA (0.5 mM) alone or their combination (i.e. for 2h at 37oC), were also 
pre-irradiated with UVA doses of 20 or 50 kJ/m2 (i.e. 20/0 and 50/0 conditions in 
Figures 3.17 and 3.18). The pre-irradiated cells were also subjected to a UVA dose 
of 10 kJ/m2 following ALA treatment (i.e. 20/10 and 50/10 condition in Figures 3.17 
and 3.18).  MTT assays were then performed 24 h after UVA irradiation. 
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The results (Figures 3.17 and 3.18) showed that in the absence of  pre-irradiation 
with UVA doses of 20 or 50 kJ/m2, BY123 or BY128 had no effect on percentage 
enzymatic activity of unirradiated (0/0 conditions) cells treated or not with ALA 0.5 
mM for 2 h. However the pre-irradiation of CIC-treated cells with either UVA doses of 
20 or 50 kJ/m2, significantly decreased the percentage enzymatic activity of ALA-
treated cells following UVA irradiation with a dose of 10 kJ/m2. Interestingly the effect 
obtained with pre-irradiated CICs + ALA was similar to that obtained with SIH + ALA 
following UVA irradiation with a dose of 10 kJ/m2. The latter data implied that both 
CICs had been efficiently uncaged inside the cells with both UVA doses of 20 or 50 
kJ/m2, as the effects observed was similar to those observed with SIH-treated cells. 
Finally the data provided in Figures 3.17 and 3.18 also clearly demonstrated that the 
pre-irradiation of CICs in cells substantially improves the efficiency of UVA-induced 
damage in ALA-treated cells when compared to ALA-treated cells alone.  
While the effect observed with SIH and pre-irradiated CICs appears to be similar in 
the treated cells, the CIC approach should have a clear advantage for topical ALA-
PDT of skin lesions, as the compounds will be applied as an inactive chelator and 
then specifically activated by UVA within the targeted lesion, providing a safer 
modality than the application of naked chelators to improve the efficiency of topical 
ALA-PDT. Furthermore the dual use of low doses of UVA for activation of CICs in 
cells and for inducing photodamage after ALA treatment justifies its use as an 








Figure 3.17 A-B: The evaluation of cytotoxicity of HaCaT cells treated with BY123 and ALA 24 h after 
irradiation of cells with UVA: 
HaCaT cells were treated with BY123 (20 µM) for 18 h at 37ºC, followed by irradiation with UVA doses of 20 (A) 
or 50 (B) kJ/m
2
. Cells were then treated/not with 0.5 mM ALA for 2 h at 37ºC in the dark and then irradiated with 
a UVA dose of 10 kJ/m
2
 (i.e. 20/10 or 50/10). Control cells were treated identically except that they were either 
not irradiated (i.e.0/0) or only pre-irradiated at UVA doses of 20 (A) or 50 (B) kJ/m
2
 (i.e. 20/0 or 50/0). MTT 
analysis was performed 24 h after the second irradiation. The results were expressed as mean ± standard 
deviation (n=3-10). 
*: p<0.05, significantly different from the UVA irradiated cells at 10 kJ/m
2
. 







































































Figure 3.18 A-B: The evaluation of cytotoxicity of HaCaT cells treated with BY128 and ALA 24 h after 
irradiation of cells with UVA 
HaCaT cells were treated with BY128 (20 µM) for 18 h at 37ºC, followed by irradiation with UVA doses of 20 (A) 
or 50 (B) kJ/m
2
.Cells were then treated or not with 0.5 mM ALA for 2 h at 37ºC in the dark and then irradiated 
with a UVA dose of 10 kJ/m
2
 (i.e. 20/10 or 50/10). Control cells were treated identically except that they were 
either not irradiated (i.e.0/0) or only pre-irradiated at UVA doses of 20 (A) or 50 (B) kJ/m
2
 (i.e. 20/0 or 50/0). MTT 
analysis was performed 24 h after the second irradiation. The results were expressed as mean ± standard 
deviation (n=3-10). 
*: p<0.05, significantly different from the UVA irradiated cells alone. 








































































 3.8.3. Measurement of the Effect of BY123 and BY128 on Cell Death in HaCaT 
Cells by Annexin V/ PI Dual Staining Assay 
The percentage of cell death was also quantified in cells treated with CICs and ALA 
following UVA irradiation by flow cytometry using AnnexinV/PI-dual staining assay.  
For this purpose, the exponentially growing HaCaT cells were treated overnight with 
either BY123 (20 M) or BY128 (20 M) after being uncaged in a simple chemical 
systemwith a UVA dose of 250 kJ/m2. The cells were then treated or not with 0.5 mM 
ALA and incubated for 2 h at 37ºC in dark condition, before being exposed to UVA 
doses of 10 and 20 kJ/m2.  The percentage of cell death was measured after staining 
the cells with Annexin V/ PI fluorescent dyes. The results (Figure 3.19A) 
demonstrated that pre-treatment of cells with the uncaged BY123 significantly 
sensitised the ALA-treated cells to UVA doses of 10 and 20 kJ/m2 in comparison to 
the corresponding ALA-treated cells  alone. The comparison of the percentage of cell 
death obtained with ALA-treated cells that were pre-treated with either SIH or 
uncaged  BY123, revealed that in  uncaged BY123 + ALA-treated cells, UVA dose of 
10 kJ/m2 caused slightly less cell death  than in SIH + ALA-treated cells (i.e. 
74.7±1.4% versus 86.6±7.1%, respectively). Also with higher UVA dose of 20 kJ/m2, 
the percentage of live cells in uncaged BY123 + ALA-treated cells was very similar to 
SIH + ALA-treated cells (i.e. 9.1±1.9% versus 10.1±4.9%, respectively).  
A similar experimental set up was also designed for BY128. The uncaging of BY128 
was also performed in a simple chemical systemwith a UVA dose of 250 kJ/m2 and 
cells were pre-treated or not with uncaged BY128 for 18 h at 37oC prior to ALA 
treatment and UVA irradiation with UVA doses of 10 or 20 kJ/m2. The results (Figure 
3.19B) demonstrated that the percentages of live cells in cells treated with uncaged 
BY128 and ALA were not significantly different at both UVA doses of 10 and 20 
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kJ/m2. On the other hand, the percentage of live cells following UVA dose of 10 
kJ/m2 was 32±10.9% for cells treated with uncaged BY128 and ALA and 19.6±7.0% 
for ALA+ SIH-treated cells. Following UVA dose of 20 kJ/m2, the percentages of live 
cells decreased to 18.4±6.7% and 10.1±4.9% in cells treated with uncaged BY128 + 
ALA and SIH + ALA, respectively. 
Taken together these results demonstrated that the photodamaging effect of 
uncaged CICs and ALA combination was more effective than the effect observed 
with ALA treatment alone. Furthermore it appeared that uncaged CICs and ALA 















Figure 3.19 A-B: The effect of uncaged BY123 and BY128 (in a simple chemical system) on the 
percentage of necrosis and apoptosis in HaCaT cells 24 h following UVA irradiation. 
 
HaCaT cells were first treated with uncaged BY123 (20 M) (A), uncaged BY128 (20 M) (B) or SIH (20 M) for 
18 h at 37ºC. Cells were then treated (or not) with 0.5 mM ALA for 2 h at 37ºC in the dark prior to irradiation with 
UVA doses of 10 or 20 kJ/m
2
. Control cells were treated identically except that they were either not irradiated and 
(or) not treated with chelators. Flow cytometry analysis was performed 24 h after the UVA irradiation following 
Annexin V-PI dual staining (n=3-13). 
 
For A: *: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 10kJ/m
2
. 
¥: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 20 kJ/m
2
. 
§: p<0.05, significantly different from the ALA+SIH  treated cells irradiated with UVA dose of 10 kJ/m
2
. 
†: p<0.05, signficantly different from the ALA+SIH treated cells irradiated with the UVA dose of 20kJ/m
2
. 




For B: *: p<0.05, significantly different from the ALA-treated cells irradiated with UVA dose of 10 kJ/m
2
. 

























































3.8.4. PPIX Measurement in HaCaT Cells Treated with BY123 and BY128: 
 
In order to compare the extent of UVA-induced damage and cell death with the level 
of PPIX accumulation in cells treated with uncaged CICs and ALA, the exponentially 
growing HaCaT cells were treated with caged BY123 and caged BY128 at final 
concentration of 20 µM and incubated for 18 h. For uncaging purposes, the BY123- 
and BY128-treated cells were irradiated   with UVA doses of 20 or 50 kJ/m2 prior to 
ALA treatment (0.5 mM). As a control, parental SIH was also added in conjunction 
with ALA to some plates and cells were then incubated for 2h at 37ºC in dark 
condition. The latter was to mimic the effect of uncaging of CICs  in a cell culture 
system that would yield SIH as the photoproduct.. Porphyrins were then extracted 
from the cells and quantified by fluorescence. 
The results (Figures 3.20 A-B) showed that in the absence of UVA irradiation (i.e. 
0/0), the level of PPIX in cells treated with either caged BY123 or BY128 alone had 
no significant effect on PPIX level when compared to untreated control cells. 
However when CICs-treated cells were uncaged in the cell culture system with UVA 
doses of 20 or 50 kJ/m2 and then treated with ALA for 2h, the intracellular level of 
PPIX increased significantly when compared to untreated cells. The comparison of 
the results obtained with uncaged BY123 + ALA- and uncaged BY128 + ALA- 
treated cells (i.e. both uncaged in cell culture systems) revealed that uncaged BY128 
+ ALA  combination  treatment is more effective in increasing the level of PPIX in 
cells thanuncaged BY123 + ALA  combined treatment. Similarly the comparison of 
uncaged CICs +ALA-treated cells in a cell culture system with cells treated with SIH 
and ALA revealed that the uncaged BY128 (in a cell sulture system) + ALA 
combination treatment is as effective as the SIH +ALA combined treatment in 
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increasing the level of PPIX in cells. However the level of PPIX accumulation for the 
uncaged BY123 (in a cell sulture system) + ALA combination treatment was much 
lower than the SIH + ALA combined treatment. One reason for this might have been 
that BY123 was not effectively uncaged inside the cells prior to ALA addition. This 
assumption was further strengthened by the observation that treatment of cells with 
ALA and BY123 that was uncaged in a simple chemical system prior to addition to 
cells  yielded the same increase in PPIX as the SIH + ALA combined treatment.  
Overall these data demonstrated that treatment of cells with either uncaging of CICs 
in a simple chemical system or in a cell culture system, are capable of increasing the 














Figure 3.20 A: The effect of ALA treatment alone and/or ALA treatment combined with SIH at 20 µM or 
BY123 at 20 µM on the accumulation of intracellular protoporphyrin IX (PPIX) in HaCaT cells. 
HaCaT cells were treated with 20 µM of caged BY123 (A) for 18 h at 37ºC and then irradiated with UVA doses of 
20 or 50 kJ/m
2
 .SIH was then added at 20 µM either alone or in combination with 0.5 mM ALA and incubated for 
2 h at 37ºC in the dark before being trypsinised with 0.25% trypsin. The caged/un-caged BY123 were also 
treated with the same dose of ALA or not. PPIX was extracted in a final solution of 1.5 N HCl. The increase in 
fluorescence was measured around 4 h post exogenous addition of ALA at excitation level of 404 nm and 
emission level of 604 nm by spectrofluorometer and expressed as fold difference in PPIX of untreated control 
(n=6-15). 
*: p< 0.05, significantly different from ALA-treated cells pre-irradiated with the UVA dose of 0 kJ/m
2
. 
¥: p< 0.05, significantly different from ALA-treated cells pre-irradiated with the UVA dose of 20 kJ/m
2
. 












































3.20 B: The effect of ALA treatment alone and/or ALA treatment combined with SIH (20 µM) or BY128 (20 
µM)  on the accumulation of intracellular protoporphyrin IX (PPIX) in HaCaT cells. 
HaCaT cells were treated with 20 µM of caged BY128 (B) for 18 h at 37ºC and then irradiated with  UVA doses of 
20 or 50 kJ/m
2
 .SIH was then added at 20 µM either alone or in combination with 0.5 mM ALA and incubated for 
2 h at 37ºC in the dark before being trypsinised with 0.25% trypsin. The caged/uncaged BY128 were also treated 
with the same dose of ALA or not. PPIX was extracted in a final solution of 1.5 N HCl. The increase in 
fluorescence was measured around 4 h post exogenous addition of ALA at excitation level of 404 nm and 
emission level of 604 nm by spectrofluorometer and expressed in terms of fold increase (n=6-15). 
*: p< 0.05, significantly different from ALA-treated cells pre-irradiated with the UVA dose of 0 kJ/m
2
. 
¥: p<0.05, significantly different from ALA-treated cells pre-irradiated with the UVA dose of 20 kJ/m
2
. 













































3.8.5. ROS Measurement in HaCaT Cells Treated with BY123 and BY128: 
For ROS measurements, exponentially growing HaCaT cells were treated with SIH 
or uncagedBY123 and -BY128 (in a simple chemical system)at a final concentration 
of 20 µM for 18 h at 37ºC prior to ALA treatment (i.e. 0.5 mM, 2h at 37ºC in dark 
condition). Cells were then irradiated with UVA doses of 5 and 10 kJ/m2. Next, cells 
were incubated with H2DCF-DA for 30 min before being stained with PI and analysed 
by flow cytometry. 
The results (Figure 3.21 A-B) demonstrated that treatment with BY123 and BY128 
in combination with ALA and UVA dose of 5 or 10 kJ/m2 showed a lower fold increase 
in ROS than cells treated with ALA alone or combined with SIH. One explanation for 
the latter result may be related to leakage of the dye from the damaged cells as 
previously discussed in section 3.6. Nevertheless the ROS values obtained for CICs 
and ALA are not significantly different from SIH and ALA treatment with UVA doses, 
consistent with the notion that the combination of CICs with ALA is almost certainly 
an effective alternative to improve the efficiency of ALA-PDT for treatment of skin 
cancer and other skin disorders. Furthermore CIC-based ALA-PDT will be a safer 
















Figure 3.21 A-B: Measurement of intracellular reactive oxygen species (ROS) produced by UVA in HaCaT 
cells pre-treated with ALA  and/or uncaged BY123 (20 µM) and BY128 (20 µM)(in a simple chemical 
system) tion in HaCaT cells. 
HaCaT cells were first treated with uncaged BY123 (A) or BY128 (B) (i.e. uncaged in a simple chemical system 
at UVA dose of 250 kJ/m
2
) for 18 h at 37ºC followed by treatment or not with 0.5 mM ALA for 2 h at 37ºC in the 
dark. Cells were then irradiated with UVA doses of 5 and 10 kJ/m
2
. Cells were then incubated with the 
fluorophore compound H
2
DCF-DA for 30 min in dark conditions at 37ºC and then analysed by flow cytometry. 











































































Topical ALA- or its methyl ester (MAL)-based PDT has considerably advanced the 
management of NMSC, providing a treatment option for AK, SCC, and BCC, with 
good clinical outcomes, low recurrence rates and enhanced cosmetic acceptability. 
However the most common and troublesome acute adverse effect of topical PDT 
remains the burning or stinging pain that occurs during light exposure, and may 
continue post-exposure in a minority of cases. Management of treatment-related 
pain still remains a considerable challenge in patients. Further optimization of the 
light source, dose and period of treatment therefore seems crucial to try and alleviate 
pain.  
The study carried out in this PhD project provides strong evidence that applying low 
doses of UVA radiation to ALA-treated skin cells is a fast and effective approach to 
promote cell death. Further improvement in the extent of cell killing with lower UVA 
doses was achieved by the use of iron chelators that were administered to cells 
either prior to or in conjunction with ALA treatment. Therefore applying low doses of 
UVA radiation in combination with iron chelators and ALA may be used as an 
effective intervention strategy to decrease considerably the time of radiation 
treatment and therefore reduce the pain associated with prolonged conventional 





4.1. UVA as a Light Source for Topical ALA-PDT  
Application of UVA as a light source in topical ALA-PDT is thought to be more 
advantageous than the red light currently used in clinics for this therapy. Porphyrins 
are important UVA chromophores and the porphyrin of interest in this project, PPIX 
has an absorption peak around 405-410 nm that tails with the UVA range (320-410 
nm). The Sellas broad spectrum UVA lamp used in this study that has a distinct peak 
in 405 nm, making it very suitable for ALA-PDT studies in skin cells. UVA also has 
the potential of generating ROS notably 1O2 and H2O2 which leads to biological 
damage and cell death in exposed cells/ tissues through iron-catalysed oxidative 
reactions (Vile and Tyrrell, 1995).  
It has previously been demonstrated that accumulating intracellular concentrations of 
PPIX by application of exogenous ALA, strongly sensitised human skin fibroblasts to 
low doses of UVA (Pourzand et al, 1999b). A study by Buchczyk et al  (2001) 
comparing red, green and UVA light sources in ALA-PDT of human skin cells further 
demonstrated that compared to red light sources, UVA-based ALA-PDT was 40-fold 
more potent in killing cultured human skin fibroblasts and still 10-fold more potent 
than ALA-PDT with green light. The high cytotoxicity of UVA-based ALA-PDT relied 
on the efficient formation of 1O2 as was demonstrated with modulators of 
1O2 half-
life. In the present project, we also provide further evidence that treatment of skin 
keratinocytes with ALA strongly sensitises the cells to low UVA doses. Keratinocytes 
are known to be highly resistant to UVA-induced cell damage and cell death (see 
Reelfs et al, 2010). The higher antioxidant defence mechanism and lower basal level 
of labile iron in epidermal keratinocytes appear to contribute to their higher 
resistance to UVA-induced oxidative damage, when compared to dermal fibroblasts 
(Pourzand and Tyrrell, 1999; Zhong et al, 2004; Reelfs et al, 2010).  
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Studies from this laboratory have demonstrated that primary skin keratinocytes as 
well as the spontaneously immortalised keratinocyte cell line HaCaT are resistant to 
UVA-induced cell killing up to a high dose of 750 kJ/m2 (see Reelfs et al, 2010). At 
natural exposure levels this UVA dose translates to over 4.5 h of sun exposure at 
sea level. The results of this thesis demonstrated that ALA-treatment sensitised 
HaCaT cells to low doses of UVA within 5-20 kJ/m2. At natural exposure levels, 
these UVA doses are achieved within 2-8 min of sunlight exposure to the skin, 
respectively. The data obtained with colony forming assay (Figure 3.10) 
demonstrated that already with a UVA dose of 5 kJ/m2, 50% of HaCaT cells are 
killed. At a higher dose of 20 kJ/m2, no colonies survived in ALA-treated HaCaT 
plates. The pre-treatment of cells with iron chelators DFO, PIH and SIH further 
sensitised the ALA-treated cells to UVA-mediated cell killing with no cell survival at a 
UVA dose of 10 kJ/m2. In a clinical setting, typically with a fluence rate of 150 W/cm2, 
and a distance of 30 cm, the irradiation time with a UVA dose of 10 kJ/m2 will be 
around 30 seconds. The efficient rate of cell killing with such short pulses of UVA is 
thought to make the pain associated with topical ALA-PDT more tolerable. In 
comparison, for example in Bath Royal United Hospital, the MAL-PDT of AK is 
carried out with an LED (631 nm) light source for 9 min to achieve a dose of 37 
J/cm2 with a distance of 5-8 cm. The more effective and specifically the fast 
damaging consequence of the UVA protocol when compared to prolonged high 
intensity light radiation treatment, highlights that the proposed strategy here is a 
rapid and simple means to improve the effectiveness of conventional ALA-PDT of 
skin lesions while decreasing considerably the time of irradiation that is directly 
related to the extent of pain endured by patients.    
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Blue light (417 nm) that tails closely with the Soret band of PPIX (410 nm) has been 
shown to be very effective in ALA-PDT of superficial skin lesions such as AK and 
superficial BCC. Compared to red light, blue light provokes a very effective cell 
inactivation down to about 2 mm from the surface of human skin and muscle tissue 
(Szeimies et al, 1995; Peng et al, 1997). In the United States, a combination of an 
alcohol-containing ALA solution (i.e. Levulan Kerastick) with blue light has been 
approved for clinical treatment of AK (see Klein et al, 2008). The work outlined here 
addresses further the suitability of UVA-based ALA-PDT as a possible therapy for 
epidermal diseases, including NMSC. Based on the data presented in this report, the 
effectiveness of UVA-based ALA-PDT could be further tuned in future studies using 
a series of cultured AK and SCC cell lines in both monolayer and 3-dimensional 
organotypic raft cultures. The best protocol could then be evaluated in an open pilot 
study in collaboration with dermatologists looking at a few patients for instance with 
symmetrical AK lesions where the effectiveness of UVA-based ALA-PDT could be 
compared with ALA-PDT with conventional light sources.  
The UVA-based ALA-PDT may also have a future in the treatment of psoriasis, as at 
present the topical ALA-PDT clinical studies with psoriatic patients are often 
interrupted because of the severe pain experienced by the patients. So decreasing 
the time of ALA-PDT with the use of UVA as the light source, may provide a powerful 
alternative to present modalities. Psoralen with UVA has already been used for 
treatment of psoriasis, but this treatment is accompanied with severe side effects. 
Furthermore while in general the PUVA therapy doses are between 5-10 kJ/m2, 
because of the necessity of repeated therapies, the cumulative UVA doses in PUVA 
could reach values up to 250-500 kJ/m2 that are detrimental to patients given the 
DNA damaging nature of psoralen. In comparison the UVA-based ALA-PDT strategy 
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is likely to be much more effective with the very low and non-toxic doses used and 
especially with no cumulative effect. 
The limitation of UVA-based ALA-PDT when compared to red light-based therapy 
may be related to the lower depth of the penetration of UVA. Indeed compared to red 
light, the proportion of UVA reaching deeper sections of epidermis will be much 
lower. This will limit the use of the UVA protocol for the treatment of superficial skin 
lesions only. Therefore the use of UVA-based ALA-PDT may be more suitable for 
the treatment of AK as well as superficial cases of SCC and BCC but not for thick 
nodular BCC or advanced SCC cases.    
 
4.2. The Use of Iron Chelators in ALA-PDT  
The use of iron chelators has been shown to improve the level of accumulation of 
PPIX in ALA-treated skin cells. Several cellular studies have evaluated this approach 
using iron chelators EDTA (Berg et al, 1996; Hanania and Malik, 1992), DFO (Berg 
et al, 1996; Ortel et al, 1993) and CP94 (Bech et al, 1997; Pye and Curnow, 2007). 
Some cellular studies have also compared directly the ability of the iron chelators 
EDTA and DFO or alternately CP94 and DFO to enhance PPIX levels in ALA-treated 
cells (Berg et al, 1996; Pye and Curnow 2007). In these studies the order of efficacy 
of iron chelators in improving the efficiency of ALA-PDT has been proposed as 
CP94>DFO>EDTA. The efficacy of CP94 compared to other two chelators has been 
linked to its lower molecular weight and higher lipophilicity (Smith et al, 1997). CP94 
has been extensively studied in animal models, and has proven to be effective in 
inducing greater tumour necrosis after light treatment than ALA-treated tumours 
alone. Nevertheless CP94 is a bidentate chelator and its ability to bind iron is lower 
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than tridentate chelators such as SIH and PIH or hexadentate chelators such as 
DFO. Furthermore bidentate chelators are not powerful iron scavengers at low iron 
concentrations (Ma et al, 2004). In the present study we evaluated the ability of 
tridentate chelators SIH and PIH to improve the efficiency of ALA-PDT in ALA-
treated HaCaT and Met2 cell lines. DFO was used as a control here so that the 
results obtained from this study could be compared to other cellular studies 
performed with DFO and ALA-PDT. Because of the highly hydrophilic nature of DFO, 
cellular studies with this chelator are performed after 6-18 h incubation time, allowing 
DFO to enter the cells and to efficiently mop up the intracellular labile iron. Because 
of this limitation of DFO, it was decided to incubate all chelators for 18 h, so that iron 
chelating effects of the compounds could be compared effectively. The results 
clearly demonstrated that all of the three chelators used were effective in enhancing 
the level of PPIX after ALA administration which then resulted in efficient photokilling 
following UVA irradiation with low UVA doses of 5-20 kJ/m2. Nevertheless the iron 
chelator SIH appeared to be the most efficient iron chelator as at a lower 
concentration (20 M) it provided equal efficiency in photokilling in ALA-treated cells 
after 2 or 18 h incubation. Furthermore in colony forming assay, in contrast to PIH 
and DFO, SIH treatment per se did not exhibit any toxicity in cells. Moreover SIH is 
more lipophilic than PIH and therefore it is more suitable for topical application in 
ALA-PDT protocols. Nevertheless topical application of ‘naked’ SIH to a skin lesion 
will affect the normal tissue surrounding the lesion, causing toxicity due to iron 
starvation. To overcome this problem, SIH-based CICs (BY123 and BY128) are 
introduced in this report as a safer alternative to topical ALA-PDT with ‘naked’ SIH.  
CICs do not chelate iron unless activated by external light sources (e.g.UVA), 
allowing for specific localised release within the targeted tissue (i.e. skin lesion) and 
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therefore substantially decreasing the exposure of the surrounding normal skin 
tissue to strong iron chelators and their toxic side effects. In practice these 
compounds could be applied topically to the affected area the night before. On the 
day of ALA-PDT, the isolated skin lesion would be irradiated with a low dose of UVA 
(20-50 kJ/m2) to provoke uncaging of the CIC  and the release of the active SIH 
within the targeted area, sparing the normal tissue surrounding the skin lesion.  ALA 
cream would then be applied to the area and isolated from light for 2 h. The skin 
lesion could then be irradiated with a low dose of UVA (10 or 20 kJ/m2) consistent 
with a clinical setting (i.e. UVA fluence rate of 150 W/cm2, and a distance of 30 cm) 














4.3. Future work 
Diagram 4.1 provides the summary of the approaches used in the present study to 
improve the efficiency of ALA-PDT in skin cells using UVA light. While approaches A 
and B were studied in depth in both HaCaT and Met 2 cells, due to lack of time the 
CIC approach illustrated in C was only performed as a pilot study using the HaCaT 
cell line. Therefore an immediate follow up to the present project will be to check the 
approach C in Met2 cells that are derived from a SCC patient. 
 
Diagram 4.1. Summary of the different strategies used in the present study to improve the efficiency of 
ALA-PDT in cultured skin cells.  
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The CIC approach will then need to be validated in cell lines derived from the skin 
biopsies of patients suffering from AK and superficial SCC and BCC conditions. The 
laboratory of Dr Pourzand has expertise in setting up three dimensional (3D) 
organotypic de-epidermalised (DED) skin raft cultures that closely mimic the 
structure of the skin. Therefore as a future investigation, it will be possible to 
evaluate the efficiency of the CIC protocol for ALA-PDT with UVA in a series of 3D-
DED raft cultures set up with keratinocytes isolated from AK and superficial SCC and 
BCC biopsies. The 3D-DED raft culture system will also allow the determination of 
the exact in situ UVA dose necessary for uncaging of the CICs, which might be 
slightly higher than those set in monolayer culture studies. Dr Reelfs from this 
laboratory has already established an enzymatic protocol that would permit the 
separation of the epidermal layer from the raft culture. Following further enzymatic 
digestions, the obtained keratinocyte cell suspension can be subjected to flow 
cytometry-based CA-assay to measure the extent of labile iron depletion by uncaged 
CICs. The level of photodamage and photokilling in CIC + ALA-treated raft cultures 
pre-irradiated or not with UVA could then be investigated either morphologically 
following haematoxylin/eosin staining of raft sections or by using more appropriate 
analytical markers of cell damage and cell death (e.g. TUNEL assay, caspase 3 
immuno-histochemistry). Furthermore Dr Eggleston’s laboratory is presently 
designing fluorescent CICs allowing the visualisation of the depth of penetration of 
the compounds in 3D-DED skin raft cultures. These investigations are crucial to 
further validate the studies performed in this thesis.  
These validation experiments may be followed by further investigations using skin 
xenografts of cancerous skin cell lines in animal models. Formulation studies may 
197 
 
also be performed in parallel in the animal models used to identify the best topical 
formulation for effective delivery of the CICs to skin. 
Future work may also include the design and study of novel CICs for the purpose of 
ALA-PDT using chelators such as CP94 for comparison purposes or other clinically 
useful iron chelators such as Deferasirox (Novartis), an oral lipophilic iron chelator 
currently in use for iron-overload diseases.  Furthermore new caging groups may be 
designed to allow uncaging at even lower UVA doses than aminocinnamoyl-based 
caging moieties used in this study. Furthermore the CIC approach offers 
considerable scope for optimisation/fine tuning, with respect to wavelength of release 
allowing the design of CICs that will be activatable within the red light range for the 
CIC-based topical ALA-PDT of advanced NMSC cases such as nBCC. The CIC 
approach could therefore offer an even wider range of applications than those 
demonstrated in the present study. 
Finally while the pilot studies presented here provide strong evidence for the 
effectiveness of CIC-based ALA-PDT with UVA, in the future studies it is necessary 
to repeat these data with MAL, as ALA is not yet approved in Europe for PDT of skin 
superficial lesions such as AK. The further tuning of the CIC-based protocol involving 
topical MAL or ALA and UVA in animal studies, could then be tested in pilot clinical 
studies involving patients with superficial AK lesions. These comparative studies 
may provide further insights into the effectiveness of either treatments for AK as well 
as the suitability of ALA- or MAL-based PDT in decreasing the pain experienced by 
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